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Abstract 
Bladder disorders such as overactive bladders affect millions of people worldwide but 
their pathogenesis is poorly understood. Recently, the role of the urothelium in 
bladder function and pathology has generated intense interest, in particular its 
regulation by inflammatory mediators. Angiotensin II is trophic factor and 
inflammatory mediator, and is involved in bladder obstruction and hypertrophy. 
However, its role in urothelial function has never been studied. The aim of this body 
of research was to identify the presence and localisation of angiotensin receptor type1 
within the bladder wall and to elucidate the role of angiotensin II in urothelial and 
bladder function. In this investigation we also looked at the presence of nicotinamide 
adenine diphosphate oxidase and its affect in bladder physiology.  
Guinea-pigs (male Dunkin-Hartley 450-550g) were chosen for their physiological 
homology to humans and were euthanized with schedule-1 procedure. Immuno-
fluorescence was performed on frozen bladder sections with an angiotensin receptor 
type1, nicotinamide adenine diphosphate oxidase 1 and nicotinamide adenine 
diphosphate oxidase 2 primary antibodies and an Alexa-586-conugated secondary 
antibody; Dihydroethidium dye was used as a superoxide dye for imaging studies. 
Mucosa-intact smooth muscle strips and mucosal strips were isolated from the urinary 
bladders. The preparations were superfused in a HEPES-buffered Tyrode’s solution 
for functional measurement. The isometric tension was recorded with a tension-
transducer via a bridge-amplifier. The superfusate adjacent to the tissue strip was 
sampled and adenosine triphosphate release from the tissue was measured using a 
luciferin-luciferase assay. 
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Immunofluorescence highlighted the novel presentation of angiotensin II type1 
receptors in the urothelium of the bladder wall. Application of angiotensin II (200nM 
and 1µM) significantly increased adenosine triphosphate release from the bladder 
mucosa and full thickness bladder tissue; angiotensin II type 1 receptor antagonist 
ZD7155 largely inhibited this effect. Angiotensin II also increased the contractile 
activity in isolated mucosa and mucosa-intact muscle strips. Experiments into the 
mechanism of angiotensin II action on adenosine triphosphate release revealed that 
this was through vesicular release, using Brefeldin A. Further data on nicotinamide 
adenine diphosphate oxidase and reactive oxygen species, exhibited the presence of 
nicotinamide adenine diphosphate oxidase 1 and nicotinamide adenine diphosphate 
oxidase 2 in the urothelium, and a positive effect of hydrogen peroxide on 
spontaneous bladder activity. Additionally, Apocynin was able to inhibit spontaneous 
activity. Dihydroethidium stains as well as reactive oxygen species detection assays 
showed that reactive oxygen species was not only present in the bladder but that 
angiotensin II is able to increase its activity.  
These data provide the first evidence that angiotensin II type 1receptor is expressed in 
the bladder urothelium and angiotensin II stimulates adenosine triphosphate release 
from the urothelium via angiotensin II type 1 receptors and vesicular transport. 
Angiotensin II is also able to generate a positive inotropic effect on mucosa-intact 
smooth muscle, partly through a paracrine effect of the released adenosine 
triphosphate. Additionally, investigations into the action of reactive oxygen species in 
the bladder, reveal its presence and regulation by angiotensin II. These findings 
suggest the significance of angiotensin II in bladder physiology and pathophysiology.  
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1. An Overview  
The human body can be described as a summation of many systems working 
synergistically to promote life and survival. These include the circulatory system, the 
nervous system and the urinary system. The urinary system comprises of the kidneys, 
ureters, urinary bladder and the urethra. The main function of the urinary system is 
the removal of waste products from the body. It achieves this purpose via the 
formation and expulsion of urine, in which the urinary bladder plays a major role.  
The urinary bladder is a hollow dome-shaped organ situated in the pelvic region of 
the body. Its main function is micturition; this describes the process of filling and 
emptying of this organ. During filling, the bladder wall expands to achieve an overall 
ovoid shape but can appear to look like a flattened tetrahedron when empty (Ansell 
1944).  
The dysfunction of the bladder affects millions of people each year (European 
Association of Urology 2016; Davis et al. 2014). With disorders such as Overactive 
Bladder disorder, Bladder Pain Syndrome and Bladder Outlet Obstruction very 
prevalent amongst the elderly population, research into their pathophysiology and 
potential drug targets are needed. Much has been brought to light within bladder 
research over the years (Yu et al. 1994; Fry et al. 1999; Birder 2010; Ford 2012; 
European Association of Urology 2016), but there is still so much that we do not 
know. Therefore, the aim of this body of research is to add to the knowledge in this 
area.  
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The presence of vasoactive hormone Angiotensin II has already been identified in the 
smooth muscle layer of the bladder in bladder outlet obstruction and bladder 
hypertrophy models, but its role has not been shown in physiological conditions and 
in the urothelium of the bladder.  
 
This research will begin with a literature review that will give a detailed exposition 
into the cellular structure of the urinary bladder, the intricate neuronal pathways 
involved in micturition, the mechano-receptive signalling required for successful 
control of the urinary bladder, a closer look at bladder disorders and highlight some 
inflammatory mediators that have been discovered to play a role.  
  
1.1 Bladder Structure 
1.1.1. An Overview  
The urinary bladder wall is made up of a detrusor layer (consisting of smooth muscle 
cells) coated by the serosa (adventitia) on its outer surface and lined by an epithelial 
membrane (known as the urothelium) on the luminal side. Figure 1 shows an 
overview of the urinary bladder and a cross section of the bladder wall. Much 
investigation has been conducted to elucidate the structures present within the 
 20 
 
bladder. The sections below explore in further detail the composition of the detrusor 
smooth muscle, sub-urothelium and urothelium layers, respectively.  
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of the urinary bladder 
This figure depicts clearly the hollow dome shape of the organ. Highlighted are the 
multiple layers found in the bladder wall. The urothelium is made up of thin epithelial 
cells situated closest to the lumen of the bladder. The detrusor smooth muscle and 
adventitia surround the urothelium. The detrusor layer is made up of circular and 
longitudinally orientated smooth muscle cells. Juxtaposed to the detrusor is the 
adventitia, which is the outer membrane of the bladder consisting of serosa and fascia 
Muscalaris Adventitia 
Detrusor Smooth Muscle 
Sub-urothelium  
Urothelium  
Internal Sphincter  
External Sphincter  
Prostate Urethra 
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cells. Additionally the urethra is highlighted, through which urine is expelled and the 
prostate which is only found in males.  
1.1.2. Detrusor Smooth Muscle  
The muscularis adventitia is the outer membrane surrounding the layer of detrusor 
smooth muscle in the urinary bladder (Figure 1). The muscularis adventitia is made 
up of a combination of serosal cells and fascia. Serosal cells are serous fluid secreting 
membranes that typically surround internal organs of the body. The fascia, on the 
other hand, is a layer of connective tissue encapsulating the detrusor smooth muscle 
layer, which lies underneath the muscularis adventitia.  
The detrusor smooth muscle constitutes three main layers of smooth muscle cells. 
Two layers of the detrusor smooth muscle, which are longitudinally oriented cells, to 
sandwich a middle layer which is arranged in a circular pattern (Andersson & Arner 
2004). The cells within this layer have been characterised as typical smooth muscle 
cells similar to smooth muscles in other organs of the body, exhibiting all of the 
classic organelles (Delancey 2002). Smooth muscle cells are long spindle shaped cells 
with a nucleus centrally positioned. Their diameter ranges from five to six microns in 
size and one to several hundred microns in length. These long detrusor smooth muscle 
cells assemble together to form smooth muscle sub-bundles, which also conglomerate 
to form a network of larger detrusor smooth muscle bundles.  
A closer look into the detrusor smooth muscle bundles reveals cell adhesion proteins 
known as cadherins that connect smooth muscles cells to each other. They belong to a 
superfamily of transmembrane glycoproteins (Halbleib & Nelson 2006); these 
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cadherins are eukaryotic membranous proteins that bind to identical proteins 
expressed on adjacent cells. This connection between neighbouring cells is similar to 
a ‘link chain’ (Bryan 2015). This connection between smooth muscle cells allows for 
cell-cell communication; indeed, recent findings reveal that cadherin functions extend 
beyond cellular adhesion (Halbleib & Nelson 2006). There are three main types of 
cadherin: classical cadherins, protocadherins and atypical cadherins (Halbleib & 
Nelson 2006). The classical types of cadherin functions in cell sorting, initiating and 
maintaining cell structure and boundary and tissue integrity. The protocadherins on 
the other hand, have more of a cell recognition role and activation of cellular 
signalling responses. Lastly, atypical cadherins are involved in the maintenance of 
tissue polarity (Halbleib & Nelson 2006). This wide breadth of tissue function of 
cadherins is suggestive that their distortion may play a role in various diseases and 
‘cadherin switching’ plays a vital role in this (Tomita et al. 2000). Within the classical 
group there are epithelial cadherins (E-cadherin), neural cadherins (N-cadherin) and 
placental cadherins (P-cadherin); the classical subgroup of cadherins has been 
highlighted for its ‘cadherin switch’ abilities (Bryan & Tselepis 2010; Jäger et al. 
2010). The expression of E-cadherin has been reported to decrease during bladder 
cancer progression and the expression of N- and P- cadherins increase (Bryan & 
Tselepis 2010; Jäger et al. 2010; Bryan 2015). The change in expression of cadherins, 
especially E-cadherin in this invasive tumour model, holds significant therapeutic 
value as the expression of classical cadherins can be used as biomarkers for tumour 
progression  
Similarly, gap junctions are involved in cell-to-cell communication. Gap junctions are 
specialised regions of plasma membranes formed by channels and pores in the 
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membrane. They function as transport channels for the movement of molecules and 
electrical impulses between neighbouring cells. This contributes to smooth muscle 
cell contraction, as gap junctions allow for the passage and conductance of electric 
currents (Kuijpers et al. 2007).  
Contraction of smooth muscle cells occurs as a result of actin-myosin filament 
interactions, as seen in other parts of the body. The orientation of detrusor smooth 
muscle cells and the structural connections support smooth muscle contraction. A 
detailed examination of urinary bladder contraction and subsequently micturition will 
be discussed further in section 1.4.  
 
1.1.3. Sub-urothelium  
The sub-urothelium layer is between the detrusor smooth muscle and urothelium 
layers. This layer is alternatively referred to as the lamina propria. The classification 
of this layer is often grouped with the urothelium and collectively known as the 
mucosa. For the purposes of this investigation, all references to the mucosa are based 
on this understanding.  
This urinary bladder layer is only a few microns thick. Unlike the detrusor smooth 
muscle layer, the thin sub-urothelial layer is composed of fibro-elastic connective 
tissue that consists of axons and nerve terminals, fibroblasts, capillaries and smooth 
muscle cells (Wiseman et al. 2003). Analogous to the smooth muscle cells in the gut, 
the smooth muscle cells here are popularly known as the ‘muscularis mucosae’, 
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however, their structure is discontinuous and not as defined as that of the gut 
(Wiseman et al. 2003).  
Additionally, another set of cells known as myofibroblasts, have been identified in 
this layer (Sui et al. 2002). Myofibroblasts cells have bundles of cytoplasmic 
microfilaments with dense bodies, a mature rough endoplasmic reticulum, 
cytoplasmic “pinocytotic vesicles” and a serrated nucleus (Wiseman et al. 2003).  
They bear some similarity to both fibroblasts and smooth muscle cells. These cells 
share properties with typical interstitial cells in other parts of the body, but the cells 
described here in the bladder can be distinguished by many factors including their 
non-pacemaking ability (Wu et al. 2004).  
Furthermore, histological investigations by Sui et al (2008) in human bladders 
revealed gap junctions between these myofibroblasts. Gap junctions in combination 
with close associations between nerves and myofibroblasts in this region are 
suggestive that these components work synergistically in the urinary bladder. A 
common proposition is that they may function together as a stretch receptor 
(Wiseman et al. 2003).  
Complementary investigations by Wu et al on the electro-physiological properties of 
myofibroblasts demonstrated that both ATP induced and spontaneously generated 
Ca2+ transients are present in the sub-urothelium (Wu et al. 2004). Thus the urothelial 
layer and the smooth muscle layer are regulated by myofibroblasts (interstitial cells) 
(Sui et al. 2006; Kanai et al. 2006). The results of these investigations are suggestive 
of an integration of information and communication role for this sub-urothelial layer. 
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There is some evidence that fluctuations in the numerical presence of myofibroblasts 
in the bladder can be reflected in overactive or underactive phenotypes (McCloskey 
2011). Most importantly, the expression of functional P2Y receptors and the ability of 
these myofibroblasts to respond to ATP released from urothelium suggest that 
myofibroblasts have a role as a transducer between its overlying epithelium and the 
underlying sensory nerves and smooth muscle. In contrast to P2X receptors on the 
smooth muscle (Fry et al. 1999) the expression of P2Y receptors in both 
uroepithelium (Wu et al. 2011) and suburothelial myofibroblasts (Wu et al. 2004), 
makes the urothelium mucosa an ideal drug target to specifically regulate bladder 
function, since it has little effect on the normal smooth muscle function seen with 
current muscarinic antagonists.   
 
1.1.4. Urothelium  
Epithelium are continuous sheets of cells that make up the skin and line a number of 
internal organs such as; the respiratory tract, digestive tract and genitourinary tract. In 
the bladder this epithelium is known as the urothelium. Similarly to the epithelial 
layers seen throughout these parts of the body, the urothelium acts as a physical 
barrier. The urothelium provides a first line of defence against toxic substances that 
may be present in urine.  
The urothelium is the innermost layer of the urinary bladder wall that sits superior to 
the sub-urothelium (Figure 1). It consists of layered transitional epithelial cells that 
line the luminal side of the urinary bladder wall. Epithelial layers are polar in nature 
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(consisting of an apical and basal layer) (Winder et al. 2014; Birder et al. 2012) figure 
2 displays that the urothelium has 3 sub-layers; a basal layer, an intermediate layer 
and an apical layer with cells known as ‘umbrella cells’ (Birder et al. 2012). The cells 
within the basal layer are on average 10µm in diameter, whereas the intermediate and 
umbrella cells are typically larger with sizes between 10-25µm and 25-250µm 
respectively (Birder & Andersson 2013).  
 
Figure 2. The 3 layers of the urinary bladder urothelium highlighted 
This figure shows the hexagonal nucleated urothelial cells. It constitutes of the basal 
layer, the intermediate layer and the apical layer. Adapted from (Birder & Andersson 
2013).  
 
The basal layer of the urothelium (highlighted in figure 2) expresses keratin 5 on its 
membrane. This protein is known to dimerise with keratin 14, within the same basal 
cell, in order to form keratin intermediate filaments that make up epithelial 
cytoskeleton (Moll et al. 2008). The identification of this protein is suggestive of a 
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mechanical role within the urothelium. The basal layer additionally has keratin 17, a 
protein involved in basal cell proliferation thus providing regeneration of cells (Shen 
et al. 2006). Keratin 13 can be found in both the basal and intermediate layers because 
it combines with keratin 4 to form an intermediate filament (Nishizawa et al. 2008). 
Similarly to the partnership between keratin 5 and 14, the keratin 4 and 13 dimer also 
provides structural support to the cells. The apical layer also express keratin, but 
keratin 20 is isolated to just this layer. There are some keratins that are expressed in 
all the layers of the urothelium: keratin – 7, 8, 18 and 19 (Moll et al. 2008).  
The basal layer as well as the intermediate layer has been shown to play a significant 
role in urothelial development and regeneration (Colopy et al. 2014). Urothelial cells 
that sustained damage due to uropathogenic Escherichia coli (UPEC) inoculation had 
a high number of proliferating cells in the basal and intermediate area. This suggests 
that the basal and intermediate work to regenerate the urothelium following 
pathological assault. This is supported by evidence for a network of vasculature under 
the basal layer of urothelium and this network of blood vessels can supply mediators, 
signalling molecules and cells for regeneration and survival (Birder & Andersson 
2013).  
The apical layer, on the other hand, is made up of umbrella cells. These umbrella cells 
(which can also be referred to as ‘facet cells’) are highly differentiated cells defined 
by their tight junctions and their distinctive apical and basal membranes (Khandelwal 
et al. 2009). Structurally, umbrella cells can be hexagonal in shape, mono- or multi-
nucleated and their size varies because of mechanical stretching, in order to 
accommodate bladder filling (Khandelwal et al. 2009). However, their most 
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distinctive feature is that their apical membrane contains plaques known as 
‘uroplakins’ (Khandelwal et al. 2009).  
Uroplakins contain four related transmembrane (TM) proteins that act as a barrier to 
water, urea, and non-electrolytes (Lee 2011). This protein group consists of UP Ia, UP 
Ib, UP II and UP III (Yu et al. 1994). The uroplakins are highly conserved proteins, 
essential to maintaining the barrier function of the urothelium with their scallop 
shaped plaque formation and are able to act as a mechanical anchorage site via their 
interaction with cytoskeleton (Lee 2011). Furthermore, in UP II knock-out mice 
models, an absence of plaque formation is observed, suggesting that this subunit is 
essential for plaque formation and thus the barrier function of the urothelium (Kong et 
al. 2004).  
The barrier function of the urothelium was once believed to be its only function, but a 
more sensory role has been elucidated for this epithelial layer, suggesting that the 
urothelium is not passive but responsive to stimuli. As previously stated, the presence 
of keratin intermediate filaments provides evidence for this function. The following 
section (Section 1.3) will explore this further.  
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1.2. An overview  
 
Micturition describes the process of the urinary bladder filling (storage phase) and 
emptying (voiding phase). The process involves a co-ordinated action of bladder 
smooth muscle, skeletal muscle and nerves. The body is governed by two main sets of 
neuronal control: the central nervous system (CNS) and the peripheral nervous system 
(PNS). The CNS consists of all the nerves in the brain and spinal cord, whereas PNS 
is made of all of the nerves outside of the CNS. This neuronal system can be divided 
further into the autonomic system (involuntary actions) and the somatic (voluntary 
control). The bladder and the process of micturition, falls under the influence of both 
the autonomic and somatic system.  
This section will describe the mechanisms of bladder activation: - filling and 
emptying and will additionally explore the neuronal signalling pathways present in 
the urinary bladder.  
 
1.2.1. Bladder Filing  
 
The aim of the bladder-filling phase (highlighted in figure 3, stage 1) during 
micturition is to store urine temporarily as a reservoir until voiding. Bladder filling is 
a passive process. As seen in figure 3, in stage 1 the voiding rate remains at zero 
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during this phase as the bladder fills, there is no change in rate until activation has 
occurred. Relaxation of the urinary bladder wall during stage 1 allows the bladder to 
extend as the hydrostatic pressure in the lumen of the bladder rises and the lumen fills 
with urine. The hydrostatic pressure in the lumen increases until the volume of the 
bladder reaches its hydrostatic threshold. At this point, the bladder triggers rhythmical 
waves of contraction that are regulated by the sacral cord in the spine (Fowler et al. 
2008). The nerve impulses from these contractions are carried by parasympathetic 
fibres of the nervi erigentes via the second and third sacral segments to the sensory 
cortex in the post-rolandic area (Fowler et al. 2008). Depending on how full the 
bladder is; the sensation may be a shallow discomfort or pain in order to encourage 
voiding.  
During filling, synaptic connections between Aδ afferent nerves and the spinal tracts 
in the lumbosacral spinal cord helps to maintain continence; which in turn stimulates 
sympathetic efferent nerves in the muscle of the bladder in a reflex manner (de Groat 
et al 2008). This reflex action is termed the ‘guarding reflex’ (Seth et al. 2013). 
Additionally, activation of the pudendal efferent nerve results in contraction of the 
external sphincter and supports continence (Seth et al. 2013)(Seth et al, 2013). The 
pudendal nerves, found in the pelvic region, extend from the pudendal plexus (a 
network of nerves). Similar to branches on a tree, the pudendal nerves reach through 
the sacral region, the pudendal canal and the perineum, their effect reaching to the 
urethral sphincter to promote contraction (Fowler et al. 2008). 
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Figure 3. A representation of the change in voiding rate during micturition. 
The illustration has been categorised into two main phases: Storage phase and 
Voiding phase, and then further divided into 4 main stages. 1. Bladder filling - during 
the storage phase the bladder stretches to fill with urine until the threshold of 
hydrostatic pressure is reached. 2. Activation occurs to initiate voluntary micturition, 
bladder wall contracts and the external sphincter relaxes. 3. Bladder emptying - the 
voiding phase where the urine is expelled and the urinary bladder hydrostatic 
pressure falls. 4. The bladder fills with urine again to repeat the cycle.  
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1.2.2. Bladder Activation 
 
The urinary bladder is a highly innervated organ; the regulation of its function occurs 
via a complex system of nerves (Seth et al 2013). The combination of involuntary and 
voluntary control makes the bladder distinctive from other organs. Voluntary control 
is learnt and developed in the early years of life. Involuntary control of the bladder 
involves the neural network supporting the bladder, controlled by regions of the CNS.  
 
Figure 3, stage 2 is a graphical representation of the change in voiding rate during 
activation. Prior to this, the bladder fills until this reaches a threshold; the volume of 
this threshold lies between 400-500 millilitres (Seth et al 2013). Once this is 
surpassed, the urge to void is activated. In contrast to other organs of the body, the 
urinary bladder is activated in a switch-like manner as opposed to the tonic control of 
other organs (Seth et al 2013). Similar to an on-off system, this switch-like activation 
allows the bladder to store urine until it is appropriate to void.  
 
1.2.3. Bladder Voiding 
Micturition, specifically voiding, requires changes in the intra-vesicular pressure in 
order to overcome the outflow tract resistance (Fry, 2005). This is achieved by the 
lower urinary tract simultaneously reducing the bladder outflow resistance and 
increasing the bladder vesicle pressure. It’s the motor cortex that is responsible for 
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transmitting excitatory impulses to the lumbo-sacral centre whilst simultaneously 
intensifying the detrusor contractions. This results in efferent stimuli being passed 
along the nervi erigentes (Ansell, 1944). This subsequently causes the external 
sphincter to relax. Activation of the parasympathetic system leads to relaxation of the 
urethral smooth muscle and NO release. Additionally, the urethral smooth muscle is 
also relaxed by suppressing adrenergic and somatic cholinergic excitatory inputs 
(Fowler et al. 2008).  
Initially only a few drops of urine are passed into the prostatic urethra – which 
increases the reflex contraction of the abdominal wall. The bladder is then emptied by 
additional supportive intra-abdominal pressure. The lower urinary tract is regulated by 
sacral parasympathetic, thoracolumbar sympathetic and somatic nerves (Birder & 
Andersson 2013). Afferent neurons - Aδ (myelinated) and C-type (unmyelinated) 
fibres, are involved in the bladder (de Groat & Yoshimura 2009). Aδ fibres are 
present in the detrusor muscle layer and are able to detect detrusor smooth muscle 
stretch during bladder filling. On the other hand, C-type fibres have a widespread 
distribution in the bladder detrusor and lamina propria layers. These C-type fibres can 
project to either the spinal cord lamina I or spinal cord lamina II and are peptidergic 
containing neurons or not, respectively (Birder & Andersson 2013). C-type fibres 
express many receptors including TRPV1, muscarinic and purinergic receptors and 
can therefore respond to many mediators such as prostaglandins, ATP, acetylcholine 
and bradykinin (Ford 2012).  
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1.2.4. Neuronal Control  
The mechanism of micturition is largely controlled by our nervous system. The 
cerebral cortex provides the ‘green light’ for voluntary voiding. The main neuronal 
pathways involved in micturition are the sensory pelvic nerve, the hypogastric nerve 
and the pudendal nerve (Fowler et al. 2008). These are highlighted in the illustration 
presented in figure 4.  
The sensory pelvic nerve, depicted by its name, is responsible for transmitting sensory 
signals from the bladder wall to the sacral section of the spinal cord. This afferent 
nerve mediates the action of a cocktail of sensory receptors (Birder et al. 2010). The 
wide array of sensory receptors is highlighted figure 5, section 1.4.3 and explored 
here in further detail. The sensory role of the urothelium, aids the ability of the 
bladder wall to respond to changes such as stretch, pressure, inflammatory mediators 
etc. (Birder et al. 2013). The sensory afferent impulses detected are transferred along 
this sensory pathway, activating nerve fibres in the sacral cord (figure 4). These nerve 
fibres can be Aδ or C-type fibres (Fowler et al. 2008). The Aδ nerve fibres are small 
myelinated nerves that have a low activation threshold, and are excited when the 
bladder is filing; allowing them to pick up small changes in sensation. These fibres 
extend from the sacral cord to the thoracolumbar region of the spine, to stimulate the 
efferent hypogastric nerve (figure 4). The hypogastric nerve, promotes urine storage 
by releasing noradrenaline to act upon α1 and β3 receptors. α1 receptors, highlighted in 
figure 4, are present on the internal sphincter and activated by the hypogastric nerves; 
thus the sphincter muscle contracts and urine is stored (Fowler et al. 2008). 
Additionally, β3 receptors on detrusor muscle are inhibited therefore promoting 
storage. This neuronal pathway, from the sensory pelvic nerve, Aδ fibres and 
hypogastric nerve is known as the guarding reflex. It does not require input from the 
cerebral cortex.  
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Figure 4. An illustration of the neuronal pathways involved in micturition.  
This illustration shows the detection of a large variety of sensory inputs from the 
bladder lumen by the sensory pelvic nerve, the transmission of this to the sacral cord 
region.  
The three efferent pathways are also highlighted: the pelvic nerve, the pudendal nerve 
and the hypogastric nerve. The figure also shows the central nervous system and the 
relation of neurons to the different regions of the CNS. Ach (acetylcholine), NA 
(Noradrenaline).  
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At the moment where larger pressures are detected, the sensory afferent nerve that 
runs from the bladder to the sacral cord, mediates is able to activate C-type fibres 
instead of Aδ fibres (De Groat, 2015). These C-type fibres, send fast signals from the 
sacral cord to the Pontine Micturition Centre. This centre, situated in the Pons area of 
the brain stem, is a switch centre for micturition. This centre is what provides us with 
voluntary control (Fowler, 2008). The activation of this centre, causes the 
transmission of nerve impulses from the PMC to the thoracolumbar region and the 
sacral region. In the thoracolumbar region, the activation of the PMC causes and 
inhibition of the hypogastric nerve. This therefore, inhibits urine storage signals via 
the internal sphincter and detrusor smooth muscle. Activation of the PMC also causes 
activation of the pelvic nerve and the inhibition of the pudendal nerve (nerves 
illustrated in figure 4) (Birder, 2013). Activation of the pelvic nerve, an efferent 
pathway, at the sacral cord results in the release of acetylcholine at the detrusor 
smooth muscle that binds to M3 receptors and the detrusor muscle contracts. 
Furthermore, the inhibition of the pudendal nerves inhibits the release of 
acetylcholine at the external sphincter, causing these muscles to relax and allow 
voiding.  
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1.3. An Overview  
Bladder disorders are a major class of chronic diseases that have important health, 
economic and societal implications due to their effect on millions of people each year. 
This section will characterise in detail a selection of major causes of dysfunction in 
urinary bladder physiology. In contrast to the previous sections (sections 1.4 – 1.5) on 
the physiology of continence, the pathophysiology of urinary bladder disorders is 
commonly associated by urinary incontinence. This section will give a brief 
background on Overactive Bladder (OAB), Bladder Pain Syndrome (BPS) and 
Bladder Outlet Obstruction (BOO) giving detail to its symptoms, prevalence, 
aetiology and treatment.  
 
1.3.1. Overactive Bladder  
OAB was first described as a term for symptomatic urgency and urge incontinence 
(Wein & Rovner 2002). Although this term is often used loosely as an umbrella to 
define a group of bladder disorders, within the parameters of this thesis it will be used 
to describe a type of pathophysiological condition. The symptoms of OAB include the 
presentation of urinary urgency - with or without urinary incontinence, urinary 
frequency and nocturia, in the absence of pathogenic and abnormal metabolic 
conditions (Ellsworth & Fantasia 2015).  
It has been reported that 16% of the population in Europe suffer from OAB. Within 
the urology field, there are strong suggestions that this statistic is not a true reflection 
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of the prevalence of OAB. It is thought that due to social stigma attached with the 
disorder, there are gross numbers of unreported cases, thus making 16% a poor 
underestimation of the impact of OAB in our society (Milsom et al. 2001).  
Due to the high prevalence of OAB, there are even greater impacts of the disorder 
psychologically, clinically and economically. Aside from clinical symptoms, the main 
impact of OAB on the patient is quality of life. The psychological implications of 
OAB include shame, fear and guilt (Ellsworth & Fantasia 2015). The nature of 
urinary incontinence requires patients to: frequently need the toilet, wear various 
adapted undergarments and suffer a constant disruption to social and work activities 
(Stewart et al. 2003). An increase in comorbidities is also witnessed in patients with 
OAB - a higher risk of depression, skin irritations, and urinary tract infections. A 
report into osteoporotic fractures associated with urinary incontinence highlighted the 
risk of falls increases by 26% and fractures by 34% in women who are diagnosed with 
OAB (Brown et al. 2000).  Patients suffer with symptoms such as nocturia and 
urinary urgency, which increases their risk of trips and falls in the night.  Ultimately, 
the implications of the personal and clinical impacts contribute to the economic 
burden of OAB.  
The exact aetiology of OAB has not been determined, since there are many possible 
causes. Malfunctions at any point in the process of micturition can cause the 
symptoms of OAB. These includes signals of high intravascular pressure at low 
volumes of urine, altered response to stimuli and changes to the smooth muscle 
structure (Banakhar et al. 2012). However, the multifactorial nature of its 
pathophysiology makes treating OAB sometimes difficult (Andersson 2009). A new 
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hypothesis proposes “urotheliogenic” mechanism for bladder overactivity (Birder & 
Andersson 2013), which hence forms the basis to investigate urothelial function in 
this current PhD project. 
At present, OAB is initially treated by conservative measures in accordance with 
NICE guidelines on urinary incontinence (NICE pathways, OAB, 2016). This 
includes lifestyle changes, pelvic floor exercises and bladder training. Following the 
failure of these measures to control or reduce the symptoms, the second line of 
management is the prescription of anti-muscarinic drugs. However, there is data 
suggesting that a large number of patients stop treatment due to side effects 
(Andersson & Arner 2004). The side effects include dry eyes, dry mouth and 
constipation. Following this, there are a number of treatments that can be considered: 
surgical bladder augmentation, posterior tibial nerve stimulation, botulinum toxin or 
sacral neuromodulator (Longworth & Fowler 2013).  
There is no preventative treatment or cure for OAB, therefore it is important to 
identify key pathological pathways and molecules for drug target to develop new 
therapies. Thus a major aim of this thesis is to identify novel molecular target in the 
urothelium – the newly recognised sensory structure, for the development of more 
specific drugs. 
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1.3.2. Bladder Pain Syndrome 
BPS is a chronic pain condition found in the urinary bladder and the surrounding 
pelvic areas, lasting more than six weeks (National Institute of Diabetes and Digestive 
and Kidney Diseases, 2011). Patients can have a variety of the following symptoms: 
supra-pubic pain, increased urgency, frequency and nocturia.  
BPS is often referred to as ‘interstitial cystitis’ and this interchangeable use can 
promote confusion across centres, institutions and countries. Consequently, the 
European Society for the Study of Interstitial Cystitis (ESSIC) attempted to solve this 
by creating an agreement on definition, diagnosis and classification (Parsons 2005). 
Thus, the decision was made to name the disease BPS. Diagnosis is based on the 
presentation of chronic pelvic pain, pressure and the sensation of discomfort related to 
the urinary bladder, with urgency or frequency (Parsons 2005).  
BPS has been reported to affect 18 people per 100,000 (Offiah et al. 2016). The 
distribution of the syndrome across gender in the population is seen in the ratio of 5:1 
for women: men (Jones & Nyberg 1997). Additionally, the most prevalent group of 
people affected are commonly women between the age of forty and sixty years old 
(Offiah et al. 2016). However, this gender difference may be due to misdiagnosis in 
men, as proposed by Arora & Shoskes (2015), that many men are wrongly diagnosed 
with prostatitis, epididymitis or even benign prostatic hyperplasia before reaching the 
correct diagnosis of BPS.  
The aetiology of BPS is still unknown. There are multiple hypotheses for the 
aetiology of BPS; one hypothesis is the disruption or damage of the urothelial layer. It 
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has been postulated that this damage to the urothelium may result in exposure of the 
sub-urothelial layers to the contents of the lumen and further damage to the urinary 
bladder wall (Offiah et al. 2016). An alternate hypothesis is that peripheral 
inflammatory disorders such as metabolic diseases (type 2 diabetes, obesity, and 
atherosclerosis) increase the expression of inflammatory mediators in the body and 
thus the urinary bladder. Activation and sensitisation of sensory afferents are thought 
to follow from the elevation of inflammatory mediators; it is believed that BPS 
symptoms are driven by this sensitisation (Offiah et al. 2016). Qian-Shen et al (2016) 
suggests an alternative hypothesis that the pathophysiology of BPS evolves 
sequentially. Firstly, urothelial damage occurs via urinary tract infection, chronic 
bladder distension or surgical trauma. Damage to the urothelium can result in 
urothelial thinning or even worse – denudation. Secondly, the disruption of the 
epithelial lining leads to sub-urothelial inflammation. Thirdly, the reoccurring 
inflammation in the sub-urothelium leads to chronic inflammatory cell infiltration to 
the area, which results in more inflammatory reactions to the sensory afferents, the 
dorsal horn and the spinal cord (Qian et al. 2016). As this project examines the role of 
angiotensin II - an important inflammatory mediator in the bladder, in regulating the 
function of the urothelium – a structure where bladder pain syndrome occurs, the 
outcome of the study will contribute to a better understanding of its pathophysiology.  
The nature of BPS is associated with increased comorbidity cases. The sensitisation of 
patients to pain may alter pain perception and pathways globally leading to increased 
risk of secondary disorders (Schrepf et al. 2015). A higher prevalence of psychiatric 
comorbidities such as depression and anxiety are seen in patients already diagnosed 
with BPS (Clemens et al. 2008). In addition, patients with BPS are 2.53 times more 
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likely to develop coronary heart disease (CHD), possibly due to their shared risk 
factors such as inflammation, autoimmunity, infection and mechanical failure (Chen 
et al. 2014). One aim of this thesis is to examine the role of inflammatory factors in 
urothelial function.  
Treatment of BPS can be categorised into four main groups; lifestyle changes, 
medication and supportive therapies. Lifestyle changes include a change of diet, a 
reduction in alcohol intake and cessation of smoking. A number of medications that 
can be prescribed are; painkillers such as paracetamol or ibuprofen, muscle relaxants 
and pentosan polysulphate sodium (NHS Choices, Interstitial cystitis, updated 2015). 
These treatment options are only able to provide symptomatic relief but not cure the 
syndrome. Due to the lack of knowledge of the specific physiological target required, 
no specific treatment has yet been developed. Therefore, any evidence and research 
provided into the physiological contributors of micturition is vital. Investigation of the 
role of inflammatory factors in urothelial function may lead to identification of new 
target for the treatment of bladder pain syndrome. 
 
1.3.3. Bladder Outlet Obstruction  
BOO is another bladder disease associated with overactive bladder (described in 
section 1.6.2) and is characterised by increased detrusor voiding pressure and low 
flow rate (Jiang et al. 2016). Symptoms mirror that of patients with OAB, but 
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additionally BOO can result in abnormal detrusor contractility and an inability to 
completely empty the bladder (Miyazaki et al. 2016).   
Similar to previous bladder disorders mentioned above, there are many possible 
causes of urinary bladder outlet obstruction. BOO commonly results from benign 
prostatic hyperplasia in men and can thus be relieved with transurethral 
prostatectomy. Investigations by Bump et al (1999) highlighted a correlation between 
BOO and detrusor instability. This may be due to increased bladder smooth muscle 
hypertrophy, hyperplasia and detrusor pressure caused by the obstruction. It is thought 
that even small obstructions can still result in pathological detrusor changes (Kershen 
& Appell 2002). 
Further to this, investigations by Koritsiadis et al (2008) demonstrated a link between 
BOO and tissue hypoxia. Their research hypothesised that the BOO disorder arose 
from chronic ischemia-reperfusion injury in the urinary bladder of patients affected. 
They demonstrated that obstruction in the urinary bladder led to a decrease in blood 
flow, subsequent ischemia and induction of hypoxia. This will have an effect on the 
urothelium, as the peripheral layer of the bladder wall, but the significance of this is 
unclear (Andersson et al. 2017).  
The certainty of the role of hypoxia and oxidative stress in bladder pathophysiology 
has yet to be established. Insight into how significant the contributions of hypoxia or 
oxidative stress are, in bladder pathology such as BOO, would help with therapeutic 
targeting and treatment. Evidence for their effects on bladder contraction, their 
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mediators and potential activators would be significant for progress in our 
understanding.  
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1.4. The Sensory Role of the Urothelium  
 
1.4.1. An Overview  
The sensory role of the urothelium was first suggested by Ferguson et al. (1997). 
Since then, further investigations have been conducted into the sensory nature of the 
urothelium, thus revealing the network of receptors, innervation and signalling 
molecules released from it (Birder 2010; Birder & Andersson 2013; Vlaskovska et al. 
2001). Additionally various receptors have been discovered on its surface such as; 
purine receptors, mechano-receptors and muscarinic receptors (Birder 2006).  
This section will explore in further detail the sensory nature of the urothelium and 
some of the signalling pathways that have been elucidated so far.  
 
1.4.2. More Than a Passive Barrier  
The sensory role of the urothelium was first suggested by Ferguson et al. (1997). 
They proposed that the urothelium acted as a detector for hydrostatic pressure 
changes in the urinary bladder during the filling phase of micturition. The bladder is 
able to detect both faint and large pressure changes leading to micturition (Denny-
Brown & Robertson et al.1933). The report by Ferguson et al. (1997), stipulated that 
in response to increased hydrostatic pressure in the lumen of the bladder, the 
urothelium released ATP which signalled to the sub-urothelium, via paracrine 
 49 
 
signalling on P2x receptors. This would provide communication between the 
urothelium and lower layers; they proposed that the apical layers of the urothelium 
contained mechanosensitive ion channels in order to detect initial mechanical 
changes. Since then, further evidence has support this idea (Birder 2010; Birder et al. 
2001). In Ferguson’s experimentation, changes to transepithelial potential caused a 
correlated increase in ATP release (demonstrated in figure 5) and this is suggestive 
that ATP release is linked to nerve excitation. This response activity of ATP to 
changes in pressure and membrane potential points to a ‘more than barrier’ nature of 
the urothelium; thus providing supporting evidence of a sensory role in urothelial 
physiology.  
 
Figure 5. A schematic diagram of the effect of electrical stimulation of the urothelium. 
The flow chart demonstrates that upon excitation of urothelial cell membranes with 
electoral field stimulation, an action potential is generated. This results in activation 
of mechano-sensitive ion channels and the release of ATP via afferent nerve firing.  
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1.4.3. A Sensory Web  
This term “sensory web” refers to the communication and interdependent relationship 
between the layers of the bladder wall. The layers involved in this group are the 
urothelium, nerve fibres, interstitial cells, detrusor smooth muscle and sphincter 
muscles (Apodaca & Lori et al. 2007).  
This Further investigations have been conducted into the sensory nature of the 
urothelium, thus revealing the network of receptors, innervation and signalling 
molecules released from it (Birder 2010; Birder & Andersson 2013; Vlaskovska et al. 
2001). This is demonstrated by figure 6, showing the urothelial cells and some of the 
various mediators that interact with the urothelium. Examples of signalling molecules 
involved are: ATP, acetylcholine and nitric oxide (NO), which mediate their actions 
on afferent nerves (Kanai et al. 2006). Additionally a detection of neuropeptides that 
were released from the sensory nerves in affiliation with the urothelium, caused 
changes in detrusor smooth muscle contraction and neurotransmitter release 
(Ferguson et al. 1997). Various receptors have been discovered on its surface such as; 
purine receptors, mechano-receptors and muscarinic receptors (Birder 2006). The 
remainder of section 1.4, will review some of the signalling pathways involved in the 
urothelial sensory web.  
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Figure 6. Neurotransmitters that associate with the urothelium 
An animation of the apical layer of the urothelium and some of the mediators and 
neurotransmitters involved in its physiology.  
1.4.4. ATP Receptor Signalling 
Purinergic signalling describes the action of purine nucleosides and nucleotides, to 
mediate cellular signalling via the activation of purinergic receptors. Purinoceptors 
have been identified to be involved in many areas of human physiology. They are 
expressed in a number of organs such as the gut, heart, kidneys, brain and adipose 
tissue. Their influences include memory, feeding and sleep (Burnstock & Williams 
2000; Düster et al. 2014). Additionally at cellular levels, the activation of these 
receptors mediates cellular proliferation, cytokine secretion, vascular reactivity and 
apoptosis (Burnstock & Williams 2000).   
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Burnstock was the first to identify ATP as an extracellular signalling molecule in the 
urinary bladder in addition to the well-established acetylcholine (Burnstock 1972). 
There are three types of purinergic receptors: P1, P2X and P2Y. P1 mediates the 
activity of nucleosides specifically, whereas, P2X and P2Y are involved in nucleotide 
action. P1 has four subtypes, which are A1, A2A, A2B and A3. All four subtypes of P1 
are expressed in the detrusor smooth muscle of the urinary bladder but to varying 
degrees; with A2B and A3 having the highest expression and A1 the least (Hussain et 
al. 2004). However, P2X has seven subtypes ranging from P2X1-7 and P2Y receptors 
have eight subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 
(Burnstock 2009). All seven subtypes of P2X are expressed in the urothelial layer of 
the urinary bladder as well as three out of the eight subtypes of P2Y – P2Y1, P2Y2 
and P2Y4 (Wang et al. 2005; Chopra et al. 2008). But only P2Y2 and P2Y4 have 
functional data, the data shows their ability to evoke greater ATP release with the 
addition of UTP (Chopra et al. 2008).  
Following various investigations, it has now been well established that ATP is 
released from the urothelium as well as the detrusor smooth muscle (Mansfield & 
Hughes 2014; Nakagomi et al. 2016). In the urothelium, ATP filled intracellular 
vesicles fuse with the cell membrane during the bladder-filling phase of micturition 
(Nakagomi et al. 2016), in order to increase the surface area of the membrane thus 
promoting stretch induced ATP release. This is supported by experiments using the 
vesicular transport inhibitor, Brefeldin A (Truschel et al., 2002). The ability of this 
inhibitor to block ATP release from the luminal side of the urinary bladder, suggests 
that vesicular transport is normally occurring at the urothelial level.  
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Receptors have been identified on a sub group of small sensory neurons of the dorsal 
root, cranial ganglia (Cockayne et al. 2000) and suburothelial sensory nerve endings 
(Burnstock & Williams 2000). These receptors have been discovered to be P2X3 
receptors specifically. There is evidence for the idea that as the bladder fills with 
urine; the bladder wall stretches in order to accommodate the increased fluid and 
hydrostatic pressure (Cockayne et al. 2000). This results in the release of ATP in 
response to the stretch of the bladder wall. ATP that is released from the urothelial 
sheets has both an autocrine and paracrine action (Wang et al. 2005). This paracrine 
action is on P2X3 receptors found on afferent nerves, myofibroblasts in the sub-
urothelium and the detrusor smooth muscle (Sui et al. 2014). At a threshold, ATP 
concentration subsequently activates the voiding pathway and promotes the emptying 
of the bladder.  
Additionally in P2X3 knockout models, where 1kb of the P2X3 gene has been deleted 
thus creating a faulty receptor, adverse effects can be seen on bladder voiding. Results 
demonstrated hyporeflexia in deficient mice and stunted pain related behaviour 
(Cockayne et al. 2000). Therefore, it is clear that P2X3 receptors must be involved in 
the bladder neural pathway and nociception. Alternatively, the use of ATP analogue 
α, β-Me-ATP, activated mechanosensitive pelvic afferents on rat bladders, providing 
further evidence of the role of P2X3 in mechanosensation in the urinary bladder 
(Cockayne et al. 2000). Thus it can be postulated that P2X3 inhibition may be a good 
therapeutic target and may result in reduced mechanosensation and increased voiding 
threshold, which would be beneficial in pathologies such as overactive bladder.  
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Furthermore, suburothelial myofibroblasts express P2Y2 receptors, which mediate the 
action of ATP that is released from their cells (Chopra et al. 2008). Therefore the 
urothelium and suburothelium can act together as a functional syncytium to amplify 
the ATP signal. Myofibroblasts, found in the suburothelial area, are a functionally 
connected cell network by connexin 43 and are in close contact with sensory nerve 
endings (Fry et al. 2007). Therefore myofibroblasts can transmit the sensory signal 
ATP from the urothelium as a transducer. 
Evidence for significant ATP release in denuded mucosa, in the absence of exogenous 
stimuli was also discovered by Sui et al (2014). Further investigations into the 
uroepithelial layer show that more than 70% of the ATP released by the urothelium is 
from the uroepithelium specifically and this is mediated predominantly by P2Y 
receptors rather than P2X (Sui et al. 2014).  
The action of ATP and purinergic receptors alters with age (Daly et al. 2014; Sui et al. 
2014). Investigations in aged mouse bladders revealed elevated receptor sensitivity in 
purinoceptors, increased bioavailabity of ATP and a higher expression of the P2X3 
receptor, in comparison to younger populations (Daly et al. 2014). Similarly, ageing 
guinea pigs have a significantly greater release of ATP and therefore indicative of an 
altered or amplified release mechanism (Sui et al. 2014).  
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1.4.5. Acetylcholine Receptor Signalling  
The action of acetylcholine is also a major contributor to bladder signalling. 
Acetylcholine is a very well-known neurotransmitter; it is commonly released from 
parasympathetic postganglionic neurons in the bladder (Kim et al. 2015). It is 
synthesised from the catalysed reaction of acetyl coenzyme A and choline, by choline 
acetyltransferase. Choline is present at a concentration of 10mM in the plasma and is 
taken up into cholinergic pre-synaptic nerve terminals via Na+/choline transporter. 
Acetyl coenzyme A, on the other hand, is synthesised during glycolysis. Following 
from the formation of acetylcholine, approximately 10,000 molecules are packed, by 
vesicular acetylcholine transporters into vesicles (Purves et al. 2001).  
The action of acetylcholine is mediated by cholinergic receptors that bind 
acetylcholine neurotransmitters and activate signalling pathways in response. There 
are two main types of cholinergic receptors: muscarinic and nicotinic receptors. 
Muscarinic receptors are G-protein coupled membrane receptors, whereas nicotinic 
receptors are ion channels (Ehlert 2003).  
There are five subtypes of muscarinic receptors - M1-5. There are large variations 
between the muscarinic subtypes, mainly found within the intracellular loops. Since 
the subtypes only share 26.3% amino acid homology (Ehlert et al. 2005; Fowler et al. 
2008), there are a large number of variations in the way they act. The subtypes differ 
in the G proteins that they are coupled to. M2 and M4 are coupled to the Gi alpha 
subunits (Gi/o) whereas M1, M3 and M5 are coupled to Gq protein (Gq/11) subunits. 
Additionally, these receptors are expressed throughout the body, with the receptors 
having a key neuro-modulatory role as seen from knockout models. M1 and M4 
 56 
 
receptors have been identified to be involved in locomotor activity, M2 receptors have 
a thermoregulatory role and M3 receptors modulate appetite (Fowler et al. 2008; 
Ehlert 2003; Yamanishi et al. 2001).  
Muscarinic receptors can be detected in areas such as the respiratory tract, the ileum 
and the iris (Caulfield 1993). Additional data highlights that subtype M2 is present 
within the urothelium, in contrast to M3’s detrusor smooth muscle expression 
(Andersson 2015).  
Furthermore knockout models for M2 receptors show a small reduction in contraction 
of the urinary bladder, M3 knockout models have a large reduction in contractile 
activity but models with an M2:M3 double knockout demonstrate complete loss in 
contractile activity (Ehlert et al. 2005). This evidence is suggestive that although M3 
is the main contributor of bladder contraction, the support role of M2 receptors is still 
vital. M2 is suggested to have an indirect support role of the direct action of the M3 
receptor, in an M2:M3 interaction (Ehlert et al. 2005).  
In addition to this, the expression of nicotinic acetylcholine receptors have also been 
found in the urothelium (Bschleipfer et al. 2007). There are 17 types of receptors that 
have been identified in the body. The receptors have been categorised into groups: 
alpha (α), beta (β), gamma (γ), delta (δ) and epsilon (ε) subtypes (Beckel et al. 2005). 
There are 10 isoforms within the α sub group, 4 in the β subgroup and one in each of 
the following – γ, δ and ε. Investigations by Beckel et al. (2005), provide evidence for 
the presence of α3 and α7 subtypes in the urothelium of rat models. Their research 
highlighted the functional role of α3 and α7 in regulating bladder physiology and 
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reflex voiding. Thus this became the first indication that the stimulation of non-
neuronal nicotinic receptors in the bladder can alter bladder physiology (Beckel et al. 
2005). More recent work into the study of these nicotinic receptors in the bladder 
brought to light their elevated expression in bladder outlet obstruction models, in 
comparison to the control (Kim et al. 2015). The immunofluorescence stains also 
revealed that, the α7 subtype specifically, had increased receptors in the detrusor 
smooth muscle of bladder outlet models (Kim et al. 2015).  
 
1.4.6. Mechano-sensitive Receptor Signalling 
TRPV (Transient Receptor Potential Vanilloid) receptors belong to the vanilloid 
family of ion channel receptors. They are a group of sensory cation channels involved 
in many cell signalling processes in both physiological and pathological states 
(Janssen et al. 2011).  
This vanilloid family of receptors has six subtypes of receptor: - TRPV1, TRPV2, 
TRPV3, TRPV4, TRPV5 and TRPV6. The TRPV1- 4 subtypes have been identified 
to have a nociceptive and thermo-sensing action, whereas TRPV5 and TRPV6 are 
involved in renal Ca2+ reabsorption (Nilius & Szallasi 2014).  
TRPV1 was the first of the TRPV receptors to be identified. The discovery of this 
receptor, using capsaicin, is indicative of its most common ligand - chillies and the 
nature of this group of receptors. The transient vanilloid receptor expressed on the 
urothelium is TRPV1 (Caterina & Julius 2001). This receptor is known to respond to 
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chemical stimuli such as capsaicin and altered pH. Its function in the bladder is 
thought to be detecting chemical signals in bladder inflammation conditions (Birder 
2006). Additionally, there is evidence for the receptor to detect mechano-sensation 
and result in elevated ATP levels (Birder et al. 2001).   
In particular TRPV4 has been revealed to be expressed on the urothelial lining in 
guinea pigs, rats and mice bladders (Birder 2006).  Furthermore, TRPV4 receptors are 
specifically localised in the adherence junctions connecting neighbouring cells within 
the urothelium of the human bladder (Janssen et al. 2011). This ion channel is able to 
detect a range of stimuli, therefore giving the urothelium a sensory function. The list 
of stimuli for TRPV4 includes stretch, temperature change and low pH (Nilius et al. 
2003); each stimulus activates a unique pathway from the others (Janssen et al. 2011). 
A stimulus, such as urothelial stretch, can activate the TRPV4 cation channel, 
instigate an influx of Ca2+ ions into urothelial cells and ultimately trigger ATP release 
from the urothelium (Janssen et al. 2011). Following TRPV4 knockout, mouse 
bladders have an increased bladder capacity with decreased ATP release from the 
urothelium, although response to ATP remains consistent (Janssen et al. 2011). The 
increased bladder capacity is similar to P2X3 knockout mice where a similar result is 
seen; however, ATP release is normal in P2X3 knockouts and ATP response is altered 
(Vlaskovska et al. 2001).  
Research is continually being undertaken to discover more signalling pathways in the 
bladder.  
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1.4.7. Epidermal Growth Factor Receptor Signalling  
Epidermal growth factor (EGF) is a hormone that has been highlighted to interact 
with the urothelium. The hormone binds to the EGF receptor which has an auto 
activation ability. The presence of EGF receptor can be seen on the apical surface of 
the urothelium (Apodaca 2007). Its function on the urothelium, is to cause long term 
change to stretch-regulated exocytosis (Apodaca 2007). It is thought that this 
hormone is released in response to stretch in the bladder wall, which acts on the EGF 
receptor and interacts with endoplasmic reticulum and golgi apparatus. These 
organelles known for their function in protein synthesis, aid EGF in its ability to 
regulate protein synthesis and thus affect exocytosis. The regulation of exocytosis can 
also be affected by intracellular calcium (Apodeca 2007). The EGF is transactivated 
by the intracellular calcium. This causes an increase in protein synthesis, thus causing 
an increase in exocytosis (Apodeca 2007). The action of EGF may be vital in the 
mediation of other neurotransmitters and substances that can act on the urothelium. 
Therefore, is it possible that EGF may have an ‘orchestral conductor’ role? Whereby 
other mediators are released or inhibited via its effect on protein synthesis and 
exocytosis. 
 
1.4.8. The Urothelium in Bladder Disease  
As seen in the pathologies described in section 1.3 of this thesis, urothelial 
degeneration has significant implications on the physiology of the bladder. Disruption 
to the structural barrier function of the urothelium leaves the bladder wall prey to 
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toxic substances that may be present in the urine, due to infection. Conditions such as 
diabetes have been shown to affect urothelial proliferation, urothelial ultrastructure 
and permeability due to increased oxidative stress (Liu & Daneshgari 2006).   
The prevalence of bacteriuria and urinary tract infections is much higher in diabetic 
women compared to healthy individuals (Stapleton, 2002). This process is initiated by 
the colonization of the vaginal and periurethral epithelium and then ascension to the 
bladder or bacteraemia will occur. Type 1 fimbriated E. coli have a higher affinity for 
epithelial cells of diabetic patients – they bind to uroplakin proteins on the luminal 
surface of bladder and then invade the bladder wall (Geerlings et al., 2002). 
Internalization of the micro-organisms and formation of intracellular colonies in 
umbrella cells may be a pathway to chronic urinary tract infection (Schilling and 
Hultgren, 2002). 
Research by Lee et al (2004) into the changes in voiding caused by diabetes mellitus 
examined a sample of 356 women. 194 of these had diabetes mellitus and the 
remaining 162 were control patients. The results showed a significant increase in a 
number of behavioural changes in patients with diabetes; increased nocturia, 
increased residual urine volume (of 100ml or greater) were amongst these and 
decreased maximal flow rates.  
In light of the urothelium’s sensory role (section 1.3), it is not only disruption of the 
physical barrier that is affected in urothelial damage but also signalling. Cell-to-cell 
communication, described in section 1.2.2, allows cells within a layer and between 
layers to exchange chemicals and electrical impulses. This also occurs in the 
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urothelium, allowing the urothelium to detect chemical or mechanical stimuli and for 
the signalling cascade to be transferred in the urothelium and across the bladder wall. 
This is also true for noxious stimuli, as mentioned in section 1.3.2 on purinergic 
signalling. Birder et al (2013) in a review of the ‘Nervous network for lower urinary 
tract function’, postulates the idea that the urothelium amplifies the sensory signal it 
detects, on itself in an autocrine manner as well as onto the other layers of the 
bladder, and that this is enhanced in pathological conditions leading to tissue damage 
and deterioration. Based on this hypothesis, the enhanced signal transduction should 
result in elevated contractions of the urinary bladder wall and may provide aetiology 
for bladder related disease.  
The discovery of some pivotal roles of the urothelium in maintaining bladder 
physiology has led to further insight into its role in pathophysiology.  However, there 
are still many questions outstanding on the action of the urothelium in pathological 
conditions and its response to inflammatory factors. In this body of research, I will 
examine the response of the urothelium to inflammatory mediators in both 
physiological and pathological conditions.   
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1.5. Angiotensin II  
 
1.5.1. An Overview  
Angiotensin II is a key mediator involved in inflammation. It is, commonly known for 
its function in the cardiovascular system, is a vasoactive octapeptide chain and a 
trophic factor. Its precursor molecule, angiotensinogen is synthesised in the liver, 
cleaved by renin (a protease) to angiotensin I and then subsequently converted to 
angiotensin II in the lungs (Palmer et al. 1997). Angiotensin II can bind to one of two 
main subtypes of receptors; AT1 and AT2 (Mukoyama et al. 1993). Not much is 
understood about the functions of AT2, this report will focus on the action of AT1.  
1.5.2. Angiotensin II 
There are five main signal transduction effectors/pathways coupled to AT1; 
phospholipase A2, phospholipase C, phospholipase D, L-type Ca
2+ channels and 
inhibition of adenylate cyclase. AT1 activation can initiate a number of pathways. Its 
action can be mediated by phospholipase A2 catalysing the release of free fatty acid - 
arachidonic acid and its derivative metabolites that result in vascular tone and 
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidation. Phospholipase C 
activation by AT1 results in increased Ca
2+ concentrations and a triggering of protein 
kinase C (PKC), due to the hydrolysis of phosphatidylinositol 4, 5-bisphosphate to 
inositol trisphosphate and diacylglycerol. The hydrolysis of phosphatidylcholine to 
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choline and phosphatidic acid by phospholipase D culminates in sustained muscle 
contraction via PKC activation. Additional increases in cytosolic Ca2+ concentrations 
can occur via L-type Ca2+ channels or IP3 mediated release from the sarcoplasmic 
reticulum (Mehta & Griendling 2006). Lastly, inhibition of adenylate cyclase inhibits 
the production of cAMP (cyclic adenosine monophosphate) thus causing 
vasoconstriction.  
1.5.3. AT1 Receptor Expression  
The AT1 receptor is expressed in many organs throughout the body including the 
heart, kidneys, reproductive organs and adrenal glands (Comiter & Phull 2012; 
Nguyen et al. 2000). It has been well established within the smooth muscle cells of 
vasculature where it has been shown to stimulate vasoconstriction, modulate blood 
pressure and promote hypertrophy (Cho et al. 2012; Comiter & Phull 2012). Thus the 
use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers has 
proven to be effective against atherosclerosis, hypertension and heart failure (Mehta 
& Griendling 2006).  
1.5.4. Angiotensin II and the Bladder  
Increasing reports have been made regarding the role of angiotensin II and AT1 in 
urinary bladder pathology. Investigations from Cheng et al (1999) hypothesised that 
obstruction in the bladder caused cellular stretches that led to increased angiotensin 
release. The downstream effects of angiotensin II release seen in bladder obstruction 
models were smooth muscle hypertrophy (Cheng et al. 1999). The mechanism of this 
increased smooth muscle cell growth and collagen production are unknown. Weaver-
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Osterholtz et al. (1996) administered bolus infusions of angiotensin I, saline and 
angiotensin converting enzyme inhibitors – enalaprilat and ramiprilat to healthy male 
rats. The results demonstrated a significant increase in angiotensin II in the bladder 
tissue, much more so than circulation, following the infusion of angiotensin I. 
therefore we know that angiotensin I was successfully being converted to angiotensin 
II in the bladder tissue. Additionally, angiotensin II significantly decreased following 
the introduction of angiotensin converting enzyme inhibitor ramiprilat; but there was 
no change seen with enalaprilat.  
The presence of the AT1 receptor has been identified in the detrusor smooth muscle 
layer (Comiter & Phull 2012) and angiotensin II has been revealed to mediate smooth 
muscle contraction. Angiotensin II has also been linked to bladder outlet obstruction; 
it is thought that this disorder may mirror that of arterial hypertension (Cho et al. 
2012). Investigations reveal the expression of AT1 increases in models of bladder 
outlet obstruction in rats, both in the detrusor layer and the urothelium using western 
blotting (Cho et al. 2012). This has also shown to be markedly down regulated by the 
specific AT1 receptor blocker telmisartan. Other bladder disorders that may be 
potentiated by angiotensin II include neurogenic bladder and interstitial cystitis.  
In support of this, work by Comiter et al (2012), showed that the use of losartan (an 
AT1R antagonist) was able to partially prohibit the urodynamic and structural changes 
that are associated with bladder outlet obstruction in mice models. Additionally, 
Rahmos-Filho et al. 2013, after chronically treating ovariectomised oestrogen 
deficient rats saw a significant decrease in urinary frequency. This is suggestive of a 
possible role between angiotensin II and oestrogen in female models. An identified 
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correlation between these two components, could provide breakthrough discoveries 
and treatments for women who suffer with bladder over-activity. Although work by 
Rahmos-Filho et al. (2013), demonstrated decreased urine frequency, it did not reveal 
changes to bladder contractions. Changes to urethral contractions were shown, and a 
2.6 fold increase in the activity of angiotensin converting enzyme was seen in urethral 
tissue. But no data is shown for bladder tissue.  
In addition to the identification of the AT1 receptor in the bladder, the presence of the 
ligand angiotensin II has also been highlighted in the urinary bladder. Inhibition 
studies by Lindberg et al (1994) discovered that the important conversion of 
angiotensin I to angiotensin II in the urinary bladder was not dependent upon ACE 
inhibition. Investigations by Waldec et al (1997), used a novel, manufactured human 
chymase inhibitor and substrate to demonstrate the presence of this enzyme in 
isolated human detrusor layers. The presence of this serine protease, chymase, partly 
responsible for the formation of angiotensin II provides further evidence for the 
presence of angiotensin II in the smooth muscle (Waldec et al. 1997).  
An interesting study by Mori et al. (2015), looked into the effect of the expression of 
both AT1 receptor and AT2 receptor on bladder activity in ageing rats. The results of 
their research, demonstrated that an upregulation in the expression of AT1 receptor 
caused a marked increase in bladder activity. Also seen alongside this result, is 
impaired voiding (Mori et al. 2015). This is suggestive that angiotensin II has 
negative effects on bladder physiology and may play a role in bladder 
pathophysiology. The expression of AT2 receptor in this investigation was thought to 
suppress the action of AT1 receptor (Mori et al. 2015). However the suppression of 
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AT1 receptor, although seen, was not significant; and may be due the action of AT1 
receptor being much greater and overshadowing that of the AT2 receptor.  
Although some investigations have been carried out into the presence of angiotensin 
II and AT1 in the bladder, their presence in the urothelium is yet to be fully 
established in physiological conditions. Further evidence is also required to show the 
functional role of angiotensin II in the bladder as whole, especially in the urothelium-
mediated function under normal physiological conditions. This report will investigate 
the evidence for the presence of AT1 receptors in the urothelium layer specifically, 
and demonstrate its role in mediating ATP release and contraction.  
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1.6. Reactive Oxygen species  
1.6.1. An Overview  
Reactive oxygen species (ROS) are free radicals produced during metabolism in the 
body. They include molecules such as peroxide, superoxide, hydroxyl radicals and 
singlet oxygen molecules. The production and release of ROS in cells is not 
completely unwanted as there are benefits to the presence of ROS. Although large 
increases contribute to oxidative stress and pathological damage; it is thought that low 
levels of ROS production by non-phagocytic cells may play a role as second 
messengers in cell signalling (Li & Shah 2003). Oxidative stress is referred to as the 
state in which there is increased concentration of free radicals that results in cellular 
damage (Yu & Chung 2006). Oxidative stress can be due to either increased 
production or decreased antioxidant activity. Under normal homeostatic conditions 
the rate of oxidative activity is equal to the rate of antioxidant action, thus creating 
equilibrium. Disturbances to the oxidant/antioxidant equilibrium can tilt the oxidative 
stress status of a cell in either direction (Li & Shah 2003; Yu & Chung 2006). If the 
rate of oxidative action is greater than antioxidant activity, the cell can be said to be in 
an ‘oxidative stress state’.  
 
1.6.2. Sources of Reactive Oxygen Species  
 
There are two main categories in the identification of in vivo ROS production; 
organelle associated ROS production and enzyme induced ROS release (Krumova & 
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Cosa 2016). Organelle associated ROS production involves the peroxisomes, 
mitochondria and endoplasmic reticulum. In peroxisomes, the supply of hydrogen 
peroxide is produced by the presence of enzymes such as glycolate oxidase, urate 
oxidase and fatty acyl-coA oxidase (Fransen et al. 2012). Hydrogen peroxide in the 
peroxisomes is utilised in the β-oxidation of lipids as well as detoxifying substances 
such as ethanol in liver peroxisomes (Krumova & Cosa 2016). Similarly the 
mitochondria also play a vital role in ROS production as oxygen acts as the final 
electron acceptor in oxidative phosphorylation. In this circumstance, ROS can act as a 
by-product of phosphorylation, although the presence of superoxide dismutase (SOD) 
keeps this at a low level (St-Pierre et al. 2002). Lastly, the organelle endoplasmic 
reticulum is involved in ROS production. Its role in lipid and protein remodelling 
physiologically means that it contains enzymes that are able to oxidize fatty acids and 
proteins (Krumova & Cosa 2016). Thus these enzymes, such as cytochrome P-450, 
are able to reduce oxygen to superoxide and hydrogen peroxide.  
Furthermore, non-organelle associated enzymes can also produce ROS. These 
enzymes include lipoxygenase, xanthine oxidase, NO synthase, cyclooxygenase and 
nicotinamide adenine dinucleotide phosphate (Sharma et al. 2012).  
 
1.6.3. Nicotinamide Adenine Dinucleotide Phosphate  
A major source of ROS is from the reaction mediated by the NADPH oxidase (NOX) 
complex. It was originally discovered in neutrophils; however non phagocytic 
analogues have been identified (Li & Shah 2003). The non-phagocytic NOX enzyme 
is membrane associated, with cytosolic subunits that translocate when activation is 
occurring. The membrane-associated unit is comprised of phagocyte oxidase 22 
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(p22phox) and gp91phox that collectively form cytochrome b558. The heterodimer 
cytochrome b558 is the catalytic core of the NOX enzyme (Groemping & Rittinger 
2005) but on its own, remains in a dormant state. p22phox is also known as the α 
subunit and consists of 195 amino acids with a molecular mass of 21.0kDa 
(Groemping & Rittinger 2005).The structure of this subunit is thought to be three 
transmembrane α-helices at its N-terminal and a proline rich region at its C-terminus 
(Faust et al. 1995).  
Gp91phox, the other component of cytochrome b558, is known as the β subunit. Its 
structure constitutes 570 amino acids, which is six times the size of the α -subunit 
p22phox. As expected, the molecular mass of the β-subunit is larger – at 65.3kDa. 
Similarly to p22phox, the N-terminal consists of transmembrane α-helices; however, 
gp91phox has 6 α-helices and a C-terminal cytoplasmic domain (Groemping & 
Rittinger 2005). This cytoplasmic domain is used to bind Flavin Adenine 
Dinucleotide (FAD) and NADPH. gp91phox is involved in the electron transfer ability 
of cytochrome b558 and contains all the co-factors essential for this. There are two 
main steps for the electron transfer; electrons are passed from NADPH to FAD, then 
subsequently to a haem group that will reduce oxygen (O2) to superoxide (O2
-) 
(Rastogi et al. 2016).  
During the dormant state, regulatory proteins are situated in the cytosol of the cell. 
One of these cytosolic subunits is Rac1, which belongs to the Rho-family of small 
GTPases. Its structure consists of six β-sheets and five α-helices; these GTPases 
function as molecular switches (Rastogi et al. 2016). This is reflected in its structure 
which contains two switch regions; switch I and switch II (Groemping & Rittinger 
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2005). It has now been established that the presence of Rac1 is essential for the 
oxidase activity of NOX. They are also able to act as docking stations for GTPase-
binding proteins, due to their switch regions being recognised by regulatory proteins 
such as GDP Dissociation Inhibitors (GDIs) (Rastogi et al. 2016).  
Other cytosolic subunits include p47phox, p67phox and p40phox. p47phox is made up of a 
Phox homology region, SH3 domains, a polybasic region and a PPR region 
(pentatricopeptide region). The Phox homology region is thought to contribute to 
anchoring the p47phox once activation induced translocation has occurred. p47phox is 
also thought to interact with the cytoskeletal protein actin to regulate NADPH activity 
(Tamura et al. 2006). p67phox is a larger protein that has a TPR (tetratricopeptide 
repeat) motif containing domain that interacts with Rac1 in a GTP dependent manner 
(Groemping & Rittinger 2005). The p67phox subunit also has PRR and SH3 domains 
similarly to p47phox. Functionally, it binds with p40phox to form a heterodimer, 
contains an activation domain required for superoxide production and associates with 
cytochrome b558 to regulate electron transfer (Hasebe et al. 1999). p40
phox was the last 
cytosolic subunit to be identified; it constitutes of a PX domain (phosphoinositide 
binding domain), a SH3 domain and a PB1 domain (a protein binding domain) (Hasebe 
et al. 1999). This PB1 domain is thought to interact with p67
phox, whereas its SH3 
domain interacts with the PRR in p47phox (El-Benna et al. 2009). The physiological 
relevance of its interactions with the other two subunits is not yet known.  
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1.6.4. The Physiological Role of Nicotinamide Adenine 
Dinucleotide Phosphate in the Bladder  
There is rising evidence for the link between oxidative stress and bladder pathology. 
The accumulation of ROS leading to oxidative stress has been shown to cause 
structural changes to the bladder (Perše 2013). Therefore, further studies may reveal 
the mechanisms by which this occur and provide more insight into pathological 
conditions. The expression of a large variety of receptors in the bladder wall involved 
in oxidative stress further supports this, receptors such as neurokinin receptor type 1 
that responds to substance P. Studies by Chen et al (2004) have shown that substance 
P can mediate oxidative stress in the bladder via neurokinin receptors on afferent 
neuron. Additionally, substances known to cause oxidative stress in other areas of the 
body can be seen to play a role in oxidative stress in the bladder. For example, 
angiotensin II, a NOX activator shown in vascular tissue, is also involved in bladder 
outlet obstruction. Work using antagonist losartan showed partial inhibition of the 
detrusor muscle changes in comparison to those seen in untreated mice bladders 
(Comiter & Phull 2012). In support of this work, antagonist telmisartan was able to 
significantly reduce AT1 expression in patients with bladder outlet obstruction (Cho et 
al. 2012). This new area of research requires further insight into the mechanisms 
involved in oxidative stress induced bladder pathologies and the role of NOX in 
mediating this.  
The first report to show the link between ROS generation and urothelial carcinoma 
was hat of Shimada et al. (2011). In this body of work, they assessed the correlation 
between NOX4 isoform and carcinogenesis of the bladder. Using flow cytometry to 
detect ROS, their results showed that silencing the NOX4 gene lead to a significant 
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decrease in cancer cell growth in urothelial cell lines (Shimada et al. 2011). Thus 
suggesting that NOX4 expression plays a role in carcinogenesis. Whether this is true 
for the other NOX isoforms is not addressed but the evidence for NOX4 adds to our 
knowledge of the role of ROS in mediating pathology. 
Miyata et al. 2017, reviewed literature to see the evidence of NOX isoforms in 
bladder carcinomas. The research identified that NOX mediated ROS played a role in 
stimulating pro-oncogenes such as Src and Ras (Miyata et al. 2017). Furthermore, 
NOX1 was seen to be highly expressed in progressive urological cancers (Shimada et 
al. 2009). This points towards the role of NOX1 in promoting tumour development 
and apoptosis resistance (Miyata et al. 2017). However, the data for NOX2 is 
inconsistent in its conclusions (Shimada et al. 2012). There is a possibility that it is 
also associated with urological carcinogenesis but the evidence is not conclusive for 
this.  
In the urothelium specifically, Perse. 2013, looked at the effect of ageing and 
oxidative stress on bladder pathophysiology. In this investigation, young models (2 
months) were compared to ageing models (20months); and the level of oxidant and 
antioxidant activity examined. Their results show that the urothelium has powerful 
antioxidant activity (Perse. 2013); making it robust against toxic assault. However, in 
ageing models the antioxidant activity was significantly reduced. This key 
observation, gives insight into the effect of age on the antioxidant activity of the 
bladder, and is suggestive that the bladder is less able to defend against oxidative 
assault over time. Additionally increased oxidative stress markers were seen in the 
ageing models in comparison to the young models (Perse. 2013) 
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Angiotensin II has been shown to interact closely with NOX (Griendling et al. 1994), 
resulting in the release of reactive oxygen species - such as superoxide anion and 
hydrogen peroxide. This interaction between angiotensin II and NOX occurs in a 
feed-forward pattern. It has been shown that angiotensin II regulates NOX; this in 
turn releases ROS, which regulates the expression and activation of AT1R (Nguyen 
Dinh Cat et al. 2013a; Nishida et al. 2011). Additionally, angiotensin II is associated 
with NOX1, NOX2, NOX5 and possibly NOX4 in vasculature (Nguyen Dinh Cat et 
al. 2013b).  
The effect of angiotensin II on NOX activity has not been previously studied. This 
thesis will be the first to investigate the role of angiotensin II in the urothelium of the 
urinary bladder. This investigation will highlight the effect of angiotensin II on NOX-
mediated ROS production in bladder function, in particular in urothelial function. 
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SUMMARY  
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In the literature review provided in this chapter, an overview of the current knowledge 
on bladder physiology is described. An examination of the bladder layers, an in depth 
look at the sensory role of the urothelium, the neuronal pathways that lead to 
micturition, bladder disorders that can occur and some of the inflammatory mediators 
that have been highlighted in the bladder.  
 
 
 
 
 
 
 
 
Figure 7. Current knowledge of ATP release 
A schematic of current knowledge on the action of Angiotensin II and NADPH 
oxidase in the bladder. Roles for both substances have been highlighted in the smooth 
muscle layer but many questions still remain unanswered.  
Various mediators  
Urothelium  
Smooth muscle  
NOX 1/NOX2?/NOX4 
ATP  ATP  
ATP  
ATP  
Angiotensin ROS  
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In figure, a schematic is contrasted to show the current knowledge of the action f 
angiotensin II and ROS in the bladder. It must be taken into consideration that the 
action of angiotensin II has been elucidated for bladder outlet obstruction models and 
the action of ROS and NOX is mainly highlighted in cancer cell lines or models. This 
is not a representation of physiological action for either of these mediators in the 
bladder, as that is not yet known.  
Figure 7 shows the role of ATP in potentiating further ATP release from the bladder. 
Currently we know that ATP is a major signalling molecule for the bladder and works 
as an indicator of bladder activity. We also know that Angiotensin II has been shown 
to have an effect on pathological models of the bladder in the detrusor smooth muscle 
layer specifically. However no data has been presented for the presence of angiotensin 
II in the urothelium. Similarly with NADPH oxidase, there is some evidence of its 
action in the bladder but no specific data in relation to the urothelium. The aims of 
this body of research is to bring to light whether the action and mechanism of 
angiotensin II extends to the urothelium in physiological as well as pathological 
conditions. I will aim to explore how this affects ATP release, thus bladder activity 
and also whether the mechanism of angiotensin II, somehow crosses paths with ROS 
and is able to enhance this.  
 
 
 
 79 
 
 
 
 
 
 
AIMS & 
HYPOTHESIS  
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The urinary bladder has been under-researched in comparison to other organs of the 
body. Despite this, much progress has been made in recent years to improve our 
understanding of bladder physiology. The discovery of the sensory function of the 
urothelium has propelled our understanding of the bladder’s mechanosensitive ability 
as well the discovery of more receptors that have functional significance in the 
bladder.  
This is crucial as the number of people affected by bladder disorders is thought to be 
even higher than current statistic. As discussed in section 1.6, due to the social stigma 
associated with bladder disorders cases are largely under reported; as well as being 
associated with many other disorders as a secondary condition, such as trips and falls.  
Current drug therapies are insufficient in treating bladder pathologies, with many 
patients no longer taking treatment after 6 months. Therefore new therapeutic targets 
and approaches are needed.  
The urothelium has been of special interest in recent studies due to the discovery of 
many neurotransmitters that are released from it and the diverse number of receptors 
on it. This thesis aims to provide a novel investigation into the presence of 
angiotensin II in the urothelium of the urinary bladder and to determine the potential 
functional significance. I aim to explore further the possible effect of angiotensin on 
NOX mediated ROS production.  
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In order to achieve the proposed aims of this research, that may provide the first 
evidence for the action of angiotensin II in the urothelium and a possible association 
with NOX, I have carefully examined the project objectives. I have set out to first 
establish the health and vitality of the samples used by conducting histological 
analysis on bladder tissue sections. The identification of cell structures and nucleus 
will allow us to ascertain whether the sample models used are suitable for further 
investigation.  
Following from this, I will look at the presence of angiotensin II in the urothelium by 
exploring the presence of angiotensin II receptor AT1, a good indication of 
angiotensin II in the urothelium. Utilising the primary purpose of immunostaining, I 
will stain the urothelium and observe whether AT1 is present and its specific 
localisation.  
Subsequently, I aim to explore the potential functional significance of AT1 in the 
urothelium. The parameters of this objective will be restricted to the effect of 
angiotensin II and other drug interventions on ATP release and the amplitude of 
muscle contraction, where ATP release and muscle contraction are used as indicators 
of bladder activity (Fry et al. 1999; Sui et al. 2014; Wu et al. 2011).  
Lastly, we will examine the possible link of angiotensin II to ROS and its pathway. 
As stated in section 1.9.4, Griendling et al (1994), has already highlighted the ability 
of angiotensin II to stimulate ROS in vascular smooth muscle cells and work by 
Nguyen Dinh Cat et al. (2013b) shows an association between angiotensin II and 
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NOX in vasculature. However, research has yet to demonstrate such an association in 
the urothelium of the bladder. Therefore our objective is to answer the question ‘does 
angiotensin II have a positive association with NOX in the urothelium of the urinary 
bladder?’ In order to do this, we aim to use a combination of staining and functional 
methods.  
In this study, I hypothesise that the potent inflammatory peptide, angiotensin II, is 
present and functionally significant to urothelial physiology. I aim to highlight the 
presence of the AT1 receptor in the bladder wall and the urothelium layer specifically. 
I propose, based on the effects of angiotensin II in other organs of the body (described 
clearly in section 1.8), that angiotensin II will have functional significance in the 
urinary bladder and be able to directly affect bladder contraction.  
Furthermore, I hypothesise that angiotensin II will mediate its action on bladder 
contraction via NOX. Similarly to the action of angiotensin II in the vasculature and 
other endothelial cells, we propose that angiotensin II and NOX work together to 
regulate bladder contraction.  
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CHAPTER 2 
METHODS  
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2.1. Manufacturers, Materials & Reagents  
Figure 8 presents a comprehensive list of manufacturers, of all materials described: 
Figure 8. A collection of all manufacturers and their corresponding addresses 
Manufacturer Address 
Abcam Abcam, Cambridge, UK  
Calbiochem, Merck Millipore Merck Millipore, Hertfordshire, UK 
Invitrogen, Fisher Thermo Fisher Scientific, Massachusetts, 
USA  
Sigma  Sigma-Aldrich Corporation, Missouri, USA 
VWR VWR, Leicestershire, UK  
Techne  Bibby Scientific Ltd, Staffordshire, UK  
The Jackson Laboratory  The Jackson Laboratory, Maine, USA  
Carl Zeiss AG Carl Zeiss AG, Oberkochen, Germany  
Sonics & Materials Inc. Sonics & Materials Inc, Connecticut, USA  
Life Technologies  Life Technologies, California, USA 
BMG Labtech  BMG Labtech, Ortenberg, Germany  
Leica Biosystems Leica Biosystems, Milton Keynes, UK 
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A comprehensive list of all materials and reagents used for this study is collated and 
tabulated below in Figure 9.  
Figure 9. A charted list of all materials and reagents used 
Reagent  Manufacturer  
2-Guandine-4-
methyluquinazoline 
(ASIC 3 ligand)  
Sigma  
Apocynin (NADPH 
Oxidase inhibitor)  
Sigma  
Bovine Serum Albumin  Fisher  
Brefeldin A Sigma  
Carbenoxolone 
Disodium Salt  
Sigma  
Sodium Pyruvate Fisher  
pH Standards (7 and 
10) 
Sigma  
Potassium Chloride  Fisher  
Magnesium Chloride  Fisher  
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Sodium Hydrogen 
Phosphate  
Sigma  
ATP mix  Sigma 
ATP buffer Sigma 
Reverse osmosis water Mili Q 
Immersion oil  Sigma 
Nicotinamide Adenine 
DiPhosphate (NADPH) 
Sigma 
Dihydroethidium stain  Sigma 
HEPES-free acid Calbiochem  
Sodium Chloride Invitrogen, Fisher 
Glucose Anhydrous VWR 
Ethylene Glycol-bis (2-
aminoethylether) – 
NNN’N’-Tetraacetic 
Acid  
Sigma 
Nail Polish Superdrug  
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Tiron  Sigma 
Dimethyl Sulfoxide  Sigma 
Prolong Gold Fisher  
AT1 receptor antibody Sigma 
NOX1, NOX2, NOX4, 
NOX5 antibody 
Sigma 
Clarke’s fluid Leica Biosystems 
100% Methanol Leica Biosystems  
Isopentane  Leica Biosystems  
Hydrogen peroxide VWR 
Phosphate buffered 
saline (PBS)  
Sigma 
Angiotensin II in 1% 
PBS 
Sigma  
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2.2. Urinary Bladder Tissue Preparation  
2.2.1. Animal Model – Guinea pigs  
All animals used in this study, were euthanized with a schedule 1 procedure, 
specifically the use of rising CO2. All animal-related procedures within the study were 
performed in accordance with The Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012.  
Wild type Dunkin Hartley guinea pigs were used. They were selected as a suitable 
model for bladder physiology, because their physiology is well studied and similar to 
that of human bladders. Based on the work done by Dr Herrera, the phasic 
contractions in the guinea pig detrusor resemble that of the spontaneous contractions 
seen in the human detrusor (Herrera et al. 2000). In addition, the ability of nifedipine 
to block detrusor muscle action potentials in guinea pigs suggests that they also 
generate action potentials via L-type Ca2+ channels (Mostwin 1985). The exploration 
of the electrophysiological properties of guinea pig bladders by Isenberg et al. 
supports the evidence presented by Mostwin et al., the guinea pig bladder possesses 
L-type Ca2+ channels and mimic action potential firing seen in humans (Montgomery 
& Fry 1992; Klockner & Isenberg 1985), therefore leading to the suggestion that their 
electrophysiology are similar. Likewise, investigations into the contractility 
parameters of the guinea pig revealed that the power generated by its bladder is 
similar to that of the human bladder (Groen & Bosch 2004). The animals used were 
either young (2 – 6 months) or ageing (18 - 24 months). Body mass was within the 
range of 550g – 650g in weight for the young models and 1 - 1.5kg for the ageing 
guinea pigs.  
 89 
 
2.2.2. Animal Model – Mice  
The use of mice as a model for urinary bladder physiology and pathophysiology has 
been well established for many years (Parsons & Drake n.d.; Kobayashi et al. 2014; 
Bassuk et al. 2000). In order to achieve the principal aim of elucidating the role of 
angiotensin II in the bladder and the potential mediation via NOX isoforms, mice 
models were important for a number of reasons. Firstly, physiologically there are 
many similarities that have been identified between the mouse bladder and the human 
bladder that make it a suitable model for investigation. The actin filaments that are a 
major contributor to smooth muscle contraction have a similar constitution in both 
mice and human bladders. Evidence provided by Malmqvist et al (1991) & Matthew 
et al (2000), show that the α-, β- and γ- subunits are expressed in the following ratio 
respectively in humans 33: 25: 42%, and 44: 10: 46% in mice. Although there are 
minor differences in the composition between mice and humans, actin filaments are 
highly conserved genes with high levels of homology (Andersson & Arner 
2004)(Andersson & Anders, 2004) therefore this strengthens the idea that mice and 
human urinary bladders have some level of homology.  
The mice used within this investigation were obtained from The Jackson Laboratory. 
Male black wild type C57BL/6J mice were kept in accordance with the housing 
conditions stated in Figure 10 below. At the University of Surrey, wild type and 
NADPH oxidase 2 knockout mice, in C57BL/6J background mice, were bred from 
heterozygotes by Prof Li’s group, as previously described in Li et al (2013), which 
were from Jackson Laboratory (Jackson Laboratory, mouse strain C57BL/6J, stock 
number: 000664, black).  Knockout models were genotyped by PCR amplification, 
followed by gel electrophoresis separation, for confirmation of gene deletion (Li et al, 
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2013). Sharing of animal tissue reduced the number of total animals required, making 
the study resource efficient in accordance with the principle of 3Rs in animal 
research: - replace, reduce, refine (Russell & Burch 1958). The knockout mice were 
kept in sterile cages. Food and bedding were irradiated and water autoclaved, to 
reduce the risk of infection.  
Figure 10. Animal-housing conditions for guinea pigs and mice models 
 Conditions 
Temperature 18 - 23°C 
Humidity 45 - 55% 
Light: Dark Cycle 12:12 hour (beginning at 7am) 
Food and Water Available ad libitum  
Diet Composition  
(Normal Chow Diet) 
9.3% kcal fat, 25.9% kcal protein, and 
64.8% kcal carbohydrate 
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2.2.3. Urinary Bladder Tissue Collection  
The culled animal was placed on its back. A superficial incision through the skin was 
made from the vulva to the mid area of the abdomen. A second incision opened up the 
skeletal muscle under the skin to expose the organs of the lower abdomen. The 
bladder is balloon shaped organ situated in pelvic region. Once the bladder was 
identified, the bladder was held at the top of the dome whilst the bladder was 
dissected from the animal at the bladder neck. The bladder was placed in a labelled 
eppendorf filled with HEPES-buffered Tyrodes solution (Figure 11) and kept on ice 
(for 3-4mins) whilst being transported to the laboratory for use or storage.  
HEPES-buffered Tyrodes was used to transport and store the urinary bladder tissue. It 
was also used as physiological solution to perfuse the bladder tissue when carrying 
out tension experiments. This solution is able to mimic the extracellular environment 
of mammalian tissue. HEPES-buffered Tyrodes acts as a pH buffer. It’s ability to 
resist dissociation with decreases in temperature; helps maintain a stable extracellular 
matrix.  
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Figure 11. HEPES-buffered Tyrodes solution composition 
 Concentration  
NaCl 132mM 
HEPES 10mM 
KCL 4mM 
MgCl2.6H2O 1mM 
NaH2PO4.2H2O 0.4mM 
CaCl2.6H2O 1.8mM 
Glucose 6.1mM 
Sodium Pyruvate 5mM 
NaOH 1M 
Final pH 7.4 
 
2.2.4. Urinary Bladder Tissue Freezing  
Frozen strips of full thickness layered bladder wall were required for imaging 
techniques and superoxide detection with Chemiluminescence. To do this, the bladder 
(kept in HEPES-buffered Tyrodes) was placed under a light microscope and an 
incision made from the bladder neck to the tip of the bladder dome. This opened up 
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the bladder, exposing the luminal side of the bladder wall. Excess HEPES-buffered 
Tyrodes solution was removed by dabbing the bladder strip on tissue paper briefly 
before freezing. The longitudinal bladder strips were cut and snap frozen in liquid 
nitrogen.  
Strips of full thickness bladder tissue were embedded in Optical Cutting Temperature 
(OCT) compound. This was so that the tissue could be positioned, to expose the cross 
section of layers of the bladder wall. OCT is made of water-soluble glycols and 
resins; used for histological analysis of tissue. The embedded strips in OCT were then 
snap frozen in liquid nitrogen, in order to solidify the gelatinous nature of the OCT 
medium. The use of liquid nitrogen allowed the medium to set quickly around the 
tissue and also provided easy transportation and storage of the tissue. Samples were 
stored at -80oC until used. 
 
2.2.5. Urinary Bladder Tissue Homogenisation & Sonication  
Some of the frozen animal tissue was broken down further by crushing, 
homogenisation and sonication. Firstly, the pestle and mortar were wrapped in foil 
separately and placed in a -80°C freezer for 1 hour to make it cold. Secondly, the 
frozen sample of bladder tissue was crushed in the cold mortar with liquid nitrogen, 
until it reached a powder-like consistency. Each crushed sample was then transferred 
into a labelled cryo-tube and 200µl of Hank’s Balance solution added to crushed mice 
or guinea pig samples respectively, regardless of its tissue mass. The tissue sample 
was homogenised (Polytron system PT1200 E, Kinematica Ag) for 3 minutes on ice. 
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This process was followed by sonication (Vibra Cell - Ultrasonic Processor, Sonics & 
Materials Inc.) for 30secs on the pulsed setting in a 4°C cold room.  
Homogenisation and sonication were used in this particular study, to break down 
bladder cell membranes, expose cytoplasmic contents and thus make it easier to target 
cytoplasmic or nuclear molecules. Homogenisation uses mechanical force, whilst 
sonication uses sound energy to agitate particles in a sample.  
 
2.2.6. Urinary Bladder Tissue Cryo-sectioning 
Cryo-sectioning is a method used to produce thin slices of a cross-section of tissue 
and is normally a prerequisite to staining methods. It is preferred to other embedding 
methods due to the preservation of antigenicity in the tissue (Fischer, 2008). In this 
study, this method was used prior to immunofluorescence staining. 
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Figure 12. Cryo-sectioning 
Pictures the Hyrax C cryostat (Carl Zeiss); which was used in this investigation to 
produce 18um thin urinary bladder sections. In the picture above, key parts of the 
cryo-sectioning apparatus are highlighted for reference in the text below. A. Cryostat 
dashboard, B. Microtome, C. Metal mound, D. Cryostat stage with blade and glass 
cover.  
Firstly, 76 x 26mm super-frosted slides were placed in polylysine solution at room 
temperature for 1hour, and then dried under a fan. The coating of microscopic slides 
in polylysine, promotes the adherence of tissue to the slide. The cryostat (Hyrax C, 
D. Cryostat stage 
with blade and 
glass cover  
C. Metal mound 
B. Microtome 
A. Cryostat dashboard  
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Carl Zeiss) was set to -22°C, 18µm thickness, the light for the microtome area 
switched on and the blade placed securely in the blade holder. The samples already 
snap frozen in OCT compound and stored at -80°C (method previously detailed in 
section 2.3.3), were transported to the cryostat using liquid nitrogen to prevent tissue 
degradation. Once the samples were safely removed from the liquid nitrogen, they 
were attached to the metal mounds using OCT compound and tightly locked into the 
microtome. The microtome, holding the tissue sample, moved up and down against 
the blade to produce 18µm thick slice of full thickness bladder wall sections found 
between the blade and the glass cover. Usable sections were picked up on the frosted 
side of, polylysine coated microscope slides kept at room temperature. The slides 
were placed in a slide holder and transferred on ice to the -80°C freezer, where they 
were stored until required. 
 
2.3. Imaging Techniques  
2.3.1. Haematoxylin & Eosin Stain  
The haematoxylin and eosin (H&E) stain is a regressive stain for the nucleus and 
cytoplasm respectively. This differential staining aids in elucidating the 
morphological and histo-pathological status of tissues. Haematoxylin’s basophilic 
nature causes it to bind to nucleic acids staining it blue whereas eosin is acidophilic 
and stains the cytoplasm a pink/red colour. Cryo-sections of thin slices of tissue 
sections attached to polylysine-coated slides are required for this method (refer to 
section 2.2.6 for method). 
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Figure 13. Haematoxylin & Eosin Stain  
Pictures a tray of reagents required for Haematoxylin and Eosin staining in a 
histology laboratory. The glass containers are numbered from depending on their 
contents and chronological order in their requisition to the stages of staining. 7. 
Haematoxylin stain 8. Water 9. 1% Acid Alcohol 10. Water 11. 1% Eosin stain 12. 
Water 13. 85% Ethanol 14. 100% Alcohol I 15. 100% Alcohol II 16. Xylene I 17. 
Xylene II.  
Slides should be placed in Clarke’s solution) in a Coplin jar for 10 minutes. Clarke’s 
solution constitutes 100% ethanol: acetic acid in a 3:1 ratio, respectively (Baker, 
1958). This solution promotes nuclear fixation and preservation of cytoplasmic 
elements and was used to enhance the probability of getting a good morphology. The 
slides were then transferred onto a slide rack and placed in Haematoxylin stain for 
12mins. Slides were transferred first onto a slide rack placed under a running tap for 
1min, then to 1% acid alcohol for differentiation for 10seconds. Following this, tissue 
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sections were positioned under running tap water for 10minutes, to rinse off unbound 
stain. The nuclei (stained blue) should be distinguishable from the cytoplasm. This 
can be checked within 1-2minutes of the 10minutes under the running tap, by 
observing the sections under a light microscope. At this stage, slides can be returned 
to the haematoxylin dye or 1% acid alcohol, if not cells are not adequately stained or 
differentiated, respectively.  
The staining of the cytoplasm is useful for the determination of healthy tissue 
morphology. A nuclear stain alone is not adequate to achieve this purpose. Sample 
slides were then placed in 1% eosin dye for 2minutes. Excess stain was washed off 
under a running tap briefly. The sample was then placed in glass containers 13 to 17 
consecutively for 0.5minutes each (displayed in figure 13); these containers contained 
85% ethanol, 100% Alcohol I, 100% Alcohol II, Xylene I and Xylene II respectively. 
Once this process was done, slides in xylene II were taken to a fume cupboard, where 
a drop of distyrene, plasticizer and xylene (DPX) mountant was added to the coverslip 
and then placed over the sample. It is a mountant that is used as a synthetic resin-
mounting medium. DPX promotes fast drying and stain preservation. Lastly, the 
edges of the coverslip were sealed with nail polish.  
 
2.3.2. Immunofluorescence Stain 
Immunofluorescence is a technique used to identify the presence and localization of 
specific proteins using antibodies. Primary antibodies are targeted against an epitope 
within the protein of specific interest; whereas secondary antibodies are raised against 
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the species of the primary antibody with a fluorophore molecule attached as a label 
for imaging.  
 
Figure 14. Immunofluorescence  
An illustration of the main principles of immunofluorescence, highlighting the central 
components involved. The principal mechanism is to identify a target protein (Protein 
X or Y) by using fluorescence labelled antibodies.  
For this method, 76 x 26 mm polylysine coated microscopic slides with cryo-sections 
of wild type full thickness bladder were prepared prior to staining. The slides were 
placed in a coplin jar filled with 100% Methanol (pre-chilled for 20minutes in a -80°C 
freezer) for 5minutes for fixation. Then slides were placed in coplin jars filled with 
1% Phosphate buffered saline (PBS) solution. Slides were allowed to soak for 5mins, 
and then in a swirling motion, slides were washed in 1% PBS solution three times. 
After allowing excess moisture on slides to air dry; a lipophilic pen was used to create 
hydrophobic zones around the samples, this aided the localisation of the antibodies to 
the sample area. Already prepared 1% BSA was applied to each sample (100μl); this 
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acted as a blocking agent to reduce non-specific binding. A humidity chamber was 
established by placing moist paper towels in a plastic tub with a closed lid at room 
temperature, to create a damp environment and prevent the tissue drying. Samples 
were then placed in a humidity chamber for 1 hour at room temperature.  
Following this, slides were washed again by soaking in 1% PBS for 5mins then 
washing in fresh 1% PBS, with gentle swirling. Primary antibodies were added to 
each sample (100μl) apart from the control sample which received 1% BSA (antibody 
dilutions displayed in Figure 14).   Samples are placed in the humidity chamber 
overnight at 4oC. Secondary antibodies were prepared and centrifuged (Biofuge, 
Fresco) at a speed of 9,520g, 4oC for 4minutes to reduce debris and provide a cleaner 
sample. The antibodies are light sensitive so the eppendorfs were wrapped in foil. 
100µl of secondary antibody was added to samples and placed in the humidity 
chamber for 1 hour at room temperature. The dilutions for the primary and secondary 
bodies were determined experimentally and also from the recommendations from the 
suppliers.  
Samples were finally washed once more in 1% PBS in the coplin jars and dried in air. 
Lastly, drops of prolong gold DAPI nuclear stain (also contained mounting medium) 
was added to the stained microscopic slide and a 22mm x 50mm cover slide is placed 
on top. This was to stop the section from drying out, protect the sample from debris or 
dirt and reduce the rate of fading from the dye. The slide and coverslip were sealed 
with nail polish around the edges.  
 101 
 
Figure 15.A list of the primary and secondary antibodies and their concentrations 
Antibody Concentration Species 
reactivity  
 
Angiotensin II receptor 1 
antibody – AT1 
1:100 Mouse, human  Sigma-aldrich 
SAB2500038 
NOX 1 antibody 1:100 Mouse, human, 
rat 
Sigma-aldrich 
SAB3500564 
NOX 2 antibody 1:100 Human  Sigma-aldrich 
SAB4200097 
Alexa 488 secondary 
antibody 
1:500  ABF278 
Alexa 568 secondary 
antibody  
1:500  SAB4600409 
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2.3.3. Dihydroethidium Stain  
Dihydroethidium (DHE) is an imaging technique for superoxide detection (Bindokas 
et al. 1996). This technique is based on the oxidation of hydroethidine. This cell 
permeable dye binds well to superoxide molecules found within the cell, which 
produces a detectable fluorescence. The product of this reaction is able to enter the 
nucleus of the cell and intercalate with DNA molecules (Owusu-Ansah et al. 2008). It 
was previously thought that the product formed from DHE binding to superoxide was 
ethidium; but further experimentation by Zhao et al (2005), revealed that the product 
is rather 2-Hydroxyethidium. The advantage of this method is that the dye is very 
specific in binding, the method is simple and cells are able to retain the dye well, thus 
providing a good indication of superoxide production (Owusu-Ansah et al. 2008). 
Tissue sections were snap frozen in OCT and cryo-sectioned onto 76 x 26mm super 
frosted polylysine coated slides. DHE stain solution (2µM) and DHE buffer solution 
were made according to the recipe in Table 2.5. Once made, the eppendorf containing 
DHE stain was wrapped in foil and kept at room temperature. However, the DHE 
buffer was kept in a 37oC warm cabinet. Using a foil-covered tray as an incubation 
chamber, moist paper towels were placed at the bottom to prevent the samples from 
drying out. A lipophilic pen was used to create a zone around the tissue, to aid with 
incubation in solution. 100µl of DHE buffer accurately and topically to each sample 
zone, covering the entire surface of each section. Samples were then equilibrated in 
the foil-covered tray at 37oC for 30minutes. Parallel sections were treated with Tiron 
(100mM) for 10 minutes post-equilibration in the DHE buffer. Tiron is a superoxide 
scavenger; Tiron-treated sections therefore acted as a primary control.  
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Figure 16.A comprehensive list of the constituents of Dihydroethidium stain and 
buffer solutions 
 Constituents 
DHE stain (2µM) 1µl of DHE stock (5mM) in 2ml of 
DHE buffer 
DHE buffer - Hanks balance salt 
solution (HBSS) with MgCl2 (50µM) 
10ml HBSS + 5µl MgCl2 
 
A confocal microscope (Nikon Confocal microscope) was used as the imaging tool 
for its high specificity and laser power (Excitation: 520nm, Emission: 605nm). Once 
equilibration occurred, the incubation chamber was placed on the bench side near the 
confocal. To the samples, 100µl of DHE stain was applied to each repeat of sample. 
The microscopic slides were immediately covered with a 22x50mm coverslip. 
Sections were viewed under the confocal microscope immediately and images 
captured through the x40 lens.  
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2.4. Bradford Assay  
The Bradford assay is fast, easy to use and a very common technique used to ascertain 
protein concentrations prior to techniques such as gel electrophoresis, where analysis 
is based on protein quantity (Bradford 1976). The principle of this assay is based on 
an acidic solution of Coomassie Brilliant Blue G-250. This acidic solution has been 
well established to shift in maximum absorbance, (from 465nm to 595nm), when 
proteins are bound. The distinctive colour change during protein binding can be 
quantified with a colorimeter. The absorbance level is directly proportional to the 
protein concentration.  
Firstly the Bradford reagent is made by, dissolving into 95% ethanol, 100mg of 
Coomassie Brilliant Blue G-250 (Sigma Aldrich). 100ml of 85% (w/v) phosphoric 
acid is then added, the solution made up to 1litre and stored at 4°C on the day of use, 
1ml of Bradford solution was pipetted into each eppendorf and an additional control 
solution used as background for the spectrophotometer.  
Secondly, in order to determine the protein concentration from the absorbance level, a 
standard curve of absorbance and protein concentration is constructed and the 
equation for the line deducted. Known concentrations of BSA protein (5µg, 10μg, 
25μg, 50μg, 75μg and 100μg) were prepared to a 100μl volume. The 
spectrophotometer was set to a wavelength of 595nm and the absorbance for each 
protein concentration recorded. These recorded values were plotted as a standard 
curve of absorbance against micrograms protein.  
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Lastly, the measurement was repeated on the spectrophotometer using the sample of 
interest and the unknown concentration detected using the standard curve.   
 
2.5. Reactive Oxygen Species Detection  
Reactive oxygen species produced from various sources in the bladder can be 
detected using the Chemiluminescence assay. This assay uses NADPH oxidase as a 
catalyst for production of reactive oxygen species.  
Figure 17.The composition and concentrations of all reagents used in the detection of 
reactive oxygen species in the urinary bladder 
 Concentration 
Sample Buffer MgCl2 (100mM), CaCl2 (1M), Hanks Balance 
Salt Solution (x1)  
Lucigenin Buffer MgCl2 (100mM), CaCl2 (1M), Hanks Balance 
Salt Solution (x1), Lucigenin 
NADPH Oxidase in Sample Buffer 0.0008mg NADPH in 1ml Sample Buffer 
Tiron  1M Tiron  
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Firstly, a strip of urinary bladder tissue (2-3mm in diameter) was crushed into a 
powdery consistency in liquid nitrogen. This breaks down the urinary bladder tissue 
to promote exposure of intracellular components. The sample was then further 
dissociated by homogenisation in 100ul of Hanks Balance Salt Solution for 3mins and 
followed by sonication in a 4°C cold room for 30seconds per sample (refer to section 
2.2.4.). The protein concentration in the sample is determined by Bradford protein 
assay, according to the protocol stated above in section 2.4.  
LUMIstar Galaxy (BMG Labtech) was the programming software for the 
chemiluminescence machine (LUMIstar Omega, BMG Labtech). Figure 2.5 displays 
screen projections that are encountered within the LUMIstar software during this 
protocol and presented to aid clarity. Prior to use the temperature incubator on the 
machine was switched on and set to 37°C. The injection lines were also primed with 
lucigenin buffer (see Figure 17) prior to the injection cycle being initiated.  
The design of the 96-well plate is presented in Figure 18. This table shows the design 
and sequence of samples placed in the Chemiluminescence but not the exact positions 
always used. The positions of samples in the wells altered between repeats but the 
sequence remained the same.  
The 96-well plate was loaded with 25µl of sample and topped with 115µl of sample 
buffer (recipe in Table 17). The two blank wells contained 115μl of sample buffer 
only. The plate was then inserted into the Chemiluminescence machine and a basal 
reading taken using the ‘Test Protocol for 3 SEC 1 INJ’ protocol. This injects 25μl of 
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the lucigenin buffer into each well, including the blanks and then reads the plate for 
21 cycles.   
Following this ‘Test Protocol for 3 SEC NO INJ’ was initiated. This protocol 
involves; shaking of the plate for 5 seconds before manual injection of 20μl of 
NADPH Oxidase solution into each well before reading. This was read for 21 cycles 
and lasted 47 minutes.  
The last cycle is the addition of 1M Tiron manually using ‘Test Protocol for 3 SEC 
NO INJ’. 4μl of Tiron was added to each well and similar to the previous cycles this 
was run for 21 cycles.  
All results were exported to Excel, Microsoft 2010. Reactive oxygen species readings 
were expressed per 100μg of protein and graphically presented.  
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Figure 18. Sample design on 96-well plate, required in the measurement of reactive 
oxygen species using Chemiluminescence assay. 
2.6. Urinary Bladder Functional Experiments  
 
2.6.1. Drug Interventions  
A complete list of all the drug and chemical interventions used in this study, used in 
comparison against the HEPES-buffered Tyrodes control, in both physiological and 
pathophysiological conditions.  
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A Blank  Blank  Tyr 
1 
Tyr 
1 
Tyr 
1 
1uM 
Ang 
II 1 
1uM 
Ang 
II 1 
1uM 
Ang 
II 1 
Tyr 
2 
Tyr 
2 
Tyr 
2 
1uM 
Ang 
II 2 
B 1uM 
Ang 
II 2 
1uM 
Ang 
II 2 
Tyr 
3 
Tyr 
3 
Tyr 
3 
1uM 
Ang 
II 3 
1uM 
Ang 
II 3 
1uM 
Ang 
II 3 
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Figure 19. Drug Interventions 
Intervention Stock Concentration  Final Concentration 
Angiotensin II 5mM dissolved in 1% PBS 1µM, 200nM 
ZD7155 10mM dissolved in H2O 10µM 
ZD7155 + Angiotensin    1µM, 10µM  
Apocynin Powder 100µM  
H2O2 10mM in H2O 100µM  
Bradykinin 10mM 0.3μM, 1μM, 10μM 
2-Guanidine -4 –methylquinazoline 
(2-GMQ) 
Powder 
 
10μM, 100μM, 500μM 
UTP 100mM 100μM 
UTP + Angiotensin II  100μM, 1μM  
Carbanoxalone 100mM 100μM 
Carbanoxalone + Angiotensin II  100μM, 1μM  
Brefeldin A 10mM in Dimethyl Sulfoxide 10μM 
Brefeldin A + Angiotensin II  10μM,  
Ca2+- free HEPES-buffered Tyrodes Recipe in table 2.7.2   
Ca2+- free HEPES-buffered Tyrodes 
+ Angiotensin II 
 1μM Angiotensin II added  
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Figure 20.Ca2+- free HEPES-buffered Tyrodes solution composition with individual 
final concentrations and final pH 
 Concentration  
NaCl 132mM 
HEPES 10mM 
KCL 4mM 
MgCl2.6H2O 1mM 
NaH2PO4.2H2O 0.4mM 
Glucose 6.1mM 
Na Pyruvate 5mM 
EDTA 1mM 
NaOH 1M 
Final pH 7.4 
 
2.6.2. Urinary Bladder Tension Measurements  
The tension transduction experiment was carried out by attaching full thickness 
muscle strips and denuded mucosa muscle strips (figure 21) in-between two hooks, 
with one hook fixed to the perfusion trough, and another attached to the tension 
transducer mounted on an adjustable micromanipulator. The tension transducer is 
connected to a bridge amplifier which is in turn connected to an A to D converter 
attached to a PC. The application program is pClamp 9 (Axon Instruments, USA). 
The strips are perfused with HEPES-buffered Tyrodes solution at a flow rate of 
2ml/min. The muscle strips were measured for length with a small laboratory ruler 
and their length extended by approximately 30%. The setup of the tension transducer 
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is displayed in Figure 21. The drug interventions and concentrations used listed above 
in Figure 19 and 20, were infused over the muscle strips in the wells at a constant 
flow rate of 2mls per minute (Sui et al., 2008;Wu & Fry, 1998;Bayliss et al., 1999).  
 
 
 
 
 
 
 
 
 
Figure 21.The setup of the physiological experiment. 
This picture shows denuded mucosa strip attached horizontally between two hooks, 
whilst HEPES-buffered Tyrodes is perfused over at a rate of 2ml/min.   
 
2.6.3. ATP Measurement & Analysis  
The main principle of the ATP assay was first discovered by (McElroy 1947); who 
noticed that ATP could stimulate the fluorescence emitted in fireflies. The ATP 
released from the strips of mucosa or full thickness bladder strips in the superfusate 
were determined by using an ATP bioluminescent assay kit (Sigma Aldrich 2006). 
This assay uses a two-step reaction in which the first reaction is a reversible reaction 
between D-luciferin and ATP and catalysed by firefly luciferase enzyme. The 
equilibrium favours the forward reaction forming an intermediate molecule of adenyl-
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luciferin, which then is directly turned into oxyluciferin, water, carbon dioxide and 
luminescence (Sigma Aldrich 2006). The luminescence can then be detected as a 
proportional indicator of ATP quantity.  
45µl samples of the superfusate were taken from a fixed point 1-2mm away from the 
muscle strip – to prevent mechanical disturbance. The time points were 3mins, 5mins, 
10mins and 20mins post-drug infusion, with the average of the pre and post drug 
infusions being taken as a control. All samples were labelled and frozen at -20oC for 
an ATP assay. The results from the ATP assay were tabulated in an excel spreadsheet. 
The difference between the luciferin-luciferase reading and the sample superfusate 
was measured. These data were then normalised by diving it by the ATP standard 
taken on the day of ATP assay measurement, then divided by the dry weight of the 
tissue (recorded on the day of the experiment, excess water removed by dabbing on 
tissue) and the flow rate (pmoles/g/min).  
The tension transducer was calibrated by Wu et al laboratory and standardised against 
a series of known weights and expressed as the gravitational force. A series (5-7) of 
lead wire with different length were used and their weights were determined on the 
weighing balance.  The range of weights are selected such that it include the range of 
possible forces generated by your muscle strips. You then measure these weights on 
your tension transducer. Each weight will generate a voltage defection. You then plot 
the gravitational force of each weight (F (N, newton) = m (mass in kg) x g 
(9.8m/s2, acceleration due to gravity force) again each voltage defection. The 
relationship is linear and also the line passes the origin of the plot (0, 0) and this is 
your standard curve. This is repeated every 3 months by Wu et al. but the line has 
never changed. Any contraction force from muscle as a voltage deflection can be then 
converted to force in N, mN, µN, (x1000 relation between them).  
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2.6.4. Bladder Strip Tension Contractions & Analysis  
Bladder samples were attached to an isometric tension and the magnitude of isometric 
contractions was recorded as voltage output that was amplified and then converted to 
the digital signal into the PC.  Data analysis was made with the software clampfit 9.0. 
Analysis of the data produced from this experiment was achieved by taking 
measurements at points in the pre-control, intervention and post-control ranges. The 
amplitude of contractions was measured at 3 points for each range and an average 
taken. These were tabulated in excel. The data points were normalised by taking into 
consideration the isometric force generated from the tissue sample, the mass of the 
tissue and the calibration of the experimental set up by known weights and their 
gravitational forces.  
 
2.7. Statistics  
In this investigation, the data observed did not follow the normal distribution and thus 
non-parametric tests were used in addition to the student’s t test. Wilcoxon signed 
rank test demonstrated the significance of the difference between two paired data sets 
(e.g., drug intervention vs. control). The difference between two unpaired data sets 
(e.g., mucosa vs. smooth muscle, ageing vs. young) was determined by unpaired t-test 
or non-parametric Mann–Whitney U test.   
In all of these statistical tests the significance level was set at 0.05.  
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3.1. Introduction 
The presence and action of Angiotensin II has been identified in the many organs of 
the body. This includes the heart, the circulatory system, the brain and the 
reproductive organs. Its main role is in the renin angiotensin system. As mentioned in 
section 1.8.1 the renin angiotensin system is responsible for the regulation of blood 
pressure, vascular tone and sodium homeostasis.  
Investigations into the role of Angiotensin II in the urinary bladder have revealed its 
presence in the detrusor muscle in pathophysiological conditions (Cho et al. 2012; 
Comiter & Phull 2012). However, its presence in the urothelium has not yet been 
identified. In this chapter, evidence for the presence and localisation of angiotensin II 
receptor AT1 in the urinary bladder urothelium will be sought. Furthermore, this 
chapter will explore the functional significance of Angiotensin II, via AT1 in the 
bladder wall and isolated mucosal layer, by examining its ability to release ATP and 
mediate bladder contraction.  
 
3.2. Methods  
Several experimental approaches and methodologies were used for the investigation.  
3.2.1. Haematoxylin & Eosin Stain  
In order to highlight the importance of angiotensin II in the bladder, investigations 
were conducted to expose the presence of its target receptor -AT1 in the urinary 
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bladder wall. Firstly histochemical analysis of the male Dunkin Hartley guinea pig 
urinary bladder was carried out. Haematoxylin and Eosin stain was done to reveal the 
normal histology and establish the health of the guinea pig bladders before continuing 
the investigation.  
 
3.2.2. Immunofluorescence 
Once the Haematoxylin & Eosin stain was done, the immunofluorescence technique 
was used to highlight whether AT1 receptors were present in the urinary bladder and 
the specific layers. As mentioned in section 2.4.2, immunofluorescence is an imaging 
tool that illuminates targeted proteins. The AT1 receptor was labelled with primary 
and fluorescence probed secondary antibodies. Using a 1:100 dilution of the primary 
antibody and a 1:500 dilution of the secondary antibody, the AT1 receptor was 
highlighted.  
 
3.2.3. Isometric Tension Experiments  
Strips of full thickness bladder wall and mucosa alone urinary bladder were isolated 
and attached between two hooks. The lengths of these strips were extended by 30% of 
their original size. HEPES-buffered Tyrodes was perfused over the tissue at a constant 
rate of 2ml/minute. The hooks were attached to a tension transducer that was able to 
record changes in muscle contractions, both spontaneous and induced.  
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3.2.4.   ATP Release  
In parallel to the drug interventions, 45ul samples of the superfusate were taken at the 
various time points during the intervention. These were stored at -4oC until measured.  
To measure the ATP released, we used a luciferase reaction to detect the quantity of 
ATP. The luciferase reaction produces a luminescence product, in direct correlation to 
quantitative ATP release. This was expressed as pica moles of ATP per gram of tissue 
per minute.  
 
3.3. Bladder Morphology  
Firstly, bladder sections were histochemically analysed for good morphology. These 
morphological investigations revealed healthy urinary bladders in our guinea pig 
animal models. The sections demonstrated urothelial layer consisting of 3-6 layers of 
transitional epithelial cells, the sub urothelial layers which are fibroblasts and 
myofibroblast and connective tissue, and the smooth muscle area which is a thick 
bulk of elongated smooth muscle cells (Figure 22).  
Secondly, the images reveal highly nucleated, microvilli-like urothelial layer 
consistent with literature. There are no tears or holes within the layer, showing that 
the urothelium is in a good morphological condition. Additionally, in support of 
literature, the sub urothelium lying immediately under the urothelium is intact.  
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Figure 22. Haematoxylin and Eosin stain of guinea pig urinary bladders.  
This histological stain reveals the urinary bladder cell nucleus (purple) and 
cytoplasm (pink/orange). These images highlight the urothelial lining and the smooth 
muscle areas of male Dunkin Hartley guinea pig bladder tissues. The images 
demonstrate that the animal models were healthy bladder models with no tissue 
damage.  
 
Smooth Muscle Layer Urothelial Layer 
10µm 
No gaps  Densely nucleated apical layer  
Microvilli structure 
Good nuclear stain 
 
Shows directional pattern of 
smooth muscle layers  
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Thirdly, the smooth muscle area is fibrous in nature, with the muscle fibres arranged 
longitudinally and circularly. These images provide evidence that there was no tissue 
damage in the animal models in this investigation. In addition they conclusively 
support the data in the literature on the nature of the urinary bladder cell.  
 
3.4. Basal Urothelial Activity  
A comparative study of the absolute quantities of ATP released spontaneously by full 
thickness bladder strips and mucosa alone strips was carried out. This was done to 
establish the basal activity of both tissue preparations (full thickness and mucosa 
alone). Figure 23 graphically presents the results of our findings. ATP release was 
detected from full thickness muscle strips (pmoles/g tissue/min, median (25%-75% 
range): 15 (7-90), n=20) and a greater significant ATP release was generated from 
mucosal strips (182 (23-286), n=20, p<0.05).  
The bladder wall is able to spontaneously release ATP. The results obtain suggest that 
this is mainly due to the mucosa as this layer when isolated from the underlying layers 
of the bladder is able to release more ATP than all the layers combined. This is 
consistent with the notion that the main source of ATP release in the bladder is from 
the urothelium.  
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Figure 23. A comparative demonstration of the basal ATP release in the urinary 
bladder layers  
The mucosal layer was isolated from young male guinea pig bladders and compared 
with full thickness bladder wall strips. The preparations were hooked onto an 
isometric tension rig and perfused with HEPES-buffered Tyrodes. ATP release in the 
superfusate was measured using an ATP assay. This result demonstrates an increased 
ATP release from the mucosal layer when compared against full thickness bladder 
strips. N=20. * P<0.05, Wilcoxon signed rank test.  
 
Following this, spontaneous contraction was also examined in both mucosa alone and 
full thickness bladder strips. Figure 24 shows a representation of the isometric 
recordings produced. Spontaneous contractions, which are not normally observed in 
smooth muscle strips, can be often observed in mucosa-intact smooth muscle strips 
and the mucosa itself did not have this activity. Thus although the mucosa did not 
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have spontaneous contractions, it enhanced the spontaneous activities of the smooth 
muscle. This observation revealed that the spontaneous contractions generated by the 
urinary bladder were highly dependent on the mucosal layer.  
 
Figure 24. Basal contraction in mucosa and full thickness bladder strips  
The mucosal layer was isolated from young male guinea pig bladders and compared 
with full thickness bladder wall strips. The preparations were hooked onto an 
isometric tension rig and perfused with HEPES-buffered Tyrodes. The isometric 
tension was detected, recorded and analysed using pClampfit 9.0 software. This result 
demonstrates a pattern of increased force of contraction from the mucosal layer when 
compared against full thickness bladder strips. N=20.  
 
The results presented here in figure 23 and 24 provides supportive evidence to the 
vital role the mucosal layer in the whole bladder activity. This is demonstrated in 
spontaneous ATP release and bladder contraction. Therefore our aim to examine the 
role angiotensin II specifically in the urothelium is needed, as this appears to be the 
layer with a large amount of bladder activity.  
Isometric tension
10 min
200 µN
Mucosa-attached Mucosa taken off
Urothelium-dependent  spontaneous smooth muscle contractions
Full Thickness Without Mucosa  
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3.5. The Presence of Angiotensin II Receptor 1 in 
Urinary Bladder 
Angiotensin II, the hormone whose action is mediated by AT1 can be logically 
assumed to work in the bladder. Previous research by Cho et al. (2012) highlighted 
the presence of AT1 in the detrusor layer of the bladder. However, there is no 
evidence for the presence and function of angiotensin II in the urothelium specifically. 
Following the establishment of the vital role of the urothelium in bladder activity, we 
looked at the role of angiotensin II in this area. This research provides the first 
evidence for the localisation of the AT1 receptor in the urothelial layer, as shown by 
the strong positive stains. Although, it is worth considering that these results do not 
show the role of Angiotensin II in the bladder, only that the mediating receptor AT1 is 
present in the bladder. 
Immuno-staining on cross sections of guinea pig urinary bladder, exhibited a positive 
result for the presence of the AT1 receptor in the urothelium and smooth muscle of the 
urinary bladder (presented in figure 25). Similarly this was supported by the results 
for the primary control; the primary control highlights the nucleus by DAPI 488 
(blue) with little non-specific binding (figure 25D).  A close examination of the 
urothelium layer specifically reveals positive AT1 fluorescence in the highly 
nucleated urothelial cells (figure 25B). These novel results are suggestive that AT1 
receptors and thus angiotensin II is involved in bladder function in the smooth muscle 
and urothelial layers of the bladder. Figure 25, also highlights strong positive staining 
near what appears to be a blood vessel-like structure. This would be consistent with 
the action of angiotensin II (Palmer at al. 1997).  
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Figure 25 Identification, in the urinary bladder urothelium and detrusor smooth 
muscle, of the AT1 receptor by immunostaining. 
A, DAPI nuclear stain at 450nm x40 magnification. B, Sigma-Aldrich AT1R primary 
antibody (1:100 dilution) and Alexa 568 secondary antibody (1:500) at x40 
magnification in urothelium. C, A combination of the nuclear and AT1R stain. D, 
Primary antibody control, no primary antibody added (x40 magnification). E, Sigma-
Aldrich AT1R primary antibody (1:100 dilution) and Alexa 568 secondary antibody 
(1:500) at x40 magnification.  
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3.6. Angiotensin II Regulation of Bladder Function  
The positive results highlighted in section 25, reveal the presence of AT1 receptors in 
the bladder but are not able to give sufficient evidence of the functional significance of 
angiotensin II in the bladder. Therefore, this investigation went on to deduce whether 
angiotensin II had an effect on bladder physiology. ATP release is the key function of 
the urothelium (Birder & Andersson 2013; Andersson 2015). Its autocrine and 
paracrine action on many structures including sub-urothelial myofibroblasts and nerve 
endings following release, give us an indication of bladder activity and urothelial 
sensory function. The functional role of angiotensin II in the urothelium was therefore 
investigated by examining the effect of angiotensin II on urothelial ATP release.  
Changes to ATP release from the mucosa and the mucosa-attached smooth muscle strip 
following application of angiotensin II (1µM) are shown in Figure 26. Angiotensin II 
caused fluctuating changes in ATP release in both tissue preparations during the 20 
minutes’ observation. Both tissues preparations show an increase in ATP release after 
20mins in comparison to the control. However this is not a consistent increase 
throughout the time. ATP release decreases for both tissue preparations after 3mins. 
This is suggestive of a time delay in the action of angiotensin II in the bladder and that 
the action of angiotensin II in the bladder in releasing ATP may require multistep 
pathway. Alternatively, this result may suggest a vesicular model of release, as it is 
supportive of an ‘all or nothing’ mechanism. The fluctuations and sharp rises point to 
grouped release of ATP. The averaged results of ATP release are shown in figure 27 
and demonstrate that angiotensin II induced ATP release is greater than spontaneous 
ATP release. Comparative analysis of angiotensin II effect in both tissue types seen in 
Figure 28, further demonstrates that the relative increase of ATP release by angiotensin 
 126 
 
II was similar between the mucosa and the full-thickness bladder strips, suggesting the 
same mode of action. The absolute quantity of ATP release in mucosa was much greater 
than that in full thickness bladder strips.  
 
A.  
 
 
B.  
 
 
 
Figure 26.Representative Graph Showing Effect of Angiotensin II on ATP release 
over time 
The mucosal layer (26.A) was isolated from the same bladder and compared with full 
thickness bladder wall strips (26.B). The preparations were perfused with HEPES-
buffered Tyrodes for 10mins followed by 1µM Angiotensin II in HEPES-buffered 
Tyrodes. ATP release in the superfusate was measured at various time points: 
HEPES-buffered Tyrodes 10mins, Angiotensin II 3,5,10 and 20mins. This result 
demonstrates the change in ATP release over time. N=1.   
The next set of results show the overall effect of angiotensin II perfusion on the 
spontaneous release of ATP for both mucosa (A) and full thickness bladder strips. 
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(B). additionally, we show the relative difference in ATP release between the mucosa 
and full thickness bladder strips as percentage change in figure 28.  
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Figure 27. Effect of Angiotensin II on ATP release 
The mucosal layers (A) and full thickness bladder wall strips (B) were perfused with 
1μM angiotensin II, presented is the ATP release measured. The bladder tissues were 
perfused with HEPES-buffered Tyrodes for 10mins followed by 1µM Angiotensin II in 
HEPES-buffered Tyrodes. ATP release was measured using a chemiluminescent ATP 
assay from samples of the superfusate at various time points. This result demonstrates 
an increased ATP release from strips of mucosa and full thickness bladder in 
comparison to their controls. N=20. *P<0.05, Wilcoxon signed rank test.  
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The ATP release measured and demonstrated in figure 27 showed, (pmoles/g 
tissue/min, control 1μM angiotensin II in isolated mucosal strips: 1828.9 and 7409.6 
but in full thickness bladder strips this we detected: 55.5 and 87.6. Although the ATP 
release in mucosal strips has a much higher trend than in full thickness strips, overall 
angiotensin II appears to have a similar effect on their ATP release relative to the 
control.  
 
 
 
Figure 28. Comparison of ATP release in mucosal and full thickness bladder strip 
The results for ATP release when 1μM Angiotensin II is added and expressed here as 
percentage increase in comparison to the control ATP release. There is little/no 
difference in the relative ATP release between the two sample groups. N=20. P<0.05, 
Wilcoxon signed rank test.  
Supporting evidence in the analysis of contractions taken during these interventions are 
presented in Figure 29. These results show that angiotensin II was able to significantly 
increase the mean amplitude of contraction as well as the maximum force of contraction 
of the full thickness bladder strips. These data suggest that angiotensin II can affect 
bladder smooth muscle contractile activity directly or indirectly. It is of interest to note 
that mucosa contraction was also increased by angiotensin II. The ability of the mucosa 
layer to contract in response to angiotensin II is an unusual finding, which will be 
discussed in detail in Discussion. However, it is apparent that full thickness bladder 
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strips generated far greater contractions than the mucosa. This is consistent with the 
smooth muscle as the predominant contractile structure in the body.  
A. 
 
 
 
B. 
 
 
 
Figure 29. Force changes in bladder strips with 1μM angiotensin II. 
This figure shows the effect of 1μM Angiotensin II on the force (A.) and the max force 
of contraction (B.) of the bladder strips - mucosa alone and full thickness bladder strips. 
An average of three readings were taken for pre- control, angiotensin II and post-
control. The results show the net increase in force (μN/mg) for angiotensin II data 
against the mean pre- and post- controls. Angiotensin II significantly increases the 
amplitude and maximum force of contraction in both tissue preparations, when 
angiotensin II induced contractions are compared with spontaneous contractions. 
N=13. *P<0.05, Student’s t test.  
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Figure 30. Representation of force changes with Angiotensin II 
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Figure 31.Effect of 200nM Angiotensin II on ATP release 
The mucosal layers and full thickness bladder wall strips were perfused with 200nM 
angiotensin II. This figure demonstrates the absolute values for ATP released (A.) and 
the percentage difference (B.) The bladder tissues were perfused with HEPES-
buffered Tyrodes for 10mins followed by 200nM Angiotensin II in HEPES-buffered 
Tyrodes. ATP release was measured using Chemiluminescence from samples of 
superfusate at various time points. This result demonstrates a significant increase in 
ATP release from a strip of mucosa and full thickness bladder in comparison to their 
controls. N=9. *P<0.05, Wilcoxon signed rank test.  
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In figure 30, the effect of a lower concentration of angiotensin II (200nM) can be seen 
in both mucosal strips and full thickness bladder strips. 200nM angiotensin II was 
able to generate the following ATP release (pmoles/g tissue/min, control: (± SEM), 
200nM angiotensin II (±SEM)), in isolated mucosal strips: 237.4 ± 57.8 and 671.2 ± 
238.3 but in full thickness bladder strips this was a much lower recording of: 23.7 ± 
7.3 and 51.5 ± 16.6. In both tissue preparations, 200nM angiotensin II was able to 
significantly increase ATP release. Similarly to 1μM angiotensin II the percentage 
change in comparison to the control is similar; 183% for mucosal strips and 154% for 
full thickness strips.  
Following this, the contribution of the detrusor smooth muscle layer to angiotensin-
induced effect on bladder physiology was examined. Similar to the previous 
functional experiments detailed above, ATP release and bladder contractions were 
used as an indicator of bladder activity.  
Results presented in figure 31 show that isolated smooth muscle strips are able to not 
only release ATP spontaneously and without the mucosa but that angiotensin II is able 
to work in this layer. This supports previous findings that show angiotensin II is able 
to affect detrusor smooth muscle action (Cho et al. 2012). The effects of 200nM and 
1μM concentrations of angiotensin II are (pmoles/g tissue/min, control: (± SEM), 
angiotensin II (±SEM)), 200nM angiotensin II: 7.9 ± 2.26 and 19.2 ± 6.3 and for 1μM 
angiotensin II: 10.8 ± 4.1 and 20.2 ± 8.6.  
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Figure 32. Angiotensin II induced ATP release from isolated detrusor smooth muscle 
The results displayed are averaged results from 8 isolated smooth muscle guinea pig 
bladder strips, in the presence of 200nM and 1μM angiotensin II. The bladder tissues 
were perfused with HEPES-buffered Tyrodes for 10mins followed by 200nM or 1µM 
Angiotensin II in HEPES-buffered Tyrodes. ATP release was measured using an ATP 
chemiluminescence assay from samples of superfusate at various time points – 3mins, 
5mins, 10mins and 20mins. This result demonstrates a significant increase in ATP 
release from the detrusor muscle layer specifically in comparison to the control. N=8. 
*P<0.05, Wilcoxon signed rank test.  
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A. 
 
 
 
 
B. 
 
 
 
 
 
 
Figure 33. Analysis of amplitude and maximum force of contraction, in detrusor 
smooth muscle bladder strips, when 200nM or 1μM angiotensin II is added 
This figure shows the effect of 200nM/1μM Angiotensin II on the force of contraction 
(A.) and the maximum force of contraction (B.) of the bladder strips – detrusor smooth 
muscle only. An average of three readings were taken for pre- control, angiotensin II 
and post-control. The results show the net increase in force (μN/mg) for angiotensin II 
data against the mean pre- and post- controls. There is an increasing trend in amplitude 
when Angiotensin II is added, and a significant increase in the maximum amplitude. 
N=8. *P<0.05, Paired Student’s T test.  
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This examination of the contribution of the detrusor smooth muscle to bladder 
activity, via the release of ATP and bladder contractility provides evidence that the 
isolated detrusor smooth muscle plays a role in bladder activity. ATP release, as seen 
in figure 31, indicates that angiotensin II is able to double the ATP release from the 
detrusor smooth muscle, even in the absence of the other bladder layers. This increase 
is statistically significant for 1μM angiotensin, and at a lower concentration of 
200nM. This suggest that angiotensin II can also directly affect ATP release from the 
smooth muscle, despite the absolute quantity of ATP release being much smaller than 
the mucosa.  
Unlike, the release of ATP, data for spontaneous contractility of the smooth muscle 
layer in response to angiotensin II also increased. At both concentrations of 
angiotensin II, displayed in figures 32A, there is insignificant difference between the 
control group and stimulated data. Therefore, angiotensin II does not impact the 
amplitude of contraction in the smooth muscle. However, measurements of the 
maximum force of contraction show a significant increase (figure 32B). So, although 
there is no significant change to the averaged amplitude, angiotensin II is able to 
increase the maximum force of contraction in denuded smooth muscle strips, in 
comparison to its spontaneous contractions. These data also suggest that angiotensin 
II may cause an irregularity to the rhythm of muscle contraction and may provide an 
explanation for the consistent amplitude results but increasing maximum amplitude 
results seen.  
To ascertain that angiotensin II acts on AT1 receptors, as evidenced in the urothelium 
and bladder smooth muscle as shown by immunostaining in figure 25, the specific 
 136 
 
AT1 receptor antagonist ZD7155 was applied. In this experiment, 10µM ZD7155 was 
applied for 20minutes to ensure sufficient binding of the antagonist to the receptor 
before 1µM angiotensin II was introduced, in the presence of ZD7155 for the duration 
of 20 minutes as seen in the previous experiments evaluating the effect of angiotensin 
II (figures 33 and 34). The effect of angiotensin II was accessed with ZD7155 as its 
control. To correct for any time-dependent changes in tissue responsiveness, pre-
control and post-control experiments using angiotensin II alone were performed in the 
same preparation and the averaged data served as internal control which was the 
effect of angiotensin II without ZD7155.  
In this series of experiments, the strips of mucosa or full thickness bladder wall were 
perfused with HEPES-buffered Tyrodes for 10mins followed by 1µM Angiotensin II 
in HEPES-buffered Tyrodes before restoration of Tyrode’s only solution as described 
in earlier section to quantify the effect of angiotensin II to act alone. After resting the 
tissue for 2hours in the Tyrode’s solution, AT1 antagonist 10µM ZD7155, was then 
perfused over the strips for 20mins, followed by 1µM Angiotensin II diluted in 10µM 
ZD7155 flowed over the tissue strips. ATP release was measured using 
chemiluminescence from 45μl samples of superfusate at various time points: HEPES-
buffered Tyrodes 10mins, Angiotensin II 10mins, Angiotensin II + ZD7155 3mins 
5mins 10mins, Angiotensin II 10mins and Tyrodes 10mins. This result demonstrates 
the relative ATP release from a strip of mucosa from the guinea pig urinary bladder 
when angiotensin II is added in the presence of AT1 antagonist ZD7155 in comparison 
to Angiotensin II alone (control), for both mucosa alone strips (Figure 26A) and full 
thickness bladder wall (Figure 26B). A pattern of decrease can be seen in both strips. 
However, ATP release is significantly reduced from the mucosa in the presence of AT1 
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antagonist in comparison to the control. From the mean net increases of 218.8% in 
AngII alone and 84.7% in AngII in the presence of ZD7155, the magnitude of effect 
was reduced by 61.7 %, consistent with 64 % receptor occupancy by the antagonist, 
with the affinities (pK) 9.15 and 8.4 for AngII and ZD7155 respectively, at 1µM AngII 
and 10µM ZD7155. This suggests that the AT1 receptor plays a vital role in the action 
of angiotensin II on the mucosa. 
A.  
 
 
 
B.  
 
 
 
Figure 34. Effect of AT1 receptor antagonist ZD7155 on Angiotensin II induced ATP 
release from the bladder tissue. 
The data for the relative ATP released from mucosa alone (A) and full thickness 
bladder strips (B) in guinea-pig bladders, when 1μM Angiotensin II is added 
with/without the presence of AT1 receptor antagonist ZD7155. These ATP release 
results are expressed relative to the control. In both the mucosa alone and full 
thickness sample, ZD7155 produces a pattern of reduction in the action of 
Angiotensin II. N=7.  
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3.7. Angiotensin II in Interaction Studies  
 
Following the discovery of angiotensin II’s presence in the urothelium; via the 
identification of the AT1 receptor in the bladder and its ability to affect the key bladder 
activity (by ATP release and muscle contraction), this investigation then observed the 
interaction of Angiotensin II with other mediators.  
Firstly, ATP analogue, UTP was used to assess the action of Angiotensin II and whether 
their action was symbiotic or independent in the mucosa alone and also in the full 
thickness of the bladder wall. UTP was chosen because it is the primary activator on 
P2Y receptors which are important functional receptors identified in the urothelium 
(Mansfield & Hughes 2014; Andersson 2015). 
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Figure 35. This is an interaction study on angiotensin II and UTP. 
This graph shows the relative percentage change for the action of angiotensin II and 
UTP independently and together. The experiment design was set up such that, firstly, 
1μM angiotensin II was perfused over mucosa alone (A.) and full thickness bladder 
strip (B.) in comparison to the HEPES-buffered control. Secondly, 100μM UTP was 
perfused over the same tissue preparation in the comparison to a HEPES-buffered 
control. Lastly, 1μM angiotensin II was perfused in the presence of UTP. A 
combination of angiotensin II and UTP does not cause greater ATP release than these 
chemicals individually. N=8. *P<0.05, Paired Student’s T test.  
 
Figure 35. Shows the interaction between UTP and angiotensin II. The results 
demonstrate a positive significant difference between the ATP release of angiotensin 
II against the control and UTP induced ATP release against the control. The action of 
UTP, which is an ATP analogue, confirms literature on the autocrine and paracrine 
action of ATP, the release of ATP leading to more ATP. However, the effect of 
angiotensin II on ATP release increased in some instances in the presence of UTP, but 
the result is not consistent or significant. The combined effect of angiotensin II in the 
presence of UTP, was not greater than their individual effect. Relative ATP release 
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(pmoles/g/min, stimulated change/spontaneous) 1μM angiotensin II/Control, 100μM 
UTP/Control and 1μM angiotensin II/100μM UTP in mucosa: 2.1, 7.6 and 3.9 and in 
full thickness strips: 2.2, 6.9 and 3.4. Thus, their interaction is not symbiotic but 
independent with an ability of UTP to positively influence the action of angiotensin 
II. 
 
 
3.8. Mechanisms of Action for Angiotensin II in ATP 
Release 
This section further explored the cellular mechanism underlying the effect of 
angiotensin II on ATP release from the bladder tissue. Intracellular Ca2+, vesicular 
release and gap junction channel conductive pathways are major mechanisms (Goette 
& Lendeckel 2008; Griendling et al. 1997) suggested so far from other types of 
tissues and cells and were thus examined in the present investigation. 
First, we removed extracellular from our experimental design by using Ca2+ free 
HEPES-buffered Tyrodes. The ability of angiotensin II to still cause additional ATP 
was measured and the results presented in figure 35. Secondly, we inhibited gap 
junction communication by using Carbenoxolone and similarly to our experiment 
design for extracellular calcium, we observed the effects of angiotensin II under this 
condition (figure 36). Lastly we utilised Brefeldin A as a vesicular transport blocker 
(figure 37).  
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Figure 36. Impact of removing extracellular Ca2+ on the action of angiotensin II 
The figure displays the results for the action of angiotensin II without the presence of 
extracellular Ca2+ in mucosa (A.) and full thickness (B.) bladder strips. 1μM 
angiotensin II was perfused over the same tissue preparation in the comparison to 
Ca2+ free HEPES-buffered control (average pre- and post- angiotensin II controls). 
Angiotensin II was able to significantly increase ATP release in the absence of 
extracellular calcium. N=11.  
In the following experimental design, a comparison of the action of angiotensin II was 
examined in the presence of no extracellular calcium, in comparison to the control. 
Figure 35 shows the results from this sophisticated experimental design; to reveal that 
angiotensin II is able to increase ATP released from the mucosa alone (A.) and full 
thickness bladder strip (B.). As reflected in the results of figure 35 A. and B. the 
absence of extracellular calcium does not inhibit the release of ATP. Angiotensin II 
was able to further increase spontaneous ATP release in the absence of extracellular 
 142 
 
Ca2+ (pmoles/g tissue/min), control, 1μM angiotensin II in Ca2+ free HEPES, in 
isolated mucosa strips: 1059.5 and 2981 and in full thickness strips: 104.3 and 208.2.  
Although the mucosa alone strips (A.) and full thickness bladder strip (B.) did not 
show significant changes, there was a pattern of greater increase seen in the mucosa 
alone strips in comparison to the full thickness bladder strip. The dependence of the 
smooth muscle layer on calcium, due to its highly contractile function may be the 
reason for the difference in response to the removal of calcium. However, the results 
displayed from this research show that intracellular calcium and its release from 
intracellular stores must be the main contributor to the action of angiotensin II in the 
bladder.  
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Figure 37. The effect of blocking gap junctions on the effect of angiotensin II 
The results for the action of angiotensin II in the presence of gap junction inhibitor 
Carbenoxolone (100µM) in mucosa (A.) and full thickness (B.) bladder strips. 1μM 
angiotensin II was perfused over tissue preparations and compared to averaged 
Carbenoxolone pre- and post-controls. Angiotensin II significantly increased ATP 
release in the presence of Carbenoxolone. N=11. *P<0.05, Paired Student’s T test 
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Figure 38. Vehicle control for Carbenoxolone 
This representation of vehicle control for 10µM Carbenoxolone, was carried out for 
mucosa alone strips (A) and full thickness strips (B). There is no significant difference 
between the vehicle control and Carbenoxolone added. N=8, P<0.05, Wilcoxon 
signed rank test.  
Subsequently, this body of research presents data for the ability of angiotensin II to 
cause increased ATP release when gap junctions are blocked. The aim was to 
examine whether angiotensin II was using gap junctions for cell to cell paracrine 
signalling and potentiating its effects via gap junctions. Therefore, Carbenoxolone 
was used to examine the effects of angiotensin II in the absence of Carbenoxolone.  
Figure 36A shows that ATP is not only released in the absence of gap junction 
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communication but that there is a trend of increase in the presence of Carbenoxolone 
(100µM) in mucosa alone strips. Angiotensin II is able to double the percentage 
change in ATP release when Carbenoxolone is present, in comparison to when 
angiotensin II is added to a HEPES-buffered control. This may be due to the up-
regulation of other communication pathways such as adherens junctions (O’Connor & 
Adams 2010). This alternative communicative pathway involves the connection of 
cytoskeletal actin or intermediate filaments to adaptor complexes such as adheren 
junctions or desosomes in neighbouring cells providing a link from cell to cell for 
signalling (O’Connor & Adams 2010). The blockage of gap junction pathways may 
also enhance the action of pathways such as adheren junctions and provide an 
explanation for the doubled effect of angiotensin II in the presence of Carbenoxolone.  
The effect of Carbenoxolone is mirrored throughout the bladder, as can be seen from 
Figure 36B, where this is done in full thickness bladder strips. Angiotensin II up-
regulates ATP release in the presence of Carbenoxolone. However, in full thickness 
bladder strips, this change in percentage release of ATP is confined to a narrower 
range than that of mucosa alone strips. This is suggestive that the mucosa may be the 
major contributing factor to the increased ATP release seen. Thus suggesting that 
there is a greater expression of other communicative pathways present in the mucosa 
in comparison to other layers of the bladder. ATP release was increased (pmoles/g 
tissue/min, control, 1μM angiotensin II, in isolated mucosa strips: 846.5 and 2286.4 
and in full thickness strips: 86.6 and 121.7. figure 37 shows the effect of the 
Carbenoxolone alone on ATP release in comparison to the HEPES-buffered control. 
It can be seen from the data that there is no significant difference between the two 
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groups. This shows that any additional release in ATP in the presence of angiotensin 
II, is due to the action of angiotensin II. 
 
 
 
 
 
Figure 39. The effect of blocking protein transport from the ER to the Golgi 
apparatus on the ability of angiotensin II to cause ATP release 
The results in this graph show the action of angiotensin II in the presence of Brefeldin 
A in mucosa (A.) and full thickness (B.) bladder strips, in comparison to the action of 
angiotensin II in the presence of the HEPES buffered control. Brefeldin A is a 
vesicular transport blocker. 1μM angiotensin II was perfused over tissue preparations 
and compared to averaged 10μM Brefeldin A pre- and post-controls. In both tissue 
preparations, Angiotensin II caused a pattern of decrease in ATP release in the 
presence of vesicular inhibition. N=10. 
The role of Brefeldin A is to cause inhibition of vesicular transport by disassembling 
the golgi complex (Fujiwara et al 1988), causing rapid tubule formation and the 
absence of tubule detachment (Sciaky et al 1997). Therefore, an extensive build-up of 
tubules forms which results in an accumulation of secretory proteins and lipids in the 
endoplasmic reticulum. Levels of angiotensin II induced release of ATP dropped in 
mucosal strips and full thickness bladder strips (figure 39). The relative ATP 
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measured expressed as stimulated release over spontaneous (pmoles/g tissue/min, 
control: (± SEM), 10μM Brefeldin A (±SEM)), in isolated mucosal strips: 21 ± 11.8 
and 7.6 ± 5.4 and in full thickness strips: 0.65 ± 0.3 and 0.36 ± 0.1. Figure 40 shows 
the results of the vehicle control, which demonstrate no significant difference between 
the vehicle and the Brefeldin A drug. Therefore any patterns of change determined are 
not due to the vehicle.  
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Figure 40. Vehicle control for Brefeldin A 
This representation of vehicle control for 10µM Brefeldin A, was carried out for 
mucosa alone strips (A) and full thickness strips (B). There is no significant difference 
between the vehicle control and Brefeldin A. N=8, P<0.05, Wilcoxon signed rank test.  
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3.9. Discussion & Summary  
Firstly, our investigations have demonstrated that the guinea pig bladder 
models, used to exemplify physiological conditions, were healthy and their 
morphologies intact (demonstrated in figure 22). The urothelium is highlighted as the 
highly nucleated ‘villi-like’ layer, with a well-connected sub-urothelial layer and 
smooth muscle. Damages to the any of these layers, would highly distort our data as it 
would not represent normal physiological conditions but rather pathological.  
Secondly, this chapter establishes the vital role of the urothelium in the release 
of ATP and muscle contraction in the urinary bladder (figure 23 and 24). Therefore 
the need for data on the role of the urothelium, molecular proteins present and its 
mediation in bladder physiology is also vital. Furthermore figure 23 highlights that 
the urothelium is able to release ATP spontaneously.  
Presented in this body of results is the first evidence for the presence of AT1 
receptor in the urothelium of the urinary bladder. Figure 25 reveals positive staining 
for the AT1 receptor in both urothelium and smooth muscle layers. The results seen 
here are consistent with literature for the detrusor smooth muscle (Cheng et al, 1999; 
Comier & Phull, 2012; Cho et al, 2012; Mori et al. 2015), but as here has not been 
any data yet for the urothelium, this novel finding contributes to the knowledge of the 
action of angiotensin II n the bladder. The primary control shows the nuclear stain and 
no/little non-specific staining. This highlights the specificity of the Alexa 568 
secondary antibody to detect the primary antibody and increases confidence that the 
positive result seen in the test samples are true.  
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Upon closer examination of the immune stain, the mucosal layer – comprising 
the urothelium and sub-urothelium, there appears to be only staining in the apical 
layers. The stain does not show up in what appears to be the basal layer of the 
urothelium or the sub-urothelium. This interesting evidence, may suggest that the AT1 
receptor is situated on the apical umbrella cells of the urothelium and only specific 
cells within the urothelium mediate its action. However, further investigations are 
required to test this idea.  
Following the identification of the AT1 receptor in the urothelium, 
investigations were undertaken to examine the functional role of the AT1 ligand, 
Angiotensin II in the bladder. As previously stated in section 1.5.4, angiotensin has 
been seen to affect bladder behaviour in pathological models, but there isn’t data for 
its physiological action. This investigation examined the effect of angiotensin II on 
bladder activity, via ATP release. Figures 26-30 demonstrate these results. An 
elevated ATP concentration can be seen in both urothelium and full thickness bladder 
strips. Although, in urothelium-alone strips there is a sharper increase in ATP levels, 
in comparison to the full thickness strips.  
Significant increases are also observed when Angiotensin II induced ATP 
release is compared to the controls in urothelium-alone and full thickness strips 
(Figure 26). These results provide novel evidence for the role of Angiotensin II in the 
urinary bladder. As seen in figure 26 the action of Angiotensin II is not isolated to the 
detrusor smooth muscle but is also present in the urothelium. Additionally these novel 
results show that Angiotensin II has an effect on the bladder under physiological 
conditions.  
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Figure 33, effect of AT1 receptor antagonist ZD7155 on Angiotensin II 
induced ATP release from the bladder tissue, examines the action of Angiotensin II in 
the presence of its antagonist ZD7155. This inhibitor is able to reduce the action of 
Angiotensin II in mediating ATP release. The ability of ZD7155 to antagonise 
Angiotensin II shows that the effects of Angiotensin II are mediated at least partially 
by the AT1 receptor. This inhibition is consistent with literature on the action of the 
ZD7155 inhibitor (IUPHAR/BPS).  
The data from interaction studies are indicative of angiotensin II being 
mediated by a pathway different to that of ATP, from the analysis of its analogue 
UTP (Figure 35. This is an interaction study on angiotensin II and UTP.). Therefore, 
ATP is able to potentiate the release of more ATP, the action of angiotensin II and 
ATP is mainly mutually exclusive in the layers of the bladder wall.   
Similarly, angiotensin II was not dependent upon the presence of extracellular 
calcium in order to cause increased bladder activity. Thus, the contribution of 
intracellular calcium release to bladder activity must be greater than that of 
extracellular calcium. Although a pattern of increased ATP release was seen in both 
tissue preparations, this data was not significant.  
Lastly the inhibition of cellular communication using Carbenoxolone (Figure 37. The 
effect of blocking gap junctions on the effect of angiotensin II) and Brefeldin A 
(Figure 39. The effect of blocking protein transport from the ER to the Golgi 
apparatus on the ability of angiotensin II to cause ATP release ) prevented gap 
junction transport and vesicular transport respectively. In the full thickness bladder 
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strips, angiotensin II was able to still increase ATP release in the presence of 
Carbenoxolone and thus generate bladder activity, leading to the conclusion that 
angiotensin II is not dependent on gap junction pathways to mediate its action. In 
contrast to literature, the use of gap junction inhibitor did not reduce released ATP 
release in mucosa or the full thickness bladder strips. Experiments by Tobu et al. 
2012, revealed the action of connexion 43 in the mucosa of rats. However, this was in 
an inflammatory bladder model and not in healthy subjects. Similarly, Dodge et al. 
1998 saw an up-regulation of connexion 43 with angiotensin II, although this was in 
myocytes. The results are also suggestive of a compensatory mechanism, where 
alternative pathways may be increased in order for the tissue to still remain active. 
There is a possibility that vesicular transport may be that alternative pathway. Figure 
37, appears to suggest Angiotensin II’s inability to stimulate ATP release equal to or 
more than spontaneous amounts. Although results are not significant and more N 
numbers are needed for confirmation, the trend portrayed here is interesting. The 
action of Brefeldin A in the mucosa and smooth muscle may point to a mechanism for 
vesicular transport in the mediation of the action of angiotensin II in the urinary 
bladder.  
Therefore the results presented in this chapter provide evidence for the 
presence and localisation of the AT1 receptor in the urinary bladder. The data 
highlights the existence of AT1 receptors in the urothelium. More importantly, the 
data exhibited in this research is not limited to just the occurrence of AT1 receptor, but 
also its physiological function. Furthermore vesicular exocytosis has been identified 
as one mechanism for angiotensin II induced ATP release from the urothelium. Thus 
this chapter also provides data for the effect of Angiotensin II, in its ability to change 
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ATP release – a major indicator of bladder functionality. As demonstrated within this 
section, Angiotensin II expressed and has a role in bladder physiology, in the bladder 
wall as well as the urothelial layer specifically.   
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4.1. Introduction  
Oxidative stress describes the state of cell where there is an accumulation of reactive 
oxygen species (ROS), due to increased production or reduced removal. The group of 
reactive molecules includes hydrogen peroxide, peroxynitrite, superoxide and 
hydroxyl radical. ROS play a role in human physiology and is involved in processes 
such as regulation of endothelial function, apoptosis and cell communication. 
However an excess of ROS can have destructive effect on cellular function as their 
reactive nature results in oxidation of structures such as proteins, DNA and lipids. 
There are many sources of ROS including; eNOS, xanthine oxidase and NADPH 
oxidase. These are explored in detail in section 1.10.  
This section aims to explore the potential presence and physiological function of 
NADPH oxidase (NOX) in the bladder. We hypothesise that NOX isoforms are 
present in the bladder and that they are expressed in urothelium of the bladder. 
Additionally, we hypothesise that they are functionally active and interact with 
angiotensin II.    
This chapter will explore whether NADPH oxidase is expressed in the bladder, the 
urothelium specifically. Similar to AT1 receptor expression, this report will evaluate 
the layer expression of NOX1 and NOX2.  
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4.2. Methods 
In the investigation of the role of reactive oxygen species in the bladder, the 
experimental approaches and methodologies described here were used.  
 
4.2.1.  Immunofluorescence 
Immunofluorescence was used to highlight whether NOX1 or NOX2 receptors were 
present in the urinary bladder and if so, the specific layers where they reside. As 
mentioned in Figure 15, immunofluorescence is an imaging tool that illuminates 
targeted proteins. The NOX receptors were labelled with primary antibodies and 
fluorescence probed secondary antibodies. Using a 1:100 dilution of the primary 
antibody and a 1:500 dilution of the secondary antibody, the NOX receptors were 
highlighted.  
 
4.2.2. Dihydroethidium Stain  
The aim of this technique is to observe the presence of superoxide in the bladder. The 
imaging technique works by the formation of hydroxyethidium; when superoxide 
binds to hydroethidium. In order to obtain the results, cross sections of urinary 
bladder were snap frozen in OCT and cryosectioned. This produced, thin, 18μm 
sections on microscopic slides. The slides were incubated in the DHE buffer (Figure 
16) for 30 minutes at 37°C. Subsequently, the DHE stain was added and the sections 
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viewed under a confocal microscope, using Alexa at 568nm and nuclear stain DAPI at 
488nm. Tiron, the superoxide scavenger, was added to as a positive control. For 
further details on this method, refer to section 2.4.  
 
4.2.3. Isometric Tension Experiments  
Strips of full thickness bladder wall and mucosa alone urinary bladder were isolated 
and attached between two hooks. The lengths of these strips were extended by 30% of 
their original size. HEPES-buffered Tyrodes was perfused over the tissue at a constant 
rate of 2ml/minute. The hooks were attached to a tension transducer that was able to 
record changes in muscle contractions, both spontaneous and induced.  
 
4.2.4. ATP release  
In parallel to the drug interventions, 45ul samples of the superfusate were taken at the 
various time points during the intervention. These were stored at -4oC until measured.  
To measure the ATP released, we used a luciferase reaction to detect the quantity of 
ATP. The luciferase reaction produces a luminescence product, in direct proportion to 
quantitative ATP release. This was expressed as pica moles of ATP per gram of tissue 
per mole.  
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4.2.5. Tension Analysis  
Experimental files were saved and loaded onto Clampfit 9.0. These recordings of 
muscle tension were analysed and reported as an expression of force in μN/mg. For 
each tissue recording, the force of contraction and the maximum force were tabulated 
for each drug intervention against the pre- and post-controls. The force of contraction 
was taken as an average of three recordings, whereas the maximum force was taken as 
the largest force detected during the drug intervention. 
4.2.6. Reactive oxygen species measurement  
ROS production was measured using chemiluminescence. The tissue samples, 2-3mm 
in diameter, were crushed, homogenised and sonicated (see chapter 2.2.5) in 100μl 
Hanks balance salt solution prior to loading in the LUMIstar Omega 
chemiluminescence machine. Protein concentrations were determined using Bradford 
assay detailed in chapter 2.4.  
LUMIstar Galaxy (BMG Labtech) software was used to set the chemiluminescence 
temperature incubator to 37°C. The injection lines were also primed with lucigenin 
buffer (Figure 17) before the injection cycle being initiated.  
An example of the 96-well plate design is presented in Figure 18. The wells were 
loaded with 25µl of sample and topped with 115µl of sample buffer (recipe in Table 
2.5.1). The two blank wells contained 115μl of sample buffer only. The plate was then 
inserted into the chemiluminescence machine and a basal reading taken. Following 
this ‘Test Protocol for 3 SEC NO INJ’ was initiated, NADPH Oxidase solution was 
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added into each well before the reading. Lastly the addition of 1M Tiron was done 
manually and the fluorescence detected using ‘Test Protocol for 3 SEC NO INJ’.  
All results were exported to Excel, Microsoft 2010. Reactive oxygen species readings 
were expressed per 100μg of protein and graphically presented.  
 
4.3. The Presence of NADPH Oxidase in Urothelium  
In the discovery of the presence and role of NADPH Oxidase in the urinary bladder, 
the detection of NOX complexes were identified first. The use of 
immunofluorescence elucidated the localisation of NOX 1 and 2 isoforms in the 
mucosa and detrusor smooth muscle of the bladder. Figures 39 – 40 show the images 
from these experiments.  
NOX1 and NOX2 are isoforms of the NADPH oxidase enzyme, with their primary 
role being in the catalytic production of intracellular ROS by electron transfer to 
oxygen (refer to section 1.6.3).  It is thought to have its cellular location mainly on the 
plasma membrane and endosome. Figure 41 presented shows that NOX1 is positively 
stained in the urothelium of the urinary bladder and the smooth muscle. There was 
little/no non-specific staining in the control images for the secondary antibody. NOX1 
appears to be present in the urothelium and not the sub-urothelium of the bladder. The 
presence of NOX1 in the epithelial cells is also similar to other organs of the body; 
for example, in the colon it is found in differentiated epithelial cells (Bánfi et al. 
2000). This layer specificity may be an indication of the role of NOX1 in the bladder. 
B 
 
 159 
 
Its presence on the plasma membrane of cells situated closest to the lumen of the 
bladder, give a strong indication of a signalling role.  
Similar to NOX1 localisation, the presence of NOX2 in the urinary bladder is mainly 
in the urothelium rather than the detrusor smooth muscle. NOX2 also seems to have a 
greater presence in the sub-urothelium than NOX1, but this is still less than the 
urothelial layer.  
 
 
 
 
 
 
  
 
Figure 41. Immunofluorescence of NOX1 in the urinary bladder 
A. Primary control for NOX1 in the urothelial layer. B. primary control for NOX1 in 
the detrusor smooth muscle layer of the urinary bladder. C. Primary antibody stain 
for NOX1 in the urothelial layer. D. Primary antibody stain for the NOX1 in the 
detrusor smooth muscle layer of the urinary bladder. 
B 
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Figure 42. Immunofluorescence of NOX2 in the urinary bladder 
A. Primary control for NOX2 in the urothelial layer. B. Primary control for NOX2 in 
the detrusor smooth muscle layer of the urinary bladder. C. Primary antibody stain 
for NOX2 in the urothelial layer. D. Primary antibody stain for the NOX2 in the 
detrusor smooth muscle layer of the urinary bladder.  
This research extended the imaging technique to obtain evidence for the presence of 
reactive oxygen species in the bladder. The use of dihydroethidium was suitable 
because it is able to stain superoxide anions inside the cells and highlight the 
localisation of this free radical species. The function of this stain is to locate 
10µm 
Umbrella cells 
Sub-urothelium  
Smooth muscle cells 
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superoxide anions only and does not include other reactive oxygen species that may 
be present in the tissue.  
4.4. The presence of Reactive Oxygen Species in the 
bladder  
The identification of NADPH oxidases in the urothelium and smooth muscle of the 
bladder is a strong indication that ROS and oxidative stress play a role in bladder 
physiology. However, the immunofluorescence stains above do not provide evidence 
for the functional role of the NOX enzymes in producing ROS in the bladder and the 
effect of this on bladder activity.  
Therefore, this investigation proceeded to identify the presence of ROS in the 
urothelium and smooth muscle of the urinary bladder. In order to do this, a 
dihydroethidium stain was used. This stain highlights superoxide anions, producing 
cross sectional images that show the localisation of superoxide anions.  
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Figure 43. Superoxide detection using Dihydroethidium fluorescence stain in the 
urinary bladder 
A. Tiron control, urothelial section B. Tiron control smooth muscle section C. smooth 
muscle D. urothelium. Cryosections of all the layers of the bladder wall were 
incubated in dihydroethidium buffer, followed by dihydroethidium stain. Sections 
were viewed under a confocal microscope at approx.650 nm. The obtained images 
displayed positive detection of superoxide anions in the urothelium and the smooth 
muscle layers of the bladder, which is greatly reduced with Tiron. x40 magnification. 
N=6.  
As displayed clearly in figure 43 at x40 magnification of the urothelium and smooth 
muscle, DHE was able to positively stain superoxide anions in both regions of the 
bladder. This was measure using the confocal microscope, the same confocal 
microscope was used for all imaging techniques. Tiron, a superoxide scavenger, acts 
as a positive control; which provides further confidence on the results of the DHE 
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stain (figure 43A, B). The evidence for the presence of superoxide anions in the 
urothelium support the immunofluorescence stains. NOX enzymes are present in the 
urothelium and smooth muscle as well as their products ROS.  
Following the detection and elucidation of NOX isoforms and superoxide production 
in the urinary bladder, this investigation observed the functional significance of ROS 
in the bladder. Using isometric tension experiments, the response of the bladder to 
hydrogen peroxide as a ROS ligand and Apocynin as an antioxidant and an inhibitor 
for NOX enzymes were measured.  
Firstly, hydrogen peroxide was added as a ROS stimulatory ligand. This was done to 
observe whether hydrogen peroxide could induce additional ATP release from the 
mucosa and full thickness bladder wall strips.  
Presented in figure 44 are the results for the action of hydrogen peroxide as a ROS 
activator in the mucosa and bladder wall. 100μM Hydrogen peroxide was a suitable 
concentration to be used based on literature research. Hydrogen peroxide has been 
shown to have effective ROS activity at micro molar concentrations (Nakamura et al. 
2003); and application of exogenous 100μM concentrations has previously been used 
to show physiological in vivo stress conditions (Jacob & Winyard 2009). Hydrogen 
peroxide was able to increase ATP release from 169.94 pmoles/g/min in the control to 
283.51 pmoles/g/min in the mucosa alone strips. This is almost double the amount of 
ATP release. In the full thickness bladder strips this was an elevation from 17.34 
pmoles/g/min to 49.44 pmoles/g/min. greater than the increase in the mucosa, the 
whole bladder wall is able to almost triple the ATP release seen in the controls.  
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This is suggestive that hydrogen peroxide plays a role in ATP release in the mucosa 
and throughout the layers of the bladder. Although, from the results presented in 
figure 44 there is a strong indication that the mucosa is a major contributor to ATP 
release, the increase seen in the whole bladder is evidence that the detrusor smooth 
muscle also responds to hydrogen peroxide. Thus hydrogen peroxide may act on both 
the mucosa and the smooth muscle effectively to induce ATP release.  
This result points to the possibility that reactive oxygen species, in general, may play 
a role in the physiological function of the urinary bladder. The ability of hydrogen 
peroxide, the end product of other reactive oxygen species to further potentiate ATP 
release, is suggestive that other reactive oxygen species may have a similar role but to 
varying degrees.  
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B.  
Figure 44. The ability of hydrogen peroxide to induce ATP release 
This data shows the change in ATP release with and without the presence of hydrogen 
peroxide – a free radical. Firstly, spontaneous ATP release was measured from 
mucosa alone (A.) and full thickness (B.) bladder strips in HEPES-buffered control. 
Then 100μM hydrogen peroxide was perfused over the same tissue preparations and 
the ATP in the superfusate measured. Hydrogen peroxide was able to significantly 
increase ATP release in the mucosa and mucosa attached muscle. N=8. *P<0.05, 
paired student’s t test.  
 
 166 
 
Secondly, the data from the induction of ATP release by hydrogen peroxide was 
reanalysed to highlight the relative ATP release in ATP release between the two tissue 
preparations. The results are displayed in figure 45.  Hydrogen peroxide caused the 
mucosa strip to release an increase of 113% in ATP release in comparison to the 
controls: the increase (pmoles/g tissue/min: control (± SEM), 100μM hydrogen 
peroxide (±SEM)), in the mucosa: 169.9 ± 54.7 and 283.5 ± 77.7. The full thickness 
bladder strips caused an increase of 32% in the stimulated response in comparison to 
the spontaneous release; the increase (pmoles/g tissue/min: control (± SEM), 100μM 
hydrogen peroxide (±SEM)), in full thickness strips: 17.3 ± 4.7 and 49.4 ± 16.3. The 
stimulated ATP release in the mucosal strips was significantly greater than that of the 
full thickness bladder (figure 45). Therefore the additional stimulated release of ATP 
must be largely from the mucosa.  
These results provide evidence for the functional action of ROS in the bladder and on 
bladder activity. ROS positively affect bladder activity by encouraging ATP release 
from the bladder wall, which as stated previously, uses both paracrine and autocrine 
to mediate an activation of bladder wall activity.  
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Figure 45.Relative ATP release with hydrogen peroxide in mucosa alone and full 
thickness strips 
This figure is a comparison of ATP release from mucosa strips (A.) with that of full 
thickness bladder strips (B.) when 100μM hydrogen peroxide is added. ATP release is 
expressed as relative ATP release (stimulated release/spontaneous release). This 
figure reveals that ATP release in the mucosa strips was significantly greater than the 
full thickness muscle strips in the presence of hydrogen peroxide. N=8. *P<0.05, 
Wilcoxon signed rank test.  
Thirdly, the action of Apocynin on bladder tissue was examined. Apocynin acts a 
NADPH Oxidase inhibitor and was used in this study for this purpose. Investigations 
using Apocynin highlighted were what was expected; this is thought to be due to the 
presence of antioxidants on bladder activity. Results were opposite to that seen with 
the addition of ROS. The results from this experiment are displayed in figure 46. As 
presented in the figure, Apocynin was able to significantly reduce ATP release in both 
mucosa strips and full thickness bladder wall.  
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A.                                                                                B.  
Figure 46. The ability of Apocynin to inhibit ATP release 
This data shows the change in ATP release with and without the presence of Apocynin 
– an antioxidant. Firstly, spontaneous ATP release was measured from mucosa alone 
(A.) and full thickness (B.) bladder strips in HEPES-buffered control. Then 100μM 
Apocynin was perfused over the same tissue preparations and the ATP in the 
superfusate measured. In the mucosa a pattern of decrease can be seen in this data 
but the inhibitory response is not significant. However there is a significant difference 
between the average inhibitions in the full thickness bladder in comparison to the 
control. N=9. *P<0.05, Wilcoxon signed rank test. 
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4.5. Stimulated production of reactive oxygen species  
Subsequent to the elucidation of ROS in the urinary bladder and evidence of its effect 
on ATP release, this investigation went on to look at the ability of angiotensin II to 
directly influence ROS production. This would provide an indication as to whether 
angiotensin and ROS, who independently affect bladder physiology, have an 
interdependent role.  
 
 
 
 
 
Figure 47. Induced superoxide production 1µM Angiotensin II in the urinary bladder 
Strips of bladder were incubated in either 1μM angiotensin II for 30mins at 37°C. The 
quantity of ROS present was measured according to a lucigenin reaction in a 
chemiluminescence machine when NADPH oxidase is added to each sample. This 
figure displays the results obtained. Angiotensin II was able to significantly increase 
ROS production in the bladder. N=16. *P<0.05, paired Student’s T test.   
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 Figure 48.Stimulated superoxide production with 200nM Angiotensin II  
Strips of bladder were incubated in either 200nM angiotensin II for 30mins at 37°C. 
The quantity of ROS present was measured according to a lucigenin reaction in a 
Chemiluminescence machine when NADPH oxidase is added to each sample. This 
figure displays the results obtained. There is no significant difference between the 
spontaneous and stimulated superoxide release. N=10. P<0.05, Wilcoxon signed rank 
test 
 
The results displayed above give evidence for the ability of 1μM angiotensin II to be 
able to significantly increase the release of ROS from bladder strips in comparison to 
the control. This data is suggestive of a communicative role between angiotensin II 
and ROS in the bladder. The action of one affects the other; figure 42, 44 and 45 show 
that ROS is able to increase ATP release (similarly to angiotensin II, figure 27.) but 
also angiotensin II is able to increase ROS.  
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4.6. Discussions and Summary  
This chapter of the thesis aimed to explore the presence of ROS in the urinary 
bladder, its presence and physiological function.  
Firstly, the presence and localisation of the NADPH oxidase isoforms 1 and 2 were 
established in figures 41 – 42. These figures show that all the above isoforms are 
present in the urinary bladder in both the urothelium and smooth and provided 
evidence that NOX 1 and 2 are most prevalent in the urothelium.  
Secondly, this report went on to look at the ability of the bladder to produce ROS. 
This was done by both staining and quantitative ROS detection methods. This 
revealed that the urinary bladder was able to produce ROS in both instances (figure 
41 – 48). It must be noted that the results of the DHE experiment (figure 43) only 
reveal to us the presence of intracellular superoxide anion, whereas ROS detection 
using a lucigenin reaction is an indication of the presence of a group of reactive 
oxygen species (figure 47-48) (Owusu-Ansah et al. 2008). This observation of 
spontaneous ROS production was evidence that the detected NADPH oxidase 
isoforms, are not only expressed in the bladder but may also lead to the detected ROS 
production seen in figures 47-48.  
Subsequently, the physiological function of ROS in the urinary bladder was 
examined. Could ROS affect bladder activity? The data presented in figures 44-46, 
demonstrate the observed results when reactive oxygen species H2O2 was perfused 
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over strips of mucosa and full thickness bladder wall. The results presented reveal that 
ROS is not only present in the bladder but also plays a significant role in ATP release. 
The inhibitory effects using Apocynin further support this conclusion. It also provides 
indirect evidence that NOX-derived ROS plays a role. The effects of H2O2 on bladder 
activity are more prominent in mucosa strips than the other layers of the bladder. This 
suggests the importance of ROS in regulating urothelial function.   
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5.1. Introduction  
The first model that was examined was ageing tissue. From literature, ROS has been 
reported to build up and be the initiator behind ageing. In Harman’s report on the 
‘theory of ageing’, he first proposed that ageing, was caused by a build-up of ROS 
within tissues resulting in protein and lipid degradation (Harman 1956). In this section 
of this investigation, we examine the effect of angiotensin II and ROS in ageing 
models. Their effects are also observed in P2Y2 knockout models, NOX2 knockout 
models and ApoE knockout models. 
 
5.2. Methods  
5.2.1. Functional experiment  
Strips of full thickness bladder wall and mucosa alone urinary bladder were isolated 
and attached between two hooks. The lengths of these strips were extended by 30% of 
their original size. HEPES-buffered Tyrodes was perfused over the tissue at a constant 
rate of 2ml/minute. The hooks were attached to a tension transducer that was able to 
record changes in muscle contractions, both spontaneous and induced. In this chapter, 
200nM angiotensin II, 1μM angiotensin II, 100μM hydrogen peroxide and 100μM 
Apocynin were used.  
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5.2.2. ATP analysis  
An ATP assay able to detect pica mole quantities of ATP was used. To measure the 
ATP released, we used a luciferase reaction to detect the quantity of ATP. The 
luciferase reaction produces a luminescence product, in direct proportion to 
quantitative ATP release. This was expressed as pica moles of ATP per gram of tissue 
per mole. In parallel to the drug interventions, 45ul samples of the superfusate were 
taken at the various time points during the intervention. These were stored at -4oC 
until measured.  
5.2.3. Bladder contractility analysis  
Experimental files were saved and loaded onto Clampfit 9.0. These recordings of 
muscle tension were analysed and reported as an expression of force in μN/mg. For 
each tissue recording, the amplitude of contraction and the maximum amplitude were 
tabulated on Microsoft Excel 2010, for each drug intervention against the pre- and 
post-controls.  
5.2.4. Measurement of ROS   
ROS production was measured using chemiluminescence. The tissue samples, 2-3mm 
in diameter, were crushed, homogenised and sonicated in 100μl Hanks balance salt 
solution prior to loading in the LUMIstar Omega chemiluminescence machine. 
Protein concentrations were determined using Bradford assay detailed in chapter 2.4.  
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LUMIstar Galaxy (BMG Labtech) software was used to set the chemiluminescence 
temperature incubator to 37°C. The injection lines were also primed with lucigenin 
buffer (Figure 17) before the injection cycle being initiated.  
An example of the 96-well plate design is presented in Figure 18. The wells were 
loaded with 25µl of sample and topped with 115µl of sample buffer (recipe in Figure 
17). The two blank wells contained 115μl of sample buffer only. The plate was then 
inserted into the Chemiluminescence machine and a basal reading taken. Following 
this ‘Test Protocol for 3 SEC NO INJ’ was initiated, NADPH Oxidase solution was 
added into each well before the reading. Lastly the addition of 1M Tiron was done 
manually and the fluorescence detected using ‘Test Protocol for 3 SEC NO INJ’.  
All results were exported to Excel, Microsoft 2010. Reactive oxygen species readings 
were expressed per 100μg of protein and graphically presented.  
 
5.3. The effect of angiotensin II and ROS in ageing 
models 
 
In this last chapter of the investigation into the role of angiotensin II in bladder 
physiology, the effects of angiotensin II were examined in pathophysiological 
conditions. The first model that was investigated was the ageing model. The effect of 
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angiotensin II on ATP release was observed in these tissues and the results are 
presented in figure 49 and 50.   
A.  
 
 
B.  
 
 
 
Figure 49. Effect of angiotensin II on ATP release in ageing guinea pig models 
This figure is a comparison of ATP release from mucosa strips (A.) with that of full 
thickness bladder strips (B.) when 1μM angiotensin II is added to an ageing model. 
Spontaneous ATP release was measured from mucosa alone (A.) and full thickness 
(B.) bladder strips in HEPES-buffered control. Then 1μM angiotensin II was perfused 
over the same tissue preparations and the ATP in the superfusate measured. This 
figure reveals that ATP release in the mucosa strips was significantly greater in the 
presence of angiotensin II but not full thickness bladder strips. N=11. *P<0.05, 
Wilcoxon signed rank test.  
The results presented in figure 49 show the effect of angiotensin II in the ageing 
model. Angiotensin II was able to significantly increase ATP release from the 
Control 1µM 
Ang II
0
100
200
300
400
500
A
T
P
 r
e
le
a
s
e
 (
p
m
o
le
s
/g
/m
in
)
*
Control 1µM Ang II
0
10
20
30
40
A
T
P
 r
e
le
a
s
e
 (
p
m
o
le
s
/g
/m
in
)
 179 
 
mucosa. The rise in ATP seen here was approximately double that of the control, 
rising to 216.7 pmoles/g/min from 106.2 pmoles/g/min in the mucosa alone bladder 
strip. However, in the full thickness bladder strip (figure 49.B) the addition of 
angiotensin II caused a small insignificant change.  
The change in ATP release in both young and ageing models were then compared 
with each other. These were expressed as relative ATP release between the stimulated 
response and the spontaneous response. This was done to make clear the observed 
difference between the increased ATP releases seen in young models against that seen 
in ageing models.                                     
 
 
                    
A.                                                          B                  
Figure 50. The relative ATP release of young and ageing models when angiotensin II 
is added 
A comparison of ATP release from young and ageing guinea pig models when 1μM 
angiotensin II is perfused over both mucosa alone strips (A.) and full thickness 
bladder strips (B.). The stimulated response expressed as relative ATP release was 
compared to the spontaneous release in HEPES-buffered Tyrode. This data was 
significant in full thickness bladder strips, but not in isolated mucosa strips. N=11. 
*P<0.05, Wilcoxon signed rank test.   
Y
o
u
n
g
A
g
e
in
g
 
0
2
4
6
8
1 0
R
e
la
ti
v
e
  
A
T
P
 R
e
le
a
s
e
(s
ti
m
u
la
te
d
/s
p
o
n
ta
n
o
u
s
 -
 p
m
o
le
s
/g
/m
in
)
Y
o
u
n
g
 
A
g
e
in
g
 
-5
0
5
1 0
1 5
2 0
R
e
la
ti
v
e
  
A
T
P
 R
e
le
a
s
e
(s
ti
m
u
la
te
d
/s
p
o
n
ta
n
o
u
s
 -
 p
m
o
le
s
/g
/m
in
)
*
 180 
 
Subsequently, the effect of ROS on ageing models was examined. In the young 
models, our data revealed a positive correlation between hydrogen peroxide and ATP 
release. Figures 48 shows the effect of this in the ageing models.  
 
A.  
 
 
 
B.  
 
Figure 51. The effect of hydrogen peroxide (ROS) on ATP release in ageing models 
This figure is a comparison of ATP release from mucosa strips (A.) with that of full 
thickness bladder strips (B.) when 100μM H2O2 is added to an ageing model. 
Spontaneous ATP release was measured from mucosa alone (A.) and full thickness 
(B.) bladder strips in HEPES-buffered control; this was contrasted against hydrogen 
peroxide induced ATP release. The results displayed here reveal that ATP release in 
the mucosa strips was greater in the presence of hydrogen peroxide for both mucosa 
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strips and full thickness bladder strips. However, the data is only significant for full 
thickness bladder strips. N=7. *P<0.05, Wilcoxon signed rank test.  
Similar to the results seen in young models (refer to Figure 27), the ageing models 
were also able to increase ATP release. In mucosa alone strips, this was from 89.10 
pmoles/g/min to 129.765 pmoles/g/min when hydrogen peroxide was added, which is 
an increase of 45%. The effect of hydrogen peroxide on full thickness bladder strips 
was an even greater increase in ATP release by 84%. Therefore the results presented 
point to a consistent effect of ROS in the bladder to mediate ATP release.  
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Figure 52. The effect of Apocynin (antioxidant) on ATP release in ageing models 
This figure is a comparison of ATP release from mucosa strips (A.) with that of full 
thickness bladder strips (B.) when 100μM H2O2 is added to an ageing Dunkin Hartley 
guinea pig model. Spontaneous ATP release was measured from mucosa alone (A.) 
and full thickness (B.) bladder strips in HEPES-buffered control; this was contrasted 
against hydrogen peroxide induced ATP release. The results displayed here reveal 
that ATP release in the mucosa strips was greater in the presence of hydrogen 
peroxide for both mucosa strips and full thickness bladder strips. However this data is 
not significant. N=7. P<0.05, Wilcoxon signed rank test.  
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The effect seen in ageing Dunkin Hartley guinea pig models is mirrored in mice 
models. In C5/7BL mice, Apocynin was able to significantly increase ATP release in 
full thickness bladder strips. This supporting evidence that ageing mice, are able 
activate ATP release in the presence of antioxidants is further evidence that in the 
ageing model, ROS plays a role – as seen by the results from hydrogen peroxide, but 
other factors are still contributory. In addition, the response of ROS to the antioxidant 
is changed in ageing bladders. Figure 46, shows the effect of Apocynin on young 
guinea pig bladders. The graphs show a significant decrease with the addition of 
Apocynin, but in ageing bladders the reverse is seen. Figure 53 below shows 
significant increase.  
 
 
 
Figure 53 The effect of Apocynin (antioxidant) on ATP release in ageing mice models 
This figure is a comparison of ATP release from mucosa strips (A.) with that of full 
thickness bladder strips (B.) when 100μM H2O2 is added to an ageing C57BL/6 mice 
model. Spontaneous ATP release was measured from mucosa alone (A.) and full 
thickness (B.) bladder strips in HEPES-buffered control; this was contrasted against 
hydrogen peroxide induced ATP release. The results displayed here reveal that ATP 
release in the mucosa strips was greater in the presence of hydrogen peroxide for 
both mucosa strips and full thickness bladder strips. N=7. *P<0.05, Wilcoxon signed 
rank test. 
Control  Apocynin
0
200
400
600
A
T
P
 r
e
le
a
s
e
 (
p
m
o
le
s
/g
/m
in
)
*
 184 
 
5.4.  P2Y2 Knockout Models  
 
The P2Y2 receptor has been widely researched for its role in mediating ATP action 
and has been specifically highlighted in the bladder. This receptor is known to be 
expressed in the urothelium (Wang et al. 2005; Chopra et al. 2008; Mansfield & 
Hughes 2014).  Investigations by Chen et al. 2010, revealed that P2Y2 receptors were 
able to sensitise sensory neurons in the urinary bladder. Additionally, they appeared 
to play a modulatory role for purinergic currents (Chen et al, 2010). Research 
suggests that P2Y2 plays a role in bladder pain syndrome and work by Birder et al. 
2013, highlights a marked loss in P2Y2 expression in the layers of the bladder wall in 
cats with bladder pain syndrome. The benefits of using a P2Y2 knockout model is that 
it allows us to observe whether there is an interaction between the ATP pathway via 
P2Y2 and the mediators being used – angiotensin II, hydrogen peroxide and Apocynin. 
This analysis, adds a greater depth to the investigation as the mediatory pathways are 
explored.  
In the figures below, angiotensin II, hydrogen peroxide and antioxidant Apocynin are 
perfused of mounted strips of P2Y2 knockout bladder and the results are presented.  
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Figure 54. The effect of angiotensin II on ATP release in P2Y2 knockout models 
This figure represents the data recorded when 200nM angiotensin II is added to full 
thickness bladder strips taken from P2Y2 knockout mice. These mice bladder strips 
were perfused with 200nM angiotensin II and the ATP from the superfusate 
measured. The results show a pattern of increase when angiotensin II although this is 
not significant. N=12. P<0.05, Wilcoxon signed rank test.  
Angiotensin II, as demonstrated in figure 54, was able to elevate released ATP from 
the full thickness bladder strips taken from P2Y2 knockout mice models. The data is 
not significant, but an increase is seen. As seen in this figure, angiotensin II is not 
dependent on P2Y2 to mediate its action of releasing ATP. Thus other receptors, 
previously known to mediate ATP’s action must be involved; such as P2Y4 (Wang et 
al. 2005; Andersson 2015). Additionally, the results of this intervention are not 
significant and therefore, P2Y2 may play a minor role in angiotensin II signalling. The 
action of angiotensin may not be dependent upon this receptor, but it may be 
involved.  
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The results seen in figure 54 are further confirmed by the action of ATP analogue 
UTP. Using UTP, an interaction study was carried out to assess whether the co-
activation of angiotensin II and UTP was able to further increase ATP release in 
comparison to their individual action. 
 
 
 
 
 
Figure 55. The effect of angiotensin II and UTP on ATP release in P2Y2 knockout 
models 
This figure represents the data recorded when 200nM angiotensin II, 100μM UTP 
and 200nM + 100μM UTP are added to full thickness bladder strips taken from P2Y2 
knockout mice. These mice bladder strips were first perfused with 200nM angiotensin 
II, followed by 100μM UTP and lastly 200nM + 100μM UTP, with 1 hour recovery 
periods between each intervention. The ATP from the superfusate was measured. The 
results show that there is a significant difference between the means of the three 
interventions, with UTP producing the largest release of ATP. N=10. *P<0.05, 
Wilcoxon signed rank test.  
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Figure 55 illustrates that all three drug interventions were able to increase ATP 
release in comparison to the control – angiotensin II, UTP and angiotensin II+UTP. 
UTP had a greater increase in ATP release than angiotensin II as expected, due to the 
autocrine and paracrine action of ATP to self-activate further ATP release. The 
release induced by UTP can be seen to be about 6 times that of angiotensin II. 
Suggesting that ATP is a potent activator of further ATP release and thus bladder 
activity.  
The difference between all three means was shown to be significant. However, co-
activation of angiotensin II and UTP did not further increase ATP release. If these 
results had been higher it would have given us insight into a co-modulatory 
mechanism between angiotensin II and ATP. But this is not the case. The action of 
angiotensin II as seen in wild type guinea pigs and mice also is not combined with 
that of ATP.  
Subsequently, the effect of ROS on P2Y2 knockout mice was explored (figure 56). 
Similar to experiments carried out on wild type mice, hydrogen peroxide and 
Apocynin were perfused over tissue preparations and the ATP measured. The tissue 
preparations were selectively full thickness bladder strips only. The results displayed 
in figure 56 show that hydrogen peroxide was able to significantly increase ATP 
release from spontaneous release seen in the control to that seen in the induced 
response.  
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Figure 56. The effect of hydrogen peroxide on ATP release in P2Y2 knockout models 
This figure represents the data recorded when 100μM hydrogen peroxide is added to 
full thickness bladder strips taken from P2Y2 knockout mice. These mice bladder strips 
were perfused with 100μM hydrogen peroxide and the ATP from the superfusate 
measured. The results show a significant rise in ATP release when hydrogen peroxide 
is added in comparison to the control. N=6. *P<0.05, Wilcoxon signed rank test.  
 
Following on from the effects of additional ROS on P2Y2 knockout mice, the 
production of ROS was measured from the tissues. The perfusion of tissue with ROS 
shows the effect of adding ROS into the system has on the output, but it does not 
provide solid evidence that ROS is already present in that tissue under normal 
physiological conditions. Therefore the examination of ROS production was 
necessary.  
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Figure 57. Spontaneous ROS production from wild type and P2Y2 knockout mice 
models 
The quantity of ROS present, in urinary bladder strips, was measured according to a 
lucigenin reaction in a Chemiluminescence machine when NADPH oxidase is added 
to each sample. Wild type male mice were compared with P2Y2 knockout male models, 
this figure displays the results obtained. Wild type mice had a significantly greater 
quantity of ROS production than P2Y2 knockout mice. N=9. *P<0.05, unpaired 
student’s T test.  
Figure 57 shows the ROS production observed from P2Y2 mice models in comparison 
to wild type mice models. This figure is evidence that the presence of superoxide 
anions is significantly decreased in P2Y2 knockout models. This is suggestive that this 
receptor is involved in the release of superoxide from the bladder tissue and that ATP 
may activate ROS release or production. However, it is not the only activator of ROS, 
as a complete inhibition of superoxide anions cannot be seen in figure 57.  
Access to both male and female P2Y2 knockout model mice, gave us the opportunity 
to compare gender differences in these models in their ability to produce superoxide. 
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The results presented in figure 58 show that female mice produced more superoxide 
anions than their male counterparts. The difference seen here are not significant.  
 
 
 
 
Figure 58. Spontaneous ROS production from P2Y2 knockout mice models 
ROS detection in urinary bladder strips, was measured according to a lucigenin 
reaction in a luminometer machine when NADPH oxidase is added to each sample. 
This figure displays the results obtained. The ROS generation was observed in both 
male and female models. Females had a higher pattern of increase in superoxide 
production than males. N=5. This data is not significant, *P<0.05 Wilcoxon signed 
rank test.  
Similar to wild type superoxide production, our investigation looked at induced 
release of superoxide anions. The results displayed in figure 59 show a quantification 
of the superoxide anions detected when full thickness bladder tissue is incubated in 
angiotensin II prior to measurement.  
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A.  
 
 
 
 
 
B.  
 
Figure 59. Stimulated ROS production from P2Y2 knockout mice models 
Bladder strips were pre-incubated in 200nm angiotensin II (A.) and 1μM angiotensin 
II (B.) for 30 minutes at 37°C. The quantity of ROS present, in the urinary bladder 
strips, was then measured according to a lucigenin reaction in a Chemiluminescence 
machine when NADPH oxidase is added to each sample. This figure displays the 
results obtained. In the absence of P2Y2 receptors, angiotensin II reduced ROS 
production. N=11 (200nM Ang II), N=4 (1μM Ang II). P<0.05, Wilcoxon signed rank 
test  
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Two concentrations of angiotensin II were used, 200nM and 1μM angiotensin II. The 
lower concentration of 200nM was not able to increase superoxide release and caused 
a decrease in superoxide instead. Conversely, a higher concentration of 1μM 
angiotensin II was able to increase superoxide but this was minimal and not 
significant.  
These results are consistent with that seen in figure 54, the P2Y2 receptor must play a 
more central role in superoxide production, such that the addition of stimulants cannot 
further increase the production of superoxide. Therefore there is room to speculate 
that perhaps the P2Y2 receptor and therefore ATP are part of the pathway for 
superoxide release in bladder tissue.  
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5.5. NADPH Oxidase 2 knockout models   
 
In addition to the ageing models and P2Y2 knockout models described above, our 
research also investigated bladder activity in NOX2 knockout models. This was vital 
to our research as our aims and hypothesis intended to observe whether there was a 
relationship between the action of angiotensin II and reactive oxygen species.  
Firstly, the effect of angiotensin II was witnessed in male wild type C57BL/6J mice 
that were young (2-6 months) and ageing (18-24 months) and also in NOX2 knockout 
mice that were intermediate age (6-10months) and ageing (12-18 months).  
The perfusion of wild type and NOX2 knockout mice with angiotensin II caused an 
increase in ATP release in all tissue preparations in comparison to their controls. 
Similar to the results presented so far in this investigation, angiotensin II is able to 
consistently increase ATP release despite varying conditions or knockouts.  
In general, the NOX2 knockout mice were able to produce more ATP release than 
their wild type counterparts. With higher spontaneous release than stimulated ATP 
release, this suggests that knocking out the NOX2 receptor may up-regulate other 
pathways to release ATP by a compensatory mechanism.  
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Figure 60. Angiotensin II in male wild type mice and male NOX2 knockout mice 
This result represents the data observed when 1μM angiotensin II is added to full 
thickness mice bladder strips. These mice bladder strips were perfused with 1μM 
angiotensin II and the ATP from the superfusate measured. The results show a 
significant rise in ATP release when angiotensin II is added in comparison to their 
controls. NOX2 knockout ageing is able to produce the highest ATP release. N=6. 
*P<0.05, Wilcoxon signed rank test.  
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In addition to the difference seen in species variation, a difference can be seen 
between ages. The young mice models in comparison to the ageing mice models had a 
lower ATP release. The ageing models had double the ATP release in respect to their 
species counterparts. This observation is indicative that ageing has increased bladder 
activity for both wild type and NOX2 knockout models.  
Figure 61. Hydrogen peroxide in male wild type mice and male NOX2 knockout mice 
This result represents the data observed when 100μM hydrogen peroxide is added to 
full thickness mice bladder strips. These mice bladder strips were perfused with 
100μM hydrogen peroxide and the ATP from the superfusate measured. The results 
show a significant rise in ATP release when angiotensin II is added in comparison to 
their controls. NOX2 knockout ageing is able to produce the highest ATP release. 
N=6. *P<0.05, Wilcoxon signed rank test.  
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In a similar fashion to the stimulation of ATP release by angiotensin II, hydrogen 
peroxide is also able to increase ATP release in both wild type and NOX2 knockout 
mice models. Analogous to data for angiotensin II, hydrogen peroxide is able to have 
its most potent effect in NOX2 knockout ageing mice.  
The species variation sets as a good backdrop to be able to see that NOX2 knockout 
mice were more receptive to hydrogen peroxide than wild type. Although, ROS 
should be an activator of NADPH oxidase and bladder activity and knocking out 
NOX2 should produce less bladder activity, the results presented here are polar to 
that. NOX2 knockout mice had greater bladder activity.  
In addition to this, younger mice models released less ATP than ageing. This may be 
due to the build-up of oxidative stress by ROS in the ageing models, thus the addition 
of further ROS to the system has a greater impact on ATP release than young mice.  
Lastly, antioxidant Apocynin was added to tissue preparations. Our hypothesis was 
that Apocynin would inhibit ATP release both in wild type and NOX2 knockout mice. 
The results presented in figure 61 show that Apocynin had minimal effect on ATP 
release in any of the tissue preparations. In both young and ageing models, the ATP 
released was not significantly different to the control. Additionally in the wild type 
and NOX2 knockout models, the difference between the antioxidant and the control 
are negligible.  
 197 
 
 
Figure 62. Apocynin effect on male wild type mice and male NOX2 knockout mice 
This result represents the data observed when 100μM Apocynin is added to full 
thickness mice bladder strips. These mice bladder strips were perfused with 100μM of 
this antioxidant and the ATP from the superfusate measured. The results show there is 
no significant difference in the ATP released when Apocynin is added in comparison 
to their controls. NOX2 knockout ageing is able to produce the most ATP release, 
although the difference against its control is not significant. N=6.  
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5.6. Apo E knockout mice models  
Apo E is a lipoprotein transporter and plays a role in lipid metabolism. It has been 
found to be expressed in various tissues of the body, including the liver, small 
intestine, brain and kidneys (Srivastava et al. 1996). The signalling effects of ROS 
include lipid peroxidation. Therefore our research extended to explore the effects of 
angiotensin II and ROS in bladder models where there was an imbalance of lipids.  
Apo E knockout mice, present with hypercholesterolemia and thus have been used to 
study atherosclerosis (Jawein, 2012). The inflammatory disease, atherosclerosis, is 
accompanied by high cholesterol levels, increased pro-inflammatory markers, damage 
to endothelial lining and lesions (Jawein, 2012). The Apo E model was used to 
examine whether there is any correlation between metabolic diseases such as 
atherosclerosis and bladder physiology. The investigation into the addition of 
inflammatory marker, angiotensin II, in an already inflammatory environment may 
further potentiate angiotensin II’s effects on the bladder.  
Figure 63 and 64 display the results of our findings so far. A trend of increase can be 
seen in the Apo E knockout models with 1μM angiotensin II, 100μM hydrogen 
peroxide and 100μM Apocynin. Further repeats are required in order to make solid 
conclusions about the effect of these interventions in this model.  
 199 
 
 
Figure 63. The effect of Angiotensin II on male ApoE knockout mice 
This figure represents the data obtained when 1μM angiotensin II is added to full 
thickness mice bladder strips isolated from Apo E knockout mice. These mice bladder 
strips were perfused with 1μM of angiotensin II and the ATP from the superfusate 
measured. The results show there is no significant difference in the ATP released 
when angiotensin II is added in comparison to their controls, due to not enough 
samples. N=3.  
 
 
 
 
Figure 64. The effect of ROS and antioxidants on male ApoE knockout mice 
This graph represents the data obtained when 100μM of hydrogen peroxide and 
100μM Apocynin is added to full thickness mice bladder strips isolated from Apo E 
knockout mice. These mice bladder strips were perfused with 100μM of hydrogen 
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peroxide or 100μM of Apocynin and the ATP from the superfusate measured. A 
pattern of increase can be seen with hydrogen peroxide addition and conversely a 
decrease with Apocynin. The results show there is no significant difference in the ATP 
released when either intervention is perfused in comparison to HEPES-buffered 
Tyrodes control. N=4.  
 
5.7. Alternative inflammatory factors  
The discovery of the effect and action of angiotensin II on bladder physiology 
described in this thesis, leads to the suggestion that other inflammatory factors may 
have a similar effect in the bladder. Alternative inflammatory factors were explored 
and their effect on ATP release is presented below.  
Bradykinin, an inflammatory factor already established for its role in increasing 
vascular permeability and thus vasodilation and blood pressure(Golias et al. 2007).  
Bradykinin was used in the following experiments on young male Dunkin-Hartley 
guinea pigs (see section 2.2.1 for more details). Three concentrations of bradykinin 
was used, 0.3μM, 1μM and 10μM.  
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Figure 65. The effect of 0.3μM Bradykinin on mucosa and full thickness bladder strips 
This graph represents the data obtained when 0.3μM bradykinin is added to mucosa 
alone bladder strips (A.) and full thickness mice bladder strips (B.) isolated from male 
Dunkin Hartley guinea pigs. These bladder strips were perfused with HEPES-
buffered Tyrodes as a control and then 0.3μM bradykinin. The ATP from the 
superfusate measured for both control and stimulated response. A pattern of increase 
can be seen with bradykinin but the results show that there is no significant difference 
in the ATP released in comparison to HEPES-buffered Tyrode control. N=8.  
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Figure 66. The effect of 1μM Bradykinin on mucosa and full thickness bladder strips 
This graph represents the data obtained when 1μM bradykinin is added to mucosa 
alone bladder strips (A.) and full thickness mice bladder strips (B.) isolated from male 
Dunkin Hartley guinea pigs. These bladder strips were perfused with HEPES-
buffered Tyrodes as a control and then 1μM bradykinin. The ATP from the 
superfusate measured for both control and stimulated response. A pattern of 
significant increase can be seen with bradykinin in both tissue preparations, in 
comparison to HEPES-buffered Tyrode control. N=8. *P<0.05, Wilcoxon signed rank 
test.  
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Figure 67. The effect of 10μM Bradykinin on mucosa and full thickness bladder strips 
This graph represents the data obtained when 10μM bradykinin is added to mucosa 
alone bladder strips (A.) and full thickness mice bladder strips (B.) isolated from male 
Dunkin Hartley guinea pigs. These bladder strips were perfused with HEPES-
buffered Tyrodes as a control and then 10μM bradykinin. The ATP from the 
superfusate measured for both control and stimulated response. A pattern of 
significant increase can be seen with bradykinin in both tissue preparations, in 
comparison to HEPES-buffered Tyrode control. N=12. *P<0.05, Wilcoxon signed 
rank test.  
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As demonstrated in figures 65– 67, bradykinin is able to significantly increase 
spontaneous ATP release from the mucosa and full thickness bladder strips at 1μM 
and 10μM concentrations. At a lower concentration of 0.3uM, bradykinin appears to 
be able to still increase ATP release, although this does not surpass the significance 
level. This provides evidence that inflammatory factors such as angiotensin II and 
bradykinin may play a part in increased bladder activity that results in pathology. 
Their ability to significantly affect ATP release, may suggest that any changes in their 
expression or an up-regulation may provide an answer for the aetiology of some 
bladder disorders. 
 
 
 
 
Figure 68. Stimulated ROS production from male Dunkin Hartley guinea pigs with 
Bradykinin 
Bladder strips were pre-incubated in 10μM bradykinin for 30 minutes at 37°C. The 
quantity of ROS present, in the urinary bladder strips, was then measured according 
to a lucigenin reaction in a Chemiluminescence machine when NADPH oxidase is 
added to each sample. This figure displays the results obtained. Incubation of the 
bladder strips in 10μM bradykinin significantly increased ROS production. N=8. 
*P<0.05, Wilcoxon signed rank test.  
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The additional evidence from figure 68, shows that Bradykinin is able to significantly 
increase ROS production from full thickness bladder strips, in comparison to the 
control. This result, coupled with that from the ATP results (figure 65-67) shows that 
Bradykinin is able to increase both ATP release and ROS production, similarly to 
angiotensin II.  
 
Another inflammatory mediator that was examined was ASIC3. The aim of this 
section of the report is to highlight the novel findings of the role of ASIC3 in bladder 
physiology. The production of ASIC3 specific ligand 2-GMQ, has given us the 
opportunity to do this. The results obtained are represented in figures 69– 71.  
Similarly to functional experiments carried out, 2-GMQ was perfused over both 
mucosa alone and full thickness bladder tissue. Both preparations were able to 
significantly increase ATP release at a concentration of 10μM. These results provide 
the first evidence that ASIC3 is present not just in the detrusor smooth muscle, but 
also in the mucosa of the bladder. The presence of ASIC3, is proof that the urothelium 
is mediating inflammatory responses and is supportive of the data presented in this 
thesis. The mucosa is highly equipped to signal inflammation and toxins, therefore 
contributing to pathology. This makes the mucosa a prime target for therapeutic 
treatment.  
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A.  
 
 
B.  
 
 
Figure 69. The effect of ASIC3 activator on mucosa and full thickness bladder strips 
This graph represents the data obtained when ASIC3 activator 2-GMQ (10μM) is 
added to mucosa alone bladder strips (A.) and full thickness mice bladder strips (B.) 
isolated from male Dunkin Hartley guinea pigs. These bladder strips were perfused 
with HEPES-buffered Tyrodes as a control and then followed by 10μM 2-GMQ. The 
ATP from the superfusate measured for both control and stimulated response. A 
pattern of significant increase can be seen with 2-GMQ in both tissue preparations, in 
comparison to HEPES-buffered Tyrode control. N=8. *P<0.05, Wilcoxon signed rank 
test.  
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Supporting the novel evidence provided in figure 69 for the concentration of 10μM 2-
GMQ, a higher concentration of 100μM was still able to also significantly increase 
ATP release from both mucosa alone and full thickness bladder strips.  
A.  
 
 
 
B. 
 
Figure 70. The effect of ASIC3 activator on mucosa and full thickness bladder strips 
This graph represents the data obtained when ASIC3 activator 2-GMQ (100μM) is 
added to mucosa alone bladder strips (A.) and full thickness mice bladder strips (B.) 
isolated from male Dunkin Hartley guinea pigs. These bladder strips were perfused 
with HEPES-buffered Tyrodes as a control and then followed by 100μM 2-GMQ. The 
ATP from the superfusate measured for both control and stimulated response. A 
pattern of significant increase can be seen with 2-GMQ in both tissue preparations, in 
comparison to HEPES-buffered Tyrode control. N=8. *P<0.05, Wilcoxon signed rank 
test.  
Control 2-GMQ
0
500
1000
1500
A
T
P
 r
e
le
a
s
e
 (
p
m
o
le
s
/g
/m
in
)
*
Control 2-GMQ
0
100
200
300
400
A
T
P
 r
e
le
a
s
e
 (
p
m
o
le
s
/g
/m
in
)
*
 208 
 
The use of a higher concentration of 500μM was perfused over the tissues. This 
concentration scale seen in figures 69 – 71 shows that both low and high 
concentrations of 2-GMQ are able to evoke bladder function to increase ATP release 
and thus bladder activity. The quantification of ATP release is not parallel to the 
increasing concentration, but ATP was increased in all three circumstances. 
A.  
 
 
 
B.  
 
 
Figure 71. The effect of ASIC3 activator on mucosa and full thickness bladder strips 
This graph represents the data obtained when ASIC3 activator 2-GMQ (500μM) is 
added to mucosa alone bladder strips (A.) and full thickness mice bladder strips (B.) 
isolated from male Dunkin Hartley guinea pigs. These bladder strips were perfused 
with HEPES-buffered Tyrodes as a control and then followed by 500μM 2-GMQ. The 
ATP from the superfusate measured for both control and stimulated response. A 
pattern of significant increase can be seen with 2-GMQ in both tissue preparations, in 
comparison to HEPES-buffered Tyrode control. N=8. *P<0.05, Wilcoxon signed rank 
test.  
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The novel identification of ASIC3 in the mucosa of the bladder using specific ligand 
2-GMQ, the ability to be able to activate the ASIC3 channel alone under 
physiological conditions gave us the ability observe the bladder’s response to it via 
ATP release. Additionally, the ability of concentrations as low as 10μM 2-GMQ to 
activate this ligand to affect bladder activity is indicative of the sensitivity of the 
bladder to this receptor. Thus giving us the impression that inflammatory mediators 
such as capsaicin have a crucial role in bladder physiology and thus their inhibition 
may proof beneficial in bladder pathophysiology treatment.  
 
5.8. Discussions and Summary  
 
In this last chapter of results in this body of research, we examined pathological 
models in order to look at how angiotensin II and ROS affected function.  
The first pathological model used was a model for ageing. Ageing male Dunkin 
Hartley guinea pigs and mice between the ages of 18-24months were used. These 
models were hypothesised to have greater bladder activity than younger models, as 
many bladder disorders are seen more commonly in the ageing population. Thus we 
hypothesised that there would be an increase in ATP release in ageing models.  
Our results concluded that although angiotensin II was still able to increase ATP 
release in ageing models, when compared to young models this was reduced. 
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Therefore, these results point to a reduction in bladder activity with age, specifically 
in its response to angiotensin II. However, the addition of a reactive oxygen species 
was able to increase ATP release. This is consistent with Dunham’s theory of ageing 
proposed in 1956, the response of the ageing model to ROS suggests that in normal 
physiological conditions ROS is contributing to ATP release. Additionally, the 
inability of Apocynin to inhibit ATP release, as seen in young models is suggestive 
that this oxidative production may be less reversible in ageing models. An indication 
that as ageing occurs, the response of tissues and cells to antioxidant activity 
deteriorates and sensitivity is lost, resulting in a promotion of oxidative stress.  
So far using wild type models, the action of angiotensin II has been established in the 
bladder, its ability to affect ATP release and bladder contraction in the mucosa 
specifically makes this finding a novel discovery. The use of P2Y2 knockout models 
gave us insight into the role of this ATP mediator in the action of angiotensin II and 
ROS. The results obtained, bring to light that both angiotensin II and hydrogen 
peroxide are able to increase ATP release in its absence. This leads to the conclusion 
that this receptor is not vital to the action of these inflammatory mediators.  
Additionally, interactive studies with ATP analogue UTP show that the action of 
angiotensin II and ATP are not co-dependent. These results do however provide 
supporting evidence for the self-activation role of ATP via autocrine and paracrine 
signalling.   
Quantification of ROS production in P2Y2 knockout mice did reveal a significant 
reduction in spontaneous release in comparison to the wild type mice models. The 
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results show that angiotensin II was still able to have an effect and ROS was able to 
increase ATP release, but the overall ROS production is inhibited and angiotensin II 
induced ROS production was negligible in the absence of P2Y2 knockout. Therefore, 
we can conclude that the action of angiotensin II and ROS on ATP activity is 
unhindered by the absence of P2Y2 but the effect is seen in ROS production. Thus, the 
P2Y2 receptor must play a more central role in ROS production in comparison to ATP 
release. Alternatively, this may be due the presence of multiple pathways for ATP 
release and fewer ROS production options for angiotensin II in P2Y2 knockout 
models.  
Subsequent experiments in NOX2 knockout mice provided further insight into 
angiotensin II’s action in the bladder. So far, the action of angiotensin II has been 
parallel with ROS thus suggesting that the knockout of a major source of ROS would 
inhibit this action. But the opposite results were observed in mice. The significant 
increase in ATP release in the absence of NOX2 is suggestive that possibly other 
NOX isoforms have a contributory role in the action of angiotensin II. Additionally it 
is believed that these other isoforms may be up-regulated in the absence of NOX2 in a 
compensatory mechanism, their expression may be increased resulting in higher ATP 
release than their wild type counterparts.  
The absence of ApoE made no significant change to the ATP release in comparison to 
wild type data. Therefore ApoE does not play a significant role in mediating the 
action of angiotensin II or ROS in the bladder.  
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The identification of the significant effects of angiotensin II on bladder physiology 
and pathophysiology led us to investigate alternative inflammatory factors. 
Bradykinin, known for its function in the vascular system, was used. At higher 
concentrations of 1μM and 10μM, ATP was significantly increased and incubation in 
bradykinin prior to ROS detection significantly increased ROS production. 
Consequently, this provides the first evidence for the stimulation of ROS in the 
mucosa by bradykinin. The combination of ATP release data and ROS effects 
suggests that bradykinin could possibly act in a similar way to angiotensin II and 
there is room for more exploration into its action.   
Comparably, the role of ASIC3 in the bladder also has the ability to increase ATP 
release. Therefore ASIC3 must be involved in bladder physiology and 
pathophysiology. Its ability to affect mucosal function shows that this receptor is not 
just present in the mucosa but functionally active. It may possibly contribute to 
conditions such as bladder pain syndrome and mediate the action of capsaicin to 
caused long-term pain. The consistent effects of angiotensin II, bradykinin and ASIC3 
activator on ATP release and ROS support the notion that inflammatory mediators 
have vital role in regulating ROS production and bladder function. 
The identification of the pathophysiological implications of this research is vital to the 
progression of treatment and therapy of bladder disorders. The models of ageing 
suggest that the elderly are at risk of underactive bladders as opposed to just 
overactive bladders and antioxidant activity may be distorted in ageing bladders. 
NOX2 knockout models have provided suggestions that the absence of a single 
isoform of NADPH Oxidase is not sufficient as a treatment as results show a 
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compensatory mechanism. Alternative inflammatory mediators show a comparable 
effect to that seen with angiotensin II. This suggests that although the identification of 
the effects of a single inflammatory are vital, the picture is much bigger than this and 
many factors play a role. Therefore future treatments may require a multi-target 
approach or a deeper study in the molecular pathways in order to find commonality.  
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CHAPTER 6 
CONCLUSION  
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The bladder has been highly under researched in comparison to the other organs of 
the body such as the heart, brain and kidney. PubMed search engines display 162,414 
articles for the search of ‘bladder’ in comparison to 1,285,370 for the search of 
‘heart’. This is a common indicator for the disparity in volume of research for the 
bladder. Therefore there is a great need for more investigations into the function of 
the bladder under physiological conditions as well as pathological conditions.  
Bladder disorders have been reported to affect approximately 16% of the population 
in Europe (Birder & Andersson 2013). However, many people believe that this 
statistic is a great underestimation of the number of people affected (Andersson & 
Arner 2004), due to underreporting. The social implications of bladder disorders mean 
that people feel embarrassed about reporting symptoms.  
Bladder disorders involve a wide variety of pathologies that include both overactive 
and underactive bladder activity. Common disorders mentioned in this report include 
overactive bladder, bladder pain syndrome and bladder outlet obstruction. Many of 
the symptoms of bladder disorders include nocturia, increased frequent urination and 
pain on urination. Patients report a significant reduction in quality of life following 
diagnosis as symptoms disturb lifestyles and increase social anxiety (Andersson & 
Arner 2004).  
Additionally, comorbidities have been reported, as patients who suffer from bladder 
disorders also present with other clinical disorders. Patients have been reported to 
have commonly shown metabolic disorders in addition to bladder pathologies. Also, 
patients affected have been noted to be of a more elderly age and thus the reports of 
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fractures has also increased in patients who suffer from bladder disorders as the 
combination of nocturia and frequent urination places them at a higher risk (Clemens 
et al. 2008).  
The treatment of bladder disorders has proved difficult due to the lack of specificity in 
drug treatments. The use of anti-muscarinics, resulted in unpleasant side effects for 
patients such as dry mouth and constipation. Therefore a large number of patients 
were reported to stop medications soon after beginning (Andersson & Arner 2004). 
More recent drug treatments have made significant progress to help patients with 
bladder disorders but there is much room for improvement of treatment and therapies 
that have lasting effects and as few side effects as possible.  
Therefore the social and economic burden of bladder disorders makes it a crucial 
target for research and investigation. The effects of increased diagnosis and non-
specific treatment strategies mean that bladder disorders are costing the NHS more 
financially but are not affectively solving the problem. Thus more research into 
bladder physiology and the aetiology of bladder disorders is needed.  
There are many factors that contribute to bladder physiology. In recent years, the 
identification of the sensory role of the urothelium has led to more focussed research 
into potential receptors and mediators involved at this site of the bladder. The 
urothelium was demonstrated to respond to ATP release but more specifically, also 
able to release ATP (Burnstock 1972). This function of the urothelium has initiated 
many studies into the role of the urothelium in bladder physiology. The release of 
ATP from the bladder wall is a strong indicator of bladder activity, especially 
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urothelial sensory function and this body of research uses ATP release as an indicator 
of bladder sensory mediator release.  
The main focus of this research is the action of angiotensin II. This potent 
inflammatory mediator has been identified for its role in the cardiovascular system 
but its function in the urothelium of the bladder has yet to be explored. This mediator 
has been shown to be associated with bladder pathologies such as bladder outflow 
obstruction and detrusor hypertrophy (Comiter & Phull 2012; Cho et al. 2012). 
Research by Cho et al (2012) discovered the effect angiotensin II in the detrusor 
smooth muscle in bladder but its effects in the urothelium have never been examined 
(figure 72).  
Comparably the effects of oxidative stress have been identified in many pathological 
conditions (Perše 2013; Yu & Chung 2006; Sharma et al. 2012). Oxidative stress is 
the build-up of ROS in tissues due to increased production or decreased degradation. 
The specific ROS source NADPH Oxidase was observed in this study. Similarly to 
angiotensin II, there was a lack of information on the role of ROS in urothelial 
derived bladder physiology (figure 72.). The relationship between angiotensin II and 
ROS produced as demonstrated in vascular tissue makes the investigation on ROS 
another key focus of this thesis.  
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Figure 72. A schematic of Angiotensin II and ROS action in bladder 
This schematic is a summary of previous knowledge concerning angiotensin II and ROS 
action in the bladder. Both mediators can be seen to have an effect in the detrusor smooth 
muscle. The action of ATP, both autocrine and paracrine, is also highlighted. It should be 
noted that the action of angiotensin II in the bladder is seen in bladder out obstruction model 
and the action of NOX in urinary cancer models.  
Therefore the aim of this research was to examine the presence and function of 
angiotensin II and NADPH Oxidase in bladder physiology and to further explore their 
effect on each other. We hypothesised that angiotensin II would have effect in the 
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mucosa of bladder and functional significance. Our hypothesis also stated that 
angiotensin II would mediate its action in the bladder via ROS.  
The results of this thesis provide novel data into the physiology of the mucosa 
specifically and the bladder wall as a whole (Figure 73). The first conclusions 
presented in this research are the identification and localisation of angiotensin II in the 
bladder via its mediating receptor AT1 (figure 25). The data shows the presence of 
AT1 receptors specifically in the urothelium of the data. Additional investigations 
support this by showing the functional significance of angiotensin II in the mucosa 
and full thickness bladder. Therefore we can conclude that angiotensin II is not only 
present in the urothelium but it also has an impact on bladder activity (figure 27-29). 
Similarly, bladder contractility analysis also supports conclusions that angiotensin II 
affects bladder physiology.  
These novel findings were further explored by using interaction studies to examine 
the mediatory pathways involved in the action of angiotensin II (section 3.7, figure35-
40).  Conclusions based on the results observed suggest that angiotensin II is not 
dependent on ATP receptor P2Y2 to mediate its actions. Analogously, the absence of 
extracellular calcium was not able to inhibit ATP release by angiotensin II and thus 
intracellular calcium release must be the main source of calcium required for the 
action of angiotensin II (Figure 36). Experimental investigations into cell-to-cell 
communications in both the bladder and mucosa specifically, revealed that 
angiotensin II was able to still activate ATP release in the absence of vesicular 
transport and gap junction communication (figure 37-38). However this is suggestive 
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that both mechanisms may have a joint role in the action of angiotensin II, therefore 
inhibition of one mediator did not have the expected outcomes.  
The experimental data presented in this thesis is the first evidence for the presence of 
angiotensin II in the bladder and its functional significance on bladder activity. Thus 
it holds much therapeutic significance, as drug therapies using AT1R may provide 
relief from some of the symptoms of bladder disorders.  
Subsequently, the presence of NADPH Oxidase isoforms was identified by 
immunostaining in the bladder but also specifically the urothelium. NOX 1 and 2 
were also present in the bladder to varying concentrations (figure 41-42). Following 
this, the presence of ROS in the bladder was identified in the bladder both 
quantitatively and by imaging localisation. Both experimental approaches show 
positive results for the presence of ROS in the mucosa. The DHE staining shows 
specifically the generation of superoxide inside the urothelial cells (figure 43). This 
demonstrates that the urothelium is an important source of ROS production (figure 
73). This finding has important implication in bladder physiology and explains why 
the urothelium is as sensitive to inflammation as seen in cystitis and bladder pain. 
Stimulated ROS production was also indication that angiotensin II could influence 
ROS release and that these two pathways were connected. This suggests that 
angiotensin II can modulate urothelial and bladder function via ROS production. As 
ROS production is increased in ageing process and many pathological conditions, it 
adds further weight to the importance of angiotensin II in ageing and pathological 
bladders. Furthermore functional experiments in the quantification of ATP release 
show that stimulation of tissues with hydrogen peroxide further activates bladder 
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activity and this is reduced by antioxidant activity. As angiotensin II is an activator in 
NOX enzymes, these data suggest that NOX –derived ROS is important new regulator 
for urothelial ATP release and hence the bladder function. Similar to the identification 
of angiotensin II, these results show functional significance as well as localisation of 
ROS production. Therefore we can conclude that ROS has a functional effect on 
bladder physiology and may also be a potential therapeutic target. 
Lastly, bladder pathology models were examined and the effect of angiotensin II and 
ROS on these models observed. This investigation looked at ageing models, P2Y2 
knockout models, NOX 2 knockout models, ApoE knockout models and other 
inflammatory mediators. We can conclude that as bladders age the effect of 
angiotensin II decreases and a distortion in bladder physiology can be seen. The 
ageing bladder still responds to ROS but appears insensitive to antioxidant activity. 
The effects of angiotensin II and ROS as stimulants are not affected by the absence of 
P2Y2 receptors but the production of ROS are. Therefore our data shows that P2Y2 
plays a vital role in release of ROS but the response of tissue to ROS is unaffected. 
Moreover, angiotensin II and ROS have an increased effect in the absence of Nox2. 
This has led us to the conclusion that other NOX isoforms must have compensatory 
expression in the absence of NOX2. It also suggests that multiple NOX subtypes are 
involved in ROS production in the urothelium. Inflammatory factors such as 
bradykinin and capsaicin are believed from this data to have similar inflammatory 
effects as angiotensin II. These extended investigations shows that inflammatory 
mediators can significantly influence the urothelial and bladder function as a class of 
bioactive substances and therefore suggest the importance of inflammatory mediators 
in the sensory function of the urothelium (figure 73).  
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Figure 73.Schematic of Angiotensin II role 
This schematic presents the finding of the data presented in this research. Angiotensin 
II works as a mediator to activate ATP directly, intracellular calcium and also can 
potentiate ROS release which can also cause ATP release.  
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The schematic presented in figure 71, highlights clearly the conclusions of this 
research. We previously knew that Angiotensin II was working in the muscle layer of 
the bladder, but these findings show that it is also present in the urothelium. Its action 
is mediated by AT1R, which is present in the urothelium. From the investigations 
described in this thesis, we know that angiotensin II can directly affect ATP, 
intracellular Ca2+ and ROS production.  
The methods used in this research were as a result of research into physiological 
experiments and training by Dr C Wu. Guinea pigs and mice have been used as 
models of bladder physiology due to their homology in contraction mechanics with 
humans (Klockner & Isenberg 1985; Kobayashi et al. 2014; Sui et al. 2002). Imaging 
techniques such as immunofluorescence and DHE were adopted as the identification 
and localisation of the receptor proteins was vital to the investigation. They were 
great tools for the initial identification of receptors, but they lacked the ability to give 
reliable quantitative data.  Additionally, physiological experiments in the functionality 
of bladder strips were used in accordance with protocols already established (Fry et 
al. 1999; Sui et al. 2014) and allowed us to see spontaneous and stimulated effects on 
ATP release and contraction. The tension experiments allowed us to create a dynamic 
experiment, where we could observe the bladder tissue respond to drug interventions. 
However, its ability to be effectively repeated is low. Each animal, also kept in the 
same environment is different and although some of these differences are minor, 
when measuring pmole measurements of ATP, it can be difficult to not have large 
standard errors. Lastly, the detection of ROS and the ability to stimulate its release 
gave us insight into the collaborative effects of angiotensin II, this method has been 
used previously by Owusu-Ansah et al. 2008 and Li & Shah 2003. The methods 
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adopted in this research did however, give us scientific rigor in experimental design, 
therefore the research has a brad wealth of mediators and interventions.  
 Future work following this body research, should first aim to solidify and further 
confirm results demostrated. Methods such as western blotting and qPCR can provide  
quantitative confirmation of the expression and presence of angiotensin II or the 
AT1R in the urothelium of the bladder specifically. This can also be used to confirm 
the presence of NOX1 and NOX2 in the urothelium of the bladder. This short-term 
goal for furhter work, will add a greater weight to the conclusions made. The 
quantificantion ability of such methods would allow us to see the differential 
expression of mediators in the different layers of the bladder as well as the layers of 
the mucosa. This will add a depth and quality to the findings of this research.  
Based on the results presented here, a recommendation for a multifaceted therapeutic 
approach is suggested as many other inflammatory factors may play a similar role. 
The future work of this research could explore deeper the pathological models such as 
the ApoE knockout model. Additionally, investigations into the molecular pathways 
of angiotensin II and ROS in the bladder could help to further increase the impact of 
these findings as more specific therapeutic targets may be found. Bradykinin, as 
presented in our findings, has a similar effect on the bladder as angiotensin II. This is 
another avenue that can be examined, its regulation and mediation in the bladder.  
Midterm goals for future work include the exploration of conditons such as diabetes 
and their correlation with bladder disorders. The investigations by Wang et al. 2016, 
shine light onto a an area of bladder physiology where  there is still so much more to 
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understand. The action of angioteinsin II may play a role in the development of 
metabolic disease or the development of metabolic disease may affect bladder 
physiology. Could there be an acceleration for people with conditions such as 
diabetes? Do we see an increase in ROS, inflammatory mediators that have a 
downstream effect in bladder deterioration, specifically the breakdown of urothelial 
signalling and barrier, resulting in damage to the bladder wall.  
Other midterm goals include studies of the action of angiotensin II over 24hours and 
live calcium signalling coupled with angiotensin II interventions (Guiping et al. 
2006). The ability to study the effects of angioteinsin II over a 24hr period would be 
so valuable. It would give us an indication of potential downstream effects or 
fluctuations caused by the action of angiotensinn II. A window into the longer term 
effects of sustained exposure to angiotensin for the bladder, will be a truer indicator of 
physiological conditons. Moreover, live calium signalling coupled with angiotensin 
II, will not only confirm the action of intracellular calium in the pathway of 
angiotensin II’s effect on bladder ATP release, but there may be new findings that are 
note expected.  
Although the bladder is a robust organ that can withstand much assault, future work 
should include the use of urothelial markers to assist in the morphological tissue 
viability. The use of urothelial markers will help to highlight the urothelium and show 
up any damage. Damaged tissue can greatly affect results, especially in the case of 
ROS detection experiements.  
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Additinally the adoption of in vivo techniques to study the urothelium in live tissue 
would also be beneficial long term goals (wang et al. 2016). Although, physiological 
conditions have been mimiced as much as possible, the true nature of the urothelium 
can be studied in vivo. Wang et al. 2016, used video urodynamic studies, this gave the 
research an additional layer of evidence and data that could be used to compare 
bladder models. Using tension machines and pressure detectors, the changes to the 
urothelium following injury, injection of angiotensin II or ACE inhibitors, would 
allow us to see the live reactive nature of the urothelium to angiotensin II. Methods 
such as uroflowmetry used by Lee et al. 2004, would add data behavourial data to our 
work. Allowing us to see changes in urine flow, rate of flow, residual volume etc.  
The data presented this body of research is the first evidence for that action of 
angiotensin II and ROS in the bladder. The data extends further to show functional 
significance of these mediators in the bladder and mucosa specifically. Lastly, the 
results presented her show pathological and therapeutic significance with the use of 
pathological models.  
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